0000320017-23-000063.txt : 20231102 0000320017-23-000063.hdr.sgml : 20231102 20231102161138 ACCESSION NUMBER: 0000320017-23-000063 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LISATA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0000320017 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222343568 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33650 FILM NUMBER: 231372421 BUSINESS ADDRESS: STREET 1: 110 ALLEN ROAD STREET 2: SECOND FLOOR CITY: BASKING RIDGE STATE: NJ ZIP: 07920 BUSINESS PHONE: 908-229-2590 MAIL ADDRESS: STREET 1: 110 ALLEN ROAD STREET 2: SECOND FLOOR CITY: BASKING RIDGE STATE: NJ ZIP: 07920 FORMER COMPANY: FORMER CONFORMED NAME: CALADRIUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20170808 FORMER COMPANY: FORMER CONFORMED NAME: Caladrius Biosciences, Inc. DATE OF NAME CHANGE: 20150608 FORMER COMPANY: FORMER CONFORMED NAME: NeoStem, Inc. DATE OF NAME CHANGE: 20060906 10-Q 1 lsta-20230930.htm 10-Q lsta-20230930
000032001712/312023Q3false.067http://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrentP1Y.3300003200172023-01-012023-09-3000003200172023-11-02xbrli:shares00003200172023-09-30iso4217:USD00003200172022-12-31iso4217:USDxbrli:shares00003200172023-07-012023-09-3000003200172022-07-012022-09-3000003200172022-01-012022-09-300000320017us-gaap:CommonStockMember2022-06-300000320017us-gaap:AdditionalPaidInCapitalMember2022-06-300000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000320017us-gaap:RetainedEarningsMember2022-06-300000320017us-gaap:TreasuryStockCommonMember2022-06-300000320017us-gaap:ParentMember2022-06-300000320017us-gaap:NoncontrollingInterestMember2022-06-3000003200172022-06-300000320017us-gaap:RetainedEarningsMember2022-07-012022-09-300000320017us-gaap:ParentMember2022-07-012022-09-300000320017us-gaap:CommonStockMember2022-07-012022-09-300000320017us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000320017us-gaap:CommonStockMember2022-09-300000320017us-gaap:AdditionalPaidInCapitalMember2022-09-300000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000320017us-gaap:RetainedEarningsMember2022-09-300000320017us-gaap:TreasuryStockCommonMember2022-09-300000320017us-gaap:ParentMember2022-09-300000320017us-gaap:NoncontrollingInterestMember2022-09-3000003200172022-09-300000320017us-gaap:CommonStockMember2021-12-310000320017us-gaap:AdditionalPaidInCapitalMember2021-12-310000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000320017us-gaap:RetainedEarningsMember2021-12-310000320017us-gaap:TreasuryStockCommonMember2021-12-310000320017us-gaap:ParentMember2021-12-310000320017us-gaap:NoncontrollingInterestMember2021-12-3100003200172021-12-310000320017us-gaap:RetainedEarningsMember2022-01-012022-09-300000320017us-gaap:ParentMember2022-01-012022-09-300000320017us-gaap:CommonStockMember2022-01-012022-09-300000320017us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000320017us-gaap:CommonStockMember2023-06-300000320017us-gaap:AdditionalPaidInCapitalMember2023-06-300000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000320017us-gaap:RetainedEarningsMember2023-06-300000320017us-gaap:TreasuryStockCommonMember2023-06-300000320017us-gaap:ParentMember2023-06-300000320017us-gaap:NoncontrollingInterestMember2023-06-3000003200172023-06-300000320017us-gaap:RetainedEarningsMember2023-07-012023-09-300000320017us-gaap:ParentMember2023-07-012023-09-300000320017us-gaap:CommonStockMember2023-07-012023-09-300000320017us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000320017us-gaap:CommonStockMember2023-09-300000320017us-gaap:AdditionalPaidInCapitalMember2023-09-300000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000320017us-gaap:RetainedEarningsMember2023-09-300000320017us-gaap:TreasuryStockCommonMember2023-09-300000320017us-gaap:ParentMember2023-09-300000320017us-gaap:NoncontrollingInterestMember2023-09-300000320017us-gaap:CommonStockMember2022-12-310000320017us-gaap:AdditionalPaidInCapitalMember2022-12-310000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000320017us-gaap:RetainedEarningsMember2022-12-310000320017us-gaap:TreasuryStockCommonMember2022-12-310000320017us-gaap:ParentMember2022-12-310000320017us-gaap:NoncontrollingInterestMember2022-12-310000320017us-gaap:RetainedEarningsMember2023-01-012023-09-300000320017us-gaap:ParentMember2023-01-012023-09-300000320017us-gaap:CommonStockMember2023-01-012023-09-300000320017us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000320017lsta:CENDMember2022-09-152022-09-15xbrli:pure0000320017lsta:CENDMember2022-09-1500003200172022-09-1500003200172022-09-152022-09-150000320017lsta:CaladriusMember2023-07-012023-07-010000320017us-gaap:FurnitureAndFixturesMember2023-09-300000320017us-gaap:ComputerEquipmentMember2023-09-300000320017us-gaap:ComputerSoftwareIntangibleAssetMember2023-09-300000320017us-gaap:RoyaltyMember2023-01-012023-09-300000320017us-gaap:CorporateDebtSecuritiesMember2023-09-300000320017us-gaap:CorporateDebtSecuritiesMember2022-12-310000320017us-gaap:CommercialPaperMember2023-09-300000320017us-gaap:CommercialPaperMember2022-12-310000320017us-gaap:MoneyMarketFundsMember2023-09-300000320017us-gaap:MoneyMarketFundsMember2022-12-310000320017us-gaap:BondsMember2023-09-300000320017us-gaap:BondsMember2022-12-310000320017us-gaap:USTreasuryBillSecuritiesMember2023-09-300000320017us-gaap:USTreasuryBillSecuritiesMember2022-12-310000320017us-gaap:USStatesAndPoliticalSubdivisionsMember2023-09-300000320017us-gaap:USStatesAndPoliticalSubdivisionsMember2022-12-310000320017us-gaap:FurnitureAndFixturesMember2022-12-310000320017us-gaap:ComputerEquipmentMember2022-12-310000320017us-gaap:LeaseholdImprovementsMember2023-09-300000320017us-gaap:LeaseholdImprovementsMember2022-12-310000320017us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000320017us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000320017us-gaap:WarrantMember2023-01-012023-09-300000320017us-gaap:WarrantMember2022-01-012022-09-300000320017us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000320017us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-09-300000320017us-gaap:FairValueMeasurementsRecurringMember2023-09-300000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000320017us-gaap:FairValueMeasurementsRecurringMember2022-12-310000320017lsta:AtTheMarketOfferingAgreementMember2021-06-0400003200172022-03-220000320017lsta:AtTheMarketOfferingAgreementMember2023-01-012023-09-300000320017lsta:AtTheMarketOfferingAgreementMember2021-06-042023-09-3000003200172023-01-012023-06-300000320017srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300000320017us-gaap:EmployeeStockOptionMember2023-01-012023-09-3000003200172022-01-012022-12-310000320017us-gaap:RestrictedStockMember2023-01-012023-09-300000320017us-gaap:RestrictedStockMember2022-01-012022-09-300000320017us-gaap:RestrictedStockMembersrt:MinimumMember2023-01-012023-09-300000320017srt:MaximumMemberus-gaap:RestrictedStockMember2023-01-012023-09-300000320017us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000320017us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000320017us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000320017us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000320017us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000320017us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000320017us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300000320017us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300000320017us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300000320017us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300000320017us-gaap:EmployeeStockOptionMember2023-09-300000320017us-gaap:RestrictedStockUnitsRSUMember2023-09-300000320017us-gaap:RestrictedStockMember2023-09-300000320017us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000320017us-gaap:DomesticCountryMember2021-12-310000320017us-gaap:DomesticCountryMember2022-01-010000320017us-gaap:DomesticCountryMember2022-12-310000320017lsta:CENDMemberus-gaap:DomesticCountryMember2022-12-310000320017lsta:CENDMemberus-gaap:DomesticCountryMember2022-09-150000320017lsta:CENDMemberus-gaap:StateAndLocalJurisdictionMember2022-09-150000320017lsta:CENDMember2022-01-012022-12-310000320017lsta:CENDMember2022-12-310000320017lsta:CENDMemberus-gaap:ForeignCountryMember2022-12-310000320017us-gaap:NewJerseyDivisionOfTaxationMemberus-gaap:StateAndLocalJurisdictionMember2022-12-310000320017us-gaap:NewJerseyDivisionOfTaxationMemberus-gaap:StateAndLocalJurisdictionMember2021-12-310000320017us-gaap:CaliforniaFranchiseTaxBoardMemberus-gaap:StateAndLocalJurisdictionMember2022-12-310000320017us-gaap:CaliforniaFranchiseTaxBoardMemberus-gaap:StateAndLocalJurisdictionMember2021-12-310000320017us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMemberus-gaap:StateAndLocalJurisdictionMember2022-12-310000320017us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMemberus-gaap:StateAndLocalJurisdictionMember2021-12-3100003200172023-04-052023-04-050000320017srt:MinimumMember2023-01-012023-09-300000320017srt:MaximumMember2023-01-012023-09-300000320017us-gaap:AustralianTaxationOfficeMember2023-09-042023-09-040000320017lsta:ImpiloMember2023-07-310000320017lsta:ImpiloMemberus-gaap:SubsequentEventMember2023-10-030000320017lsta:SanfordBurnhamPrebysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2016-12-310000320017lsta:ImpiloMemberlsta:SanfordBurnhamPrebysMember2023-07-310000320017lsta:SanfordBurnhamPrebysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-10-310000320017srt:MinimumMemberlsta:SanfordBurnhamPrebysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-10-310000320017srt:MaximumMemberlsta:SanfordBurnhamPrebysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-10-310000320017lsta:SanfordBurnhamPrebysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-09-300000320017lsta:UniversityOfCaliforniaAtSanDiegoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-03-310000320017srt:MinimumMemberlsta:UniversityOfCaliforniaAtSanDiegoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-03-310000320017srt:MaximumMemberlsta:UniversityOfCaliforniaAtSanDiegoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-03-310000320017lsta:CENDMemberlsta:MassachusettsInstituteOfTechnologyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-09-300000320017lsta:MassachusettsInstituteOfTechnologyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-10-310000320017srt:MinimumMemberlsta:MassachusettsInstituteOfTechnologyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-10-310000320017srt:MaximumMemberlsta:MassachusettsInstituteOfTechnologyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-10-310000320017lsta:MassachusettsInstituteOfTechnologyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-09-300000320017us-gaap:LicenseMemberlsta:QiluMemberlsta:ExclusiveLicenseAndCollaborationAgreementMember2021-02-280000320017us-gaap:LicenseMemberlsta:QiluMemberlsta:ExclusiveLicenseAndCollaborationAgreementMember2022-09-142022-09-140000320017us-gaap:LicenseMemberlsta:QiluMembersrt:MinimumMemberlsta:ExclusiveLicenseAndCollaborationAgreementMember2021-02-280000320017us-gaap:LicenseMembersrt:MaximumMemberlsta:QiluMemberlsta:ExclusiveLicenseAndCollaborationAgreementMember2021-02-280000320017us-gaap:LicenseMemberlsta:QiluMemberlsta:ExclusiveLicenseAndCollaborationAgreementMember2021-02-012021-02-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Quarterly Period Ended September 30, 2023
 
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Transition Period from __________________   to _________________________
 
Commission File Number 001-33650
 
LISATA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)


Delaware22-2343568
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
  
110 Allen Road, 2nd Floor, Basking Ridge, New Jersey
07920
(Address of principal executive offices)(zip code)
 
Registrant’s telephone number, including area code: 908-842-0100
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareLSTA
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐     No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
ClassOutstanding as of November 2, 2023
Common stock, $0.001 par value per share8,139,449 shares



CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report (this “Quarterly Report”) contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words “plan,” “project,” “forecast,” “outlook,” “intend,” “may,” “will,” “expect,” “anticipate,” “likely,” “believe,” “could,” “anticipate,” “estimate,” “continue,” “target” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:
•our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including collecting amounts owed to us under various licensing and other strategic arrangements, meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;
•our ability to build and maintain the management and human resources infrastructure necessary to support the operation and/or growth of our business;
•whether a market is established for our products and our ability to capture a meaningful share of this market;
•scientific, regulatory and medical developments beyond our control;
•our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;
•whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business, and our ability to commercialize products without infringing upon the claims of third-party patents;
•whether any potential strategic or financial benefits of various licensing agreements will be realized;
•our ability to diversify our pipeline of development product candidates, which could include an acquisition, merger, business combination, in-license or other strategic transaction, and whether any of such efforts will result in us entering into or completing any transaction or that any such transaction, if completed, will add to shareholder value;
•the results of our development activities;
•our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population, competition with other clinical trials for similar subjects, patient and/or investigator site availability and accessibility due to external macroenvironmental factors and the need of patients to meet the inclusion criteria of the trial or otherwise;
•the extent to which the COVID-19 pandemic and any future pandemic and/or their long-term effects may impact, directly or indirectly, our business, including our clinical trials and financial condition; and
•other factors discussed in “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2023 (our “2022 Form 10-K”).
The factors discussed herein, including those risks described in “Item 1A. Risk Factors” and elsewhere in our 2022 Form 10-K and in our other periodic filings with the SEC, which are available for review at www.sec.gov, could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue
2
reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

3
TABLE OF CONTENTS
PART I- FINANCIAL INFORMATION
Page No.
Item 1.
 
 
 
 
 
Notes to Unaudited Consolidated Financial Statements
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Item 4.
Controls and Procedures
PART II- OTHER INFORMATION
Item 1.
Legal Proceedings
Item 1A.
Risk Factors
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.
Defaults Upon Senior Securities
Item 4.
Mine Safety Disclosures
Item 5.
Other Information
Item 6.
Exhibits
 
Signatures
4
PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS



LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
September 30,
2023		December 31,
2022
ASSETS(Unaudited)
Cash and cash equivalents$32,428 $32,154 
Marketable securities
21,966 37,072 
Prepaid and other current assets2,839 2,650 
Total current assets57,233 71,876 
Property and equipment, net204 296 
Acquired license - intangible281 334 
Other assets371 528 
Total assets$58,089 $73,034 
LIABILITIES AND STOCKHOLDERS' EQUITY  
Liabilities  
Accounts payable$1,312 $2,655 
Accrued liabilities3,820 3,728 
Total current liabilities5,132 6,383 
Other long-term liabilities253 327 
Total liabilities5,385 6,710 
Commitments and Contingencies (Note 14)
Stockholders' Equity 
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,140,187
and 7,866,799 shares at September 30, 2023 and December 31, 2022, respectively; and
outstanding, 8,139,449 and 7,866,061 shares at September 30, 2023 and December 31, 2022,
respectively
8 8 
Additional paid-in capital576,474 574,548 
Treasury stock, at cost; 738 shares at September 30, 2023 and December 31, 2022
(708)(708)
Accumulated deficit(522,716)(507,241)
Accumulated other comprehensive loss(100)(29)
Total Lisata Therapeutics, Inc. stockholders' equity52,958 66,578 
Non-controlling interests(254)(254)
Total stockholders' equity52,704 66,324 
Total liabilities, non-controlling interests and stockholders' equity$58,089 $73,034 
See accompanying notes to consolidated financial statements.
5

LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)
(In thousands, except per share data)
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Operating Expenses:
Research and development$3,380 $3,335 $9,721 $9,853 
In-process research and development— 30,393 — 30,393 
General and administrative2,584 3,992 9,962 10,815 
Total operating expenses5,964 37,720 19,683 51,061 
Operating loss(5,964)(37,720)(19,683)(51,061)
Other income (expense):
Investment income, net714 337 2,053 496 
Other expense, net(11)— (175)(149)
Total other income (expense)703 337 1,878 347 
     Net loss before benefit from income taxes and noncontrolling interests(5,261)(37,383)(17,805)(50,714)
Benefit from income taxes— — (2,330)(2,479)
Net loss$(5,261)$(37,383)$(15,475)$(48,235)
Less - net income attributable to noncontrolling interests
— — — — 
Net loss attributable to Lisata Therapeutics, Inc. common stockholders$(5,261)$(37,383)$(15,475)$(48,235)
Basic and diluted loss per share
Lisata Therapeutics, Inc. common stockholders$(0.65)$(7.88)$(1.92)$(11.28)
Weighted average common shares outstanding
Basic and diluted shares
8,141 4,747 8,050 4,276 

See accompanying notes to consolidated financial statements.
6
LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited) 
(In thousands)
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Net loss$(5,261)$(37,383)$(15,475)$(48,235)
Other comprehensive loss:
Available for sale securities - net unrealized gain— 5 1 5 
Cumulative translation adjustment arising during the period(50)(25)(72)(25)
Total other comprehensive loss(50)(20)(71)(20)
Comprehensive loss attributable to Lisata Therapeutics, Inc. common
stockholders
$(5,311)$(37,403)$(15,546)$(48,255)
 
See accompanying notes to consolidated financial statements.
7
LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited) 
(In thousands)
 Common StockAdditional
Paid-in
Capital		Accumulated
Other
Comprehensive
Loss		Accumulated
Deficit		Treasury
Stock		Total
Lisata Therapeutics,
Inc.
Stockholders'
Equity		Non-
Controlling
Interest in
Subsidiary		Total
Equity
 SharesAmount
Balance at June 30, 20224,038 $4 $547,032 $(70)$(463,868)$(708)$82,391 $(254)$82,137 
Net loss— — — — (37,383)— (37,383)— (37,383)
Share-based compensation52 — 940 — — — 939 — 939 
Issuance of common stock in connection with Merger3,773 4 26,094 — — — 26,098 — 26,098 
Unrealized gain on marketable securities— — — 5 — — 5 — 5 
Foreign currency translation adjustment— — — (25)— — (25)— (25)
Balance at September 30, 20227,863 $8 $574,066 $(90)$(501,251)$(708)$72,025 $(254)$71,771 
 Common StockAdditional
Paid-in
Capital		Accumulated
Other
Comprehensive Loss		Accumulated
Deficit		Treasury
Stock		Total
Lisata Therapeutics,
Inc.
Stockholders'
Equity		Non-
Controlling
Interest in
Subsidiary		Total
Equity
 SharesAmount
Balance at December 31, 20213,986 $4 $546,044 $(70)$(453,016)$(708)$92,254 $(254)$92,000 
Net loss— — — — (48,235)— (48,235)— (48,235)
Share-based compensation100 — 1,899 — — — 1,899 — 1,899 
Net proceeds from issuances of common stock4 — 29 — — — 29 — 29 
Issuance of common stock in connection with Merger3,773 4 26,094 — — — 26,098 — 26,098 
Unrealized gain on marketable securities— — — 5 — — 5 — 5 
Foreign currency translation adjustment— — — (25)— — (25)— (25)
Balance at September 30, 20227,863 $8 $574,066 $(90)$(501,251)$(708)$72,025 $(254)$71,771 

8
 Common StockAdditional
Paid-in
Capital		Accumulated
Other
Comprehensive
Loss		Accumulated
Deficit		Treasury
Stock		Total
Lisata Therapeutics,
Inc.
Stockholders'
Equity		Non-
Controlling
Interest in
Subsidiary		Total
Equity
 SharesAmount
Balance at June 30, 20238,133 $8 $576,173 $(50)$(517,455)$(708)$57,968 $(254)$57,714 
Net loss— — — — (5,261)— (5,261)— (5,261)
Share-based compensation7 — 301 — — — 301 — 301 
Foreign currency translation adjustment— — — (50)— — (50)— (50)
Balance at September 30, 20238,140 $8 $576,474 $(100)$(522,716)$(708)$52,958 $(254)$52,704 
 Common StockAdditional
Paid-in
Capital		Accumulated
Other
Comprehensive Loss		Accumulated
Deficit		Treasury
Stock		Total
Lisata Therapeutics,
Inc.
Stockholders'
Equity		Non-
Controlling
Interest in
Subsidiary		Total
Equity
 SharesAmount
Balance at December 31, 20227,867 $8 $574,548 $(29)$(507,241)$(708)$66,578 $(254)$66,324 
Net loss— — — — (15,475)— (15,475)— (15,475)
Share-based compensation114 — 1,474 — — — 1,474 — 1,474 
Net proceeds from issuances of common stock76 — 297 — — — 297 — 297 
Proceeds from option exercises83 — 155 — — — 155 — 155 
Unrealized gain on marketable securities— — — 1 — — 1 — 1 
Foreign currency translation adjustment— — — (72)— — (72)— (72)
Balance at September 30, 20238,140 $8 $576,474 $(100)$(522,716)$(708)$52,958 $(254)$52,704 
See accompanying notes to consolidated financial statements.
 
9
LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 
 Nine Months Ended September 30,
 20232022
Cash flows from operating activities:  
Net loss$(15,475)$(48,235)
Adjustments to reconcile net loss to net cash used in operating activities:  
Share-based compensation
1,565 2,168 
Depreciation and amortization142 22 
Loss on disposal of fixed assets3 — 
In process research and development expenses— 30,393 
Amortization/accretion on marketable securities(709)893 
Changes in operating assets and liabilities:  
Prepaid and other current assets(314)29 
Other assets130 178 
Accounts payable, accrued liabilities and other liabilities(1,305)(150)
Net cash used in operating activities(15,963)(14,702)
Cash flows from investing activities:  
Purchase of marketable securities(77,355)(68,481)
Sale of marketable securities93,171 93,865 
Asset acquisition costs, net of cash acquired related to merger with Cend— (3,320)
Purchase of property and equipment— (259)
Net cash provided by investing activities15,816 21,805 
Cash flows from financing activities:  
Proceeds from exercise of options155 — 
Tax withholding payments on net share settlement equity awards(91)(267)
Net proceeds from issuance of common stock297 29 
Net cash provided by (used in) financing activities361 (238)
           Effect of exchange rate changes on cash60 (34)
Net increase in cash and cash equivalents274 6,831 
Cash and cash equivalents at beginning of period32,154 24,647 
Cash and cash equivalents at end of period$32,428 $31,478 
Supplemental disclosure of noncash investing activities:
Issuance of common stock in connection with merger$— $23,580 
Incremental fair value of Cend's fully vested stock options assumed$— $2,136 
See accompanying notes to consolidated financial statements.
10
LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
 
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 – The Business
Overview
Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment (“TME”), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it is seeking to partner while incurring no additional capital outlay.
The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company’s current development pipeline includes:
•LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including, metastatic pancreatic ductal adenocarcinoma (mPDAC) and other forms of pancreatic cancer, cholangiocarcinoma, esophageal cancer, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.
Merger with Cend Therapeutics, Inc. and Name Change
On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (“Caladrius”), completed its acquisition of Cend Therapeutics, Inc. (“Cend”), a Delaware corporation (the “Merger”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (“Merger Sub”).
Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the “Effective Time”): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (“Reverse Stock Split”) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata’s common stock based on an exchange ratio of 0.5338, after taking into account the Reverse Stock Split (the “Exchange Ratio”). In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.
Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the “Cend Plan”), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata’s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock.
Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team provided a vast majority of the individuals on the management team and holds the chief executive officer (“CEO”), chief medical officer (“CMO”) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend’s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The
11
Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). Cend’s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&D with no alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.
Reverse Stock Split
On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company’s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company’s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.
Basis of Presentation
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). Accordingly, actual results could differ from those estimates and assumptions.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.

12
Foreign Currency Remeasurement
The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.

Note 2 – Summary of Significant Accounting Policies
Cash and Cash Equivalents
Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.
Concentration of Risks
The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Marketable Securities
The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.
Property and Equipment
The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:
Furniture and fixtures10 years
Computer equipment3 years
Software3 years
Leasehold improvementsLife of lease
Long-lived Assets
Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.
13

Share-Based Compensation  
The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.
Loss Per Share
Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.
Treasury Stock
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.
Research and Development Costs 
Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.
To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.
In-process Research and Development Expense
Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.
Intangible Asset
The Company’s intangible asset consists of a single asset, Cend’s license agreement with Qilu Pharmaceutical, Co., Ltd. (“Qilu”) acquired in the Merger, with a value of $0.4 million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18 thousand for the three months ended September 30, 2023 and $53 thousand for the nine months ended September 30, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable. The projected amortization expense is $71 thousand per year for the next five years.


14
Revenue Recognition
The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September 30, 2023 and 2022.
Milestones
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September 30, 2023 and September 30, 2022, the Company has not recognized revenue related to milestones.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.









15
Note 3 – Merger
The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&D. Cend’s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&D being expensed. The fair value of total consideration was $36.1 million. The following table is a summary of the purchase price calculation (in thousands except per share data).
Number of common shares of the combined company owned by Cend stockholders3,772,768 
Multiplied by the fair value per share of Lisata common stock on September 15, 2022$6.25
Total$23,580
Carrying value of Lisata's cost method investment in Cend10,000 
Incremental fair value of Cend's fully vested stock options2,136 
Lisata transaction costs382 
Total purchase price$36,098
The allocation of the purchase price was as follows (amounts in thousands):

Cash and cash equivalents$7,062
Net working capital (excluding cash)(1,690)
Other liabilities(22)
Acquired in-process research and development 30,393 
License355 
Net assets acquired$36,098


Note 4 – Available-for-Sale-Securities
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):
September 30, 2023December 31, 2022
CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueCostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate debt securities$28,828 $— $(16)$28,812 $44,308 $— $(17)$44,291 
Commercial paper1,978 — — 1,978 7,953 — — 7,953 
Money market funds13,572 — — 13,572 4,871 — — 4,871 
Agency bonds1,987 — (1)1,986 — — — — 
Treasury bills3,996 — — 3,996 — — — — 
Municipal debt securities725 — — 725 7,626 — (1)7,625 
Total$51,086 $— $(17)$51,069 $64,758 $— $(18)$64,740 


Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):
September 30, 2023December 31, 2022
Cash equivalents$29,103 $27,668 
Marketable securities21,966 37,072 
Total$51,069 $64,740 

16


The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):
September 30, 2023
Amortized CostEstimated Fair Value
Less than one year$51,086 $51,069 
Greater than one year— — 
Total$51,086 $51,069 


Note 5 – Property and Equipment
Property and equipment consisted of the following (in thousands):
September 30, 2023December 31, 2022
Furniture and fixtures$— $25 
Computer equipment589 589 
Leasehold improvements72 99 
Property and equipment, gross661 713 
Accumulated depreciation(457)(417)
Property and equipment, net$204 $296 

The Company’s results included depreciation expense of approximately $89 thousand and $22 thousand for the nine months ended September 30, 2023 and 2022, respectively.

Note 6 – Income (Loss) Per Share
For the nine months ended September 30, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September 30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):
 September 30
 20232022
Stock options1,321 1,399 
Warrants1,422 1,424 
Restricted stock units202 48 
 
Note 7 – Fair Value Measurements
The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
Level 3 inputs are defined as unobservable inputs for the assets or liabilities.
Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires
17
judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands):
September 30, 2023December 31, 2022
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$29,103 $— $— $29,103 $27,668 $— $— $27,668 
Marketable securities - available for sale— 21,966 — 21,966 — 37,072 — 37,072 
$29,103 $21,966 $— $51,069 $27,668 $37,072 $— $64,740 

The carrying values of accounts payable and accrued expenses approximate fair value as of September 30, 2023 and December 31, 2022, due to the short maturity nature of these items.

Note 8 – Accrued Liabilities
Accrued liabilities as of September 30, 2023 and December 31, 2022 were as follows (in thousands):
September 30, 2023December 31, 2022
Salaries, employee benefits and related taxes$2,366 $2,586 
Clinical and R&D related liabilities915 785 
Accounting & tax consulting liabilities230 — 
Operating lease liabilities — current164 180 
Other145 177 
Total$3,820 $3,728 

Note 9 – Operating Leases
The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.

18
Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):
September 30, 2023December 31, 2022
Right-of-Use Assets:
Other assets$348 $487 
Total Right-of-Use Asset$348 $487 
Operating Lease Liabilities:
Accrued liabilities$164 $180 
Other long-term liabilities181 305 
Total Operating Lease Liabilities$345 $485 
    
As of September 30, 2023, the weighted average remaining lease term for our operating lease was 2.0 years, and the weighted average discount rate for our operating lease was 9.625%. As of December 31, 2022, the weighted average remaining lease term for our operating leases was 1.5 years, and the weighted average discount rate for our operating leases was 9.625%.
Future minimum lease payments under the lease agreement as of September 30, 2023 were as follows (in thousands):
Years endedOperating Leases
202348 
2024190 
2025143 
Total lease payments381 
Less: Amounts representing interest(36)
Present value of lease liabilities$345 

Note 10 – Stockholders' Equity
Reverse Stock Split
On September 14, 2022, in connection with the Merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.
Equity Issuances
At The Market Offering Agreement
On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the nine months ended September 30, 2023, the Company issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.



19
Common Stock
In connection with the Merger closing on September 15, 2022, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.
Stock Options and Warrants
In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2023:
Stock OptionsWarrants
SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 20221,391,352 $10.83 7.03$187.6 1,423,774 $42.57 3.37$— 
Changes during the period:
Granted180,896 3.46 — — 
Exercised(82,500)1.88 — — 
Forfeited(144,594)3.63 — — 
Expired(24,603)29.60 (2,000)88.35 
Outstanding at September 30, 20231,320,551 $10.82 6.30$78.7 1,421,744 $42.51 2.67$— 
Vested at September 30, 2023
or expected to vest in the future		1,316,134 $10.84 6.29$78.7 1,421,744 $42.51 2.67$— 
Vested at September 30, 20231,229,103 $11.25 6.09$78.2 1,421,744 $42.51 2.67$— 


Restricted Stock
During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):
Nine Months Ended September 30,
  20232022
Number of restricted stock issued159,950 70,740 
Value of restricted stock issued$480 $973 

The vesting terms of restricted stock issuances are generally between one and four years.
Restricted Stock Units
During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):
Nine Months Ended September 30,
20232022
Number of restricted stock units issued188,850 111,170 
Value of restricted stock units issued $567 $1,386 

The weighted average estimated fair value of restricted stock units issued for services in the nine months ended September 30, 2023 and 2022 was $3.00 and $12.46 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.

20

Note 11 – Share-Based Compensation
Share-Based Compensation
We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2023 and 2022 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Research and development$103 $271 $517 $631 
General and administrative203 769 1,048 1,537 
Total share-based compensation expense$306 $1,040 $1,565 $2,168 

Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September 30, 2023 were as follows (in thousands):
Stock OptionsRestricted Stock UnitsRestricted Stock
Unrecognized compensation cost$221 $161 $483 
Expected weighted-average period in years of compensation cost to be recognized1.851.101.69

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2023 and 2022 were as follows (in thousands):
Stock Options
Nine Months Ended September 30,
20232022
Total fair value of shares vested$1,001 $853 
Weighted average estimated fair value of shares granted$2.10 $1.23 

Valuation Assumptions
The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Note 12 – Income Taxes
In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.
As of December 31, 2021, the Company had approximately $281.0 million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $168.8 million of the $281.0 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112.3 million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173 thousand under Internal Revenue Code Section 382.
As of December 31, 2022, the Company had approximately $34.0 million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an
21
ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0 million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations.
As of December 31, 2022, Cend Therapeutics had approximately $10.9 million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $10.7 million of Federal and $15.0 million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years. Using a fair market value of $36.1 million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $106 thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. Cend’s wholly owned Australian subsidiary has $1.8 million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.
As of December 31, 2022 and 2021, the Company had State NOLs available in New Jersey of $35.5 million and $97.0 million, respectively, California of $10.0 million and $69.5 million, respectively, and New York City of $1.9 million and $13.0 million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.
The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.
As of December 31, 2022 and 2021, the Company’s uncertain tax positions were $344 thousand and $0, respectively. Due to the acquisition of Cend, the Company’s uncertain tax positions increased by $344 thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of September 30, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.
For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from the date of filing.
On April 5, 2023, the Company received final approval from the New Jersey Economic Development Authority (“NJEDA”) under the Technology Business Tax Certificate Transfer Program (“Program”) to sell a percentage of its New Jersey net operating losses (“NJ NOLs”), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2 million. The $2.3 million of NJ NOLs related tax benefits has been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).
On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts & Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company’s results of operations for the year ended December 31, 2022. The Company will continue to monitor the future impact of changes in tax legislation.

Note 13 – Australia Research and Development Tax Incentive

The Company’s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the nine months ended September 30, 2023, $0.5 million was recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed. On
22
September 4, 2023 the Company's Australian subsidiary received a $0.6 million tax refund from the Australian Taxation Office related to the 2022 tax year.
Note 14 – Contingencies
Contingencies
From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.
In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (“Lingmed”) claiming Lingmed was entitled to a success fee based on Cend’s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend’s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend’s response on July 11, 2022. At a Case Management Conference held on August 4, 2023, the Court set a trial date in the matter for August 2, 2024. The Company denies these allegations made by Lingmed and intends to vigorously defend itself.

Note 15 – Technology Transfer Agreement
Impilo Therapeutics
In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (“Impilo”) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 in connection with the Sanford Burnham Prebys license agreement (Note 16) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company.

Note 16 – License Agreements
Sanford Burnham Prebys
In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (“SBP”) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend’s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6 million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company’s pre-seed preferred stock in Impilo on October 3, 2023.
The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days’ prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.
23
In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2 million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. On September 14, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.
SBP owned 382,030 shares of the Company’s common stock as of September 30, 2023 and is a related party.
University of California at San Diego
In March 2021, Cend entered into a license agreement with the University of California at San Diego (“UCSD”) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2 million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached.
The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days’ prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.
On August 2, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.
Massachusetts Institute of Technology
In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0 million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3 million.
The agreement expires upon the expiration or abandonment of all valid claims. The agreement may be earlier terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may also be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.
On June 30, 2023, in accordance with the provisions of the license agreement, the Company provided notice to MIT that the license agreement would terminate effective December 30, 2023. Until such date, the license remains in full force and effect.
MIT owned 43,236 shares of the Company’s common stock as of September 30, 2023.
24

Note 17 – Research Collaboration and License Agreement
Exclusive License and Collaboration Agreement
In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the “Qilu Agreement”) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10 million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5 million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95 million and $125 million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.
Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.

25
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Cautionary Note Regarding Forward-Looking Statements” herein and under “Risk Factors” in our 2022 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2022 Form 10-K.
Overview
We are a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Our lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment (“TME”), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability, and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. We are exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, we have development programs based on our autologous CD34+ cell therapy technology platform that we are seeking to partner while incurring no additional capital outlay.
Our leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Our goal is to develop and commercialize products that address important unmet medical needs. Our current development pipeline includes our product candidate LSTA1, which is the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including, metastatic pancreatic ductal adenocarcinoma (mPDAC) and other forms of pancreatic cancer, cholangiocarcinoma, esophageal cancer, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.
Targeted Solid Tumor Penetration via CendR Active Transport
Many solid tumor cancers, including pancreatic ductal adenocarcinoma (“PDAC”), are surrounded by dense fibrotic tissue, or stroma. This limits the efficacy of current chemotherapies for these cancers. Emerging immunotherapy treatments, including checkpoint inhibitors, adoptive cell therapies such as chimeric antigen receptor T (“CAR-T”) cells, as well as nucleic acid-based therapies, such as short interfering RNA (“siRNA”), antisense oligonucleotides (“ASO”), and messenger RNAs (“mRNAs”) also face challenges in penetrating solid tumors. Many tumors also exhibit an immunosuppressive tumor microenvironment (“TME”), which suppresses patients’ immune systems’ ability to fight their cancer and can limit effectiveness of immunotherapies and/or contribute to metastases. These factors negatively impact the ability of many therapeutic agents to effectively treat these cancers.
To address the tumor stroma’s role as a primary impediment to effective treatment, our approach is to activate the C-end rule (“CendR”), or CendR system, a naturally occurring active transport system. Our lead investigational drug, LSTA1 (a specific internalizing R-G-D or iRGD peptide), activates this transport system in a tumor-specific manner (Sugahara, Science, 2010). LSTA1 enables more selective and efficient uptake of systemically administered anti-cancer drugs resulting in more intratumoral drug accumulation. The overall result is enhanced anticancer activity without an increase in side effects. While it is possible to couple/tether or conjugate some anticancer drugs to LSTA1, we believe that the co-administration approach is an advantage because it does not create a new chemical entity with its attendant development and regulatory hurdles, thereby providing an anticipated faster-to-clinic and faster-to-market product opportunity for a range of co-administration therapies.
LSTA1 has demonstrated favorable safety/tolerability and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for mPDAC. LSTA1’s cancer-targeted delivery may enable such emerging treatment modalities to treat a range of solid tumors potentially more effectively.


26

LSTA1 as a treatment for solid tumor cancers in combination with other anti-cancer agents
LSTA1 is an investigational drug that actuates the CendR active transport mechanism while also having the potential to modify the TME and make it less immunosuppressive, thereby making the tumor more susceptible to attack by the immune system and/or inhibiting the metastasis cascade. It is targeted to tumor vasculature, endothelial cells, tumor cells and some intratumoral immunosuppressive cells by its affinity for alpha-v, beta-3 and beta-5 integrins that are upregulated on these cells. LSTA1 is a nine amino acid cyclic internalizing RGD (“iRGD”) peptide that, once bound to these integrins, is cleaved by proteases expressed in tumors to release a peptide fragment, called a CendR fragment. The CendR fragment then binds to an adjacent receptor, called neuropilin-1 receptor, to activate a novel uptake pathway that allows circulating moieties such as anticancer drugs to more selectively and effectively penetrate solid tumors. The ability of LSTA1 to modify the TME to enhance delivery and efficacy of co-administered drugs has been demonstrated in many preclinical models in a range of solid tumors with the results from Lisata, collaborators and research groups around the world having been the subject of over 300 related scientific publications.
With regard to clinical development, LSTA1 is the subject of a completed Phase 1b clinical trial of 31 first-line metastatic pancreatic ductal adenocarcinoma patients, of which 29 were evaluable. Results from the trial showed that the safety profile of the LSTA1 combination regimen was similar to standard of care (“SoC”) alone with LSTA1 being well-tolerated with no-dose limiting toxicities. An Objective Response Rate (“ORR”) of fifty nine percent was observed, including a rare complete response, which compares favorably to the twenty three percent ORR observed in the “MPACT” clinical trial that served as the basis for approval of nab-paclitaxel for use in combination with gemcitabine for the treatment of first line, metastatic pancreatic ductal adenocarcinoma (Von Hoff, et al. 2013). A Disease Control Rate (“DCR”); (partial and complete responses plus stable disease) of over seventy nine percent was observed in comparison to a DCR of forty eight percent observed in the MPACT trial. Reduction in the level of circulating tumor biomarker CA19-9 was observed in 96% of patients versus 61% in the MPACT trial. Importantly, median progression-free survival and median overall survival of nearly ten months and over thirteen months were observed, respectively, vs. less than six months and less than nine months, respectively, in the MPACT trial. These results have been published in The Lancet Gastroenterology and Hepatology (Dean, et al. 2022).
Additionally, LSTA1 is the subject of multiple ongoing and planned clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens. The following diagram summarizes these studies.
Slide1.jpg


27

Slide2.jpg


Ischemic Repair (CD34+ Cell Technology)
The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.
Our proprietary cell technology using autologous (a patient’s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, we seek to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. We believe that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology, including, but not limited to, Buerger's disease, critical limb ischemia (“CLI”), coronary microvascular dysfunction (“CMD”), refractory angina, and diabetic kidney disease (“DKD”).
HONEDRA® for Treatment of Critical Limb Ischemia
Our randomized, open-label, registration-eligible study of HONEDRA® in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA® study's enrollment, however, was significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that persisted for much of 2020, 2021, and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, we suspended further enrollment in the fourth quarter of 2021. Following study suspension, we completed all protocol-defined patient observations and completed the clinical study report. Data from the follow-up of all patients completed in the registration-eligible clinical trial in Japan have been compiled and are the subject of discussions with the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan as part of the Japanese regulatory pre-consultation process and in preparation for the formal clinical consultation meetings which precede a Japanese new drug application (“JNDA”). To date, the PMDA has provided advice on how to prepare for the formal consultation meeting and has indicated their preference for additional clinical information to accompany the filing of a JNDA. Concomitantly, the Company has reinforced its efforts to secure a Japanese partner to complete the remaining steps of development/registration as well as eventual commercialization in Japan.
28
Merger with Cend Therapeutics, Inc. and Name Change
On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (“Caladrius”), completed its acquisition of Cend Therapeutics, Inc. (“Cend”), a Delaware corporation (the “Merger”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (“Merger Sub”).
Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the “Effective Time”): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc. in connection with and immediately following to the Effective Time, and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (“Reverse Stock Split”) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata’s common stock based on an exchange ratio of 0.5338 (the “Exchange Ratio”), after taking into account the Reverse Stock Split. In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.
Pursuant to the Merger Agreement, we assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the “Cend Plan”), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata’s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, we assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock.
Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team has more individuals on the management team and will hold the CEO, CMO and other senior management roles; (iii) Caladrius paid a premium to acquire Cend’s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). Cend’s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&D with no alternative future use being expensed. The prior reported operating results prior to the Merger close are those of Caladrius.
Additional Out-licensing Opportunities
Our broad intellectual property portfolio of assets includes notable programs available for out-licensing in order to augment or continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.










29
Results of Operations
Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022
The following table summarizes our results of operations for the three months ended September 30, 2023 and September 30, 2022 (in thousands):
 Three Months Ended September 30,
 20232022Change
Operating Expenses:
  Research and development$3,380 $3,335 $45 
  In-process research and development— 30,393 (30,393)
  General and administrative2,584 3,992 (1,408)
     Total operating expenses5,964 37,720 (31,756)
  Loss from operations(5,964)(37,720)31,756 
Total other income (expense)703 337 366 
Benefit from income taxes— — — 
  Net loss$(5,261)$(37,383)$32,122 
 Overall, net losses were $5.3 million for the three months ended September 30, 2023, compared to $37.4 million for the three months ended September 30, 2022.
Operating Expenses
For the three months ended September 30, 2023, operating expenses totaled $6.0 million, compared to $37.7 million for the three months ended September 30, 2022, representing a decrease of 84.2%. Excluding the in-process research and development expense of $30.4 million relating to the Merger, operating expenses decreased by $1.4 million, or 18.6% compared to the three months ended September 30, 2022. Operating expenses comprised the following: 
•Research and development expenses were approximately $3.4 million for the three months ended September 30, 2023, compared to $3.3 million for the three months ended September 30, 2022, representing an increase of $45.0 thousand or 1.3%. This was primarily due to expenses associated with our study activities in the current year for our LSTA1 Phase 2a proof-of-concept Bolster trial in various solid tumors in combination with the corresponding standards of care, enrollment activities for the LSTA1 Phase 2b ASCEND study, chemistry, manufacturing and control (“CMC”) activities for LSTA1 and study start up activities for the LSTA1 Phase 2a study for the treatment of glioblastoma multiforme being offset by expenses associated with our Ischemic Repair programs (XOWNA® Phase 2b study, HONEDRA® and diabetic kidney disease) in the prior year.
•General and administrative expenses were approximately $2.6 million for the three months ended September 30, 2023, compared to $4.0 million for the three months ended September 30, 2022, representing a decrease of $1.4 million or 35.3%. This was primarily due to non-recurring merger related costs in the prior year, a decrease in equity expense due to prior year performance stock unit vesting, Merger option assumption expense and departing board member restricted stock unit vesting and timing of our annual stockholder meeting versus the prior year.
Historically, to minimize our use of cash, we have used a variety of equity instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.
30
Other Income (Expense)
Total other income (expense) is comprised primarily of investment income from cash, cash equivalents and marketable securities for both three months ended September 30, 2023 and 2022.

Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022
The following table summarizes our results of operations for the nine months ended September 30, 2023 and September 30, 2022 (in thousands):
 Nine Months Ended September 30,
 20232022Change
Operating Expenses:
  Research and development$9,721 $9,853 $(132)
  In-process research and development— 30,393 (30,393)
  General and administrative9,962 10,815 (853)
     Total operating expenses19,683 51,061 (31,378)
  Loss from operations(19,683)(51,061)31,378 
Total other income (expense)1,878 347 1,531 
Benefit from income taxes(2,330)(2,479)(149)
  Net loss$(15,475)$(48,235)$32,760 
 Overall, net losses were $15.5 million for the nine months ended September 30, 2023, compared to $48.2 million for the nine months ended September 30, 2022.
Operating Expenses
For the nine months ended September 30, 2023, operating expenses totaled $19.7 million compared to $51.1 million for the nine months ended September 30, 2022, representing a decrease of 61.5%. Excluding the in-process research and development expense of $30.4 million relating to the Merger, operating expenses decreased by $1.0 million, or 4.8% compared to the nine months ended September 30, 2022. Operating expenses comprised the following: 
•Research and development expenses were approximately $9.7 million for the nine months ended September 30, 2023, compared to $9.9 million for the nine months ended September 30, 2022, representing a decrease of $0.1 million or 1.3%. This was primarily due to expenses associated with our study activities in the current year for our LSTA1 Phase 2a proof-of-concept Bolster trial in various solid tumors in combination with the corresponding standards of care, enrollment activities for the LSTA1 Phase 2b ASCEND study, chemistry, manufacturing and control (“CMC”) activities for LSTA1 and study start up activities for the LSTA1 Phase 2a study for the treatment of glioblastoma multiforme being offset by expenses associated with our Ischemic Repair programs (XOWNA® Phase 2b study, HONEDRA® and diabetic kidney disease) in the prior year.
•General and administrative expenses were approximately $10.0 million for the nine months ended September 30, 2023, compared to $10.8 million for the nine months ended September 30, 2022, representing a decrease of $0.9 million or 7.9%. This was primarily due to non-recurring Merger related costs in the prior year, a decrease in equity expense due to prior year performance stock unit vesting, Merger option assumption expense and departing board member restricted stock unit vesting, lower annual stockholder meeting expenses and a decrease in directors and officers insurance premiums, partially offset by severance costs associated with the elimination of the Chief Business Officer position on May 1, 2023.
Historically, to minimize our use of cash, we have used a variety of equity instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.
31
Other Income (Expense)
Total other income (expense) is comprised of investment income from cash, cash equivalents and marketable securities for both nine months ended September 30, 2023 and 2022 and a loss on sale related to the sale of our NJ NOLs in the nine months ended September 30, 2023 and 2022.
Income Tax Benefit
In April 2023, we received final approval from the NJEDA under the Program to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2 million. The $2.3 million of our NJ NOL Tax Benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).
In February 2022, we received final approval from the NJEDA under the Program to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3 million. The $2.5 million of our NJ NOL Tax Benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).
32
Analysis of Liquidity and Capital Resources
As of September 30, 2023, we had cash, cash equivalents and marketable securities of approximately $54.4 million, working capital of approximately $52.1 million, and stockholders’ equity of approximately $53.0 million.
During the nine months ended September 30, 2023, we met our immediate cash requirements through existing cash balances. Additionally, we used equity and equity-linked instruments to pay for services and compensation.
Net cash (used in) or provided by, operating, investing and financing activities were as follows (in thousands): 
 Nine Months Ended September 30,
 20232022
Net cash used in operating activities$(15,963)$(14,702)
Net cash provided by investing activities15,816 21,805 
Net cash provided by (used in) financing activities361 (238)
 
Operating Activities
Our cash used in operating activities during the nine months ended September 30, 2023 was $16.0 million, which is comprised of (i) our net loss of $15.5 million, adjusted for non-cash expenses totaling $1.0 million (which includes adjustments for equity-based compensation, depreciation and amortization, a loss on disposal of fixed assets, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $1.5 million.
Our cash used in operating activities during the nine months ended September 30, 2022 was $14.7 million, which is comprised of (i) our net loss of $48.2 million, adjusted for non-cash expenses totaling $33.5 million (which includes adjustments for equity-based compensation, depreciation and amortization, in process research and development expenses, and amortization/accretion of marketable securities) and (ii) changes in operating assets and liabilities providing approximately $0.1 million.
Investing Activities
Our cash provided by investing activities during the nine months ended September 30, 2023 totaled $15.8 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities).
Our cash provided by investing activities during the nine months ended September 30, 2022 totaled $21.8 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities) partially offset by the asset acquisition costs, net of cash acquired related to the Merger and purchase of property and equipment.
Financing Activities
Our cash provided by financing activities during the nine months ended September 30, 2023 totaled $0.4 million and consisted of proceeds from the issuance of shares through our ATM Agreement (as defined below) of $0.3 million, option exercise proceeds of $0.2 million partially offset by tax withholding-related payments of $0.1 million on net share settlement equity awards to employees.
Our cash used in financing activities during the nine months ended September 30, 2022 totaled $0.2 million and consisted primarily of tax withholding-related payments on net share settlement equity awards to employees.
Liquidity and Capital Requirements Outlook
To meet our short and long-term liquidity needs, we expect to use existing cash balances, marketable securities and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of pharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand and marketable securities will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements. Our future capital requirements are difficult to forecast and will depend on many factors including the timing and nature of any other strategic transactions that we undertake;
33
and our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and the financial terms of such agreements.
On June 4, 2021, we entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC as sales agent, in connection with an “at the market offering” under which we from time to time may offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. Since inception we have issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.
While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable.

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Critical Accounting Policies and Estimates
There have been no material changes in our critical accounting policies and estimates during the three and nine months ended September 30, 2023, compared to those reported in our 2022 Form 10-K.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
ITEM 4.  CONTROLS AND PROCEDURES
(a)  Disclosure Controls and Procedures
Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer, who serves as our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.
As of September 30, 2023, we evaluated, with the participation of our management, including our Chief Executive Officer, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.
34
(b)  Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


35
PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS
Other than as disclosed in “Note 14 – Contingencies” set forth in the Notes to Unaudited Consolidated Financial Statements, which are included herein, there are no material changes to the disclosures previously reported in our 2022 Form 10-K.
ITEM 1A. RISK FACTORS
There have been no material changes to the risk factors previously reported in our 2022 Form 10-K. See the risk factors set forth in our 2022 Annual Report on Form 10-K under the caption “Item 1A - Risk Factors.”

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
None.

ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.

ITEM 5. OTHER INFORMATION
None.

ITEM 6. EXHIBITS
The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.
36
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
   
  LISATA THERAPEUTICS, INC.
November 2, 2023 
By: /s/ David J. Mazzo, PhD
Name: David J. Mazzo, PhD
Title: President & Chief Executive Officer
(Principal Executive Officer, Principal Financial Officer
 and Principal Accounting Officer)





37
LISATA THERAPEUTICS, INC.
FORM 10-Q

Exhibit Index
*Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
**Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCHInline XBRL Taxonomy Extension Schema
101.CALInline XBRL Taxonomy Extension Calculation Linkbase
101.DEFInline XBRL Taxonomy Extension Definition Linkbase
101.LABInline XBRL Taxonomy Extension Label Linkbase
101.PREInline XBRL Taxonomy Extension Presentation Linkbase
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
_______________
*Filed herewith.
**Furnished herewith.
38
EX-31.1 2 lsta-ex311_20230930.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATIONS UNDER SECTION 302
 
I, David J. Mazzo, PhD, certify that:
 
1.  I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
 
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 2, 2023

/s/ David J. Mazzo, PhD    
Name: David J. Mazzo, PhD
Title: President & Chief Executive Officer
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

 EX-32 3 lsta-ex32_20230930.htm EX-32 Document

Exhibit 32
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the “Company”) for the quarter ended September 30, 2023 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David J. Mazzo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.
 
Dated:  November 2, 2023
 
 /s/ David J. Mazzo, PhD
 David J. Mazzo, PhD
 President & Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
 
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.
 



 EX-101.SCH 4 lsta-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - The Business link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Merger link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Available-for-Sale-Securities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Australia Research and Development Tax Incentive link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Technology Transfer Agreement link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Research Collaboration and License Agreement link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Merger (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Available-for-Sale-Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - The Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Merger - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Merger (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Operating Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Operating Leases - Balance Sheet Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Stockholders' Equity - Equity Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Australia Research and Development Tax Incentive (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Technology Transfer Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Research Collaboration and License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 lsta-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 lsta-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 lsta-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Percentage held by non-affiliates Sale of Stock Available for Sale, Percentage Sale of Stock Available for Sale, Percentage Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Award Type [Domain] Award Type [Domain] Investment, Name [Domain] Investment, Name [Domain] Warrants, Vested and expected to vest (in shares) shares, vested and expected to vest shares, vested and expected to vest Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Available-for-sale Securities Reconciliation Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Long-lived Assets Property, Plant and Equipment, Impairment [Policy Text Block] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Accounts payable Accounts Payable, Current Computer equipment Computer Equipment [Member] Investment, Name [Axis] Investment, Name [Axis] Corporate debt securities Corporate Debt Securities [Member] Total other income (expense) Nonoperating Income (Expense) Commitments and Contingencies (Note 14) Commitments and Contingencies Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Stockholders' Equity Equity [Text Block] Options, Vested and expected to vest, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Option to terminate Research Collaboration and License Agreement, Option to Terminate Research Collaboration and License Agreement, Option to Terminate Income Taxes Income Tax Disclosure [Text Block] Warrants, Vested, Weighted Average Exercise Price (in dollars per share) Weighted Average Exercise Price, Warrants Exercisable Weighted Average Exercise Price, Warrants Exercisable Leases Lessee, Leases [Policy Text Block] Income Tax Holiday [Line Items] Income Tax Holiday [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) Earnings Per Share, Diluted Schedule of Investments [Table] Schedule of Investments [Table] Issuance of common stock in connection with Merger Stock Issued During Period, Value, New Issues Related to Merger Stock Issued During Period, Value, New Issues Related to Merger Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Options, Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock (in shares) Treasury Stock, Common, Shares Options, Outstanding, Beginning of Period (in shares) Options, Outstanding, End of Period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Proceeds from option exercises Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Options, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Marketable securities - available for sale Investments, Fair Value Disclosure Sublicensing fee Collaborative Arrangement, Rights and Obligations, Sublicensing Fees Collaborative Arrangement, Rights and Obligations, Sublicensing Fees Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Weighted average estimated fair value of shares granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss attributable to Lisata Therapeutics, Inc. common stockholders Net Income (Loss) Total current liabilities Liabilities, Current Shares canceled (in shares) Investment Owned, Canceled, Shares Investment Owned, Canceled, Shares Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Foreign Currency Remeasurement Foreign Currency Transactions and Translations Policy [Policy Text Block] Operating Leases Lessee, Operating Leases [Text Block] Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share) Weighted Average Exercise Price, Warrants Vested And Expected To Vest Weighted Average Exercise Price, Warrants Vested And Expected To Vest Shares issued (in shares) Shares, Issued LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Warrants, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term warrant outstanding Weighted Average Remaining Contractual Term warrant outstanding Stockholders' Equity Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Contract with customer, liability Contract with Customer, Liability Proceeds from option exercises (in shares) Options, Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Annual license maintenance fee Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Vesting term Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Schedule of Total Compensation Cost Related to Nonvested Awards Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Warrants, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Options, Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Statement, Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Asset Acquisition [Domain] Asset Acquisition [Domain] Entity Small Business Entity Small Business Expected amortization, year four Finite-Lived Intangible Asset, Expected Amortization, Year Four Less than one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year Local Phone Number Local Phone Number In process research and development expenses Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Available for sale securities - net unrealized gain OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Frequency [Axis] Measurement Frequency [Axis] Warrants Warrant [Member] Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Investments Classified by Contractual Maturity Date Investments Classified by Contractual Maturity Date [Table Text Block] Change of control fee Collaborative Arrangement, Rights and Obligations, Change of Control Fee Collaborative Arrangement, Rights and Obligations, Change of Control Fee Restricted stock units Restricted Stock Units (RSUs) [Member] Depreciation Depreciation Schedule of Marketable Securities Marketable Securities [Table Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Research tax credit rate Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Research and development Research and Development Expense (Excluding Acquired in Process Cost) Technology Transfer Agreement [Abstract] Technology Transfer Agreement Schedule of Future Minimum Lease Payments Under Lease Agreements Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Potential milestone payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product Other liabilities Asset Acquisition, Other Liabilities Asset Acquisition, Other Liabilities Asset Acquisition Asset Acquisition [Table Text Block] Product and Service [Domain] Product and Service [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Total fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Award Type [Axis] Award Type [Axis] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document Quarterly Report Document Quarterly Report Revenue from collaborative arrangement Revenue from contract Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Shares held by third party (in shares) Shares Held by Third Party Shares Held by Third Party Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative General and Administrative Expense [Member] Property and equipment, gross Property, Plant and Equipment, Gross Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Income tax incentive receivable Income Tax Incentive Receivable Income Tax Incentive Receivable Expected amortization, remainder of fiscal year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Less: Amounts representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] Debt Securities, Available-for-sale [Abstract] Debt Securities, Available-for-Sale [Abstract] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating lease liabilities — current Operating lease liabilities, current Operating Lease, Liability, Current License License [Member] California California Franchise Tax Board [Member] Warrants, Granted (in shares) Warrants Granted Warrants Granted Software Computer Software, Intangible Asset [Member] Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Acquired license - intangible Finite-Lived Intangible Assets, Net Warrants Outstanding, Beginning of Period (in dollars per share) Warrants Outstanding, End of Period (in dollars per share) Weighted Average Exercise Price, Warrants Outstanding Weighted Average Exercise Price, Warrants Outstanding Counterparty Name [Domain] Counterparty Name [Domain] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Fair Value of Share-based Compensation Awards Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Treasury stock, at cost; 738 shares at September 30, 2023 and December 31, 2022 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Assets, fair value disclosure Assets, Fair Value Disclosure Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] General and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax License Agreements Research Collaboration and License Agreement Collaborative Arrangement Disclosure [Text Block] Stock options Employee Stock Option [Member] Right-of-Use Assets: Operating Lease, Right-Of-Use Asset [Abstract] Operating Lease, Right-Of-Use Asset Expected weighted-average period in years of compensation cost to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Asset Acquisition [Table] Asset Acquisition [Table] Maximum Maximum [Member] Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Caladrius Caladrius [Member] Caladrius Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Cash equivalents Cash Equivalents, at Carrying Value Document Type Document Type Federal Domestic Tax Authority [Member] Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Entity Address, Address Line One Entity Address, Address Line One Operating loss carryforwards subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Merger Asset Acquisition [Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Exclusive License and Collaboration Agreement Exclusive License and Collaboration Agreement [Member] Exclusive License and Collaboration Agreement Share-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Stock Options, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Operating loss carryforwards, post acquisition Operating Loss Carryforwards, Post Acquisition Operating Loss Carryforwards, Post Acquisition Subsequent event Subsequent Event [Member] Net operating loss carryforwards Operating Loss Carryforwards Investment owned (in shares) Investment Owned, Balance, Shares Warrants Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants Outstanding Aggregate Intrinsic Value, Warrants Outstanding Income Statement [Abstract] Income Statement [Abstract] Net proceeds from issuances of common stock (in shares) Stock issued (in shares) Stock Issued During Period, Shares, New Issues Options, Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Asset Acquisition [Line Items] Asset Acquisition [Line Items] Treasury Stock Stockholders' Equity, Policy [Policy Text Block] Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Incremental fair value of Cend's fully vested stock options assumed Liabilities Assumed ATM Agreement At The Market Offering Agreement [Member] At The Market Offering Agreement Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Purchase of marketable securities Payments to Acquire Marketable Securities Warrants, Outstanding, Beginning of Period (in shares) Warrants, Outstanding, End of Period (in shares) Common Stock Warrants, Shares Common Stock Warrants, Shares Statistical Measurement [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Net working capital (excluding cash) Asset Acquisition, Net Working Capital Asset Acquisition, Net Working Capital Issuance of common stock in connection with Merger (in shares) Stock Issued During Period, Shares, New Issues Related to Merger Stock Issued During Period, Shares, New Issues Related to Merger Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Schedule of Available-for-sale Securities [Table] Debt Securities, Available-for-Sale [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Greater than one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost Total Lisata Therapeutics, Inc. Stockholders' Equity Parent [Member] NOL annual limitation Net Carryforward Operating Loss Carryforward Annual Limitation Net Carryforward Operating Loss Carryforward Annual Limitation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Number of shares issued (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Annual license maintenance fee, year four Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four Leases [Abstract] Leases [Abstract] Basic and diluted loss per share EPS [Abstract] EPS Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Income Tax Holiday [Table] Income Tax Holiday [Table] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Warrants, Weighted Average Contractual Term and Intrinsic Value Warrants Other Disclosures [Abstract] Warrants Other Disclosures Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Expected amortization, year one Finite-Lived Intangible Asset, Expected Amortization, Year One Unrealized gain on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock outstanding (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Number of common shares of the combined company owned by Cend stockholders (in shares) Common Stock, Shares, Outstanding Concentration of Risks Concentration Risk, Credit Risk, Policy [Policy Text Block] Percentage of ownership after transaction Sale of Stock, Percentage of Ownership after Transaction Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Treasury bills US Treasury Bill Securities [Member] Greater than one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value Stock Options, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Technology Transfer Agreement Technology Transfer Agreement [Text Block] Technology Transfer Agreement Effective income tax rate reconciliation Effective Income Tax Rate Reconciliation, Percent Operating lease liabilities Present value of lease liabilities Operating Lease, Liability Options, Vested, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value In-process research and development In-Process Research and Development In-Process Research and Development Total liabilities Liabilities New York New York State Division of Taxation and Finance [Member] Asset Acquisition [Axis] Asset Acquisition [Axis] Options, Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Total Cash, Cash Equivalents, and Short-Term Investments Measurement Frequency [Domain] Measurement Frequency [Domain] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Shares issued under license agreement (in shares) Shares Issued Under License Agreement Shares Issued Under License Agreement Earnings Per Share [Abstract] Earnings Per Share [Abstract] Sale of stock available for sale Sale of Stock Available for Sale Sale of Stock Available for Sale Research and Development Costs Research, Development, and Computer Software, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,140,187 and 7,866,799 shares at September 30, 2023 and December 31, 2022, respectively; and outstanding, 8,139,449 and 7,866,061 shares at September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Total Asset Acquisition, Consideration Transferred, Equity Value Asset Acquisition, Consideration Transferred, Equity Value Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Operating lease liabilities, noncurrent, balance sheet line item Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Total current assets Assets, Current Annual license maintenance fee, year seven Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven Investment income, net Investment Income, Net Loss on sale of NOL Loss On Sale of NOL Loss On Sale of NOL Share-based compensation Issuance of Stock and Warrants for Services or Claims Supplemental disclosure of noncash investing activities: Supplemental Cash Flow Information [Abstract] Other expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Warrants, Exercised (in dollars per share) Weighted Average Exercise Price, Warrants Exercised Weighted Average Exercise Price, Warrants Exercised Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Loss Per Share Earnings Per Share, Policy [Policy Text Block] Unrecognized tax benefits, increase resulting from acquisition Unrecognized Tax Benefits, Increase Resulting from Acquisition Unrecognized tax benefits Unrecognized Tax Benefits Available-for-Sale-Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Income Tax Authority [Axis] Income Tax Authority [Axis] Options, Vested, Weighted Average Remaining Contractual Term Options, Vested, weighted Average Remaining Contractual Term Options, Vested, weighted Average Remaining Contractual Term Warrants, Expired (in shares) Warrants Expired Warrants Expired Weighted average estimated fair value (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Warrants, Exercised (in shares) Warrants Exercised Warrants Exercised Options, Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Impilo Impilo [Member] Impilo Other Other Accrued Liabilities, Current Furniture and fixtures Furniture and Fixtures [Member] Royalties, net of sales Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total Lisata Therapeutics, Inc. stockholders' equity Equity, Attributable to Parent Commercial paper Commercial Paper [Member] Warrants, Vested (in shares) Warrants, Vested Warrants, Vested Restricted Stock Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance Minimum Lease Payments Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Cumulative translation adjustment arising during the period Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Net loss before benefit from income taxes and noncontrolling interests Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest The Business The Business [Text Block] The Business [Text Block] Municipal debt securities US States and Political Subdivisions Debt Securities [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Warrants, Vested, Weighted Average Remaining Contractual Term weighted Average Remaining Contractual Term, warrants vested weighted Average Remaining Contractual Term, warrants vested Entity Emerging Growth Company Entity Emerging Growth Company Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Carrying value of Lisata's cost method investment in Cend Payments to Acquire Productive Assets Intangible assets, net Intangible Assets, Net (Excluding Goodwill) New Jersey New Jersey Division of Taxation [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Less - net income attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Antidilutive Securities [Axis] Antidilutive Securities [Axis] Options, Outstanding. Beginning of Period (in dollars per share) Options, Outstanding, End of Period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common Stock Common Stock [Member] Foreign Tax Authority Foreign Tax Authority [Member] Income tax refunds Proceeds from Income Tax Refunds Options, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income (Loss) Per Share Earnings Per Share [Text Block] Total share-based compensation expense Income Statement Location [Domain] Royalty Royalty [Member] Document Fiscal Year Focus Document Fiscal Year Focus Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Total stockholders' equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest University of California at San Diego University of California at San Diego [Member] University of California at San Diego CEND CEND [Member] CEND Minimum Minimum [Member] Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Schedule of Stock Option and Warrants Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Warrants, Expired (in dollars per share) Weighted Average Exercise Price, Warrants Expired Weighted Average Exercise Price, Warrants Expired Incremental fair value of Cend's fully vested stock options Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Tax withholding payments on net share settlement equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Liabilities Liabilities [Abstract] Right-of-use assets, balance sheet line item Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Schedule of Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Contingencies Commitments and Contingencies Disclosure [Text Block] Warrants, Forfeited (in shares) Warrants Canceled Warrants Canceled Percentage of sublicensing revenues Revenue, Performance Obligation, Percentage of Sublicensing Revenues Revenue, Performance Obligation, Percentage of Sublicensing Revenues Accumulated Deficit Retained Earnings [Member] License Asset Acquisition, Intangibles Asset Acquisition, Intangibles Less than one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year Schedule Share-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Amortization/accretion on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities, non-controlling interests and stockholders' equity Liabilities and Equity Australian Taxation Office Australian Taxation Office [Member] Cost Debt Securities, Available-for-Sale, Amortized Cost Other income (expense): Nonoperating Income (Expense) [Abstract] Other assets Other Assets, Noncurrent Percentage of net sale Revenue, Performance Obligation, Percentage of Net Sale Revenue, Performance Obligation, Percentage of Net Sale Right-of-use assets Operating Lease, Right-of-Use Asset Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Sale of Stock, Name of Transaction [Domain] Sale of Stock [Domain] 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Entity Address, City or Town Entity Address, City or Town Issuance of common stock in connection with merger Stock Issued Options, Vested and expected to vest, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options, Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Principles of Consolidation Consolidation, Policy [Policy Text Block] Investments in and Advances to Affiliates [Line Items] Investments in and Advances to Affiliates [Line Items] Operating lease liabilities, current, balance sheet line item Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Document Transition Report Document Transition Report Variable consideration amounts, milestones Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Fair value market of tax NOLs Fair Value Market of Tax NOLs Fair Value Market of Tax NOLs Multiplied by the fair value per share of Lisata common stock on September 15, 2022 Asset Acquisition, Share Price Asset Acquisition, Share Price Sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Common stock, shares authorized (in shares) Common Stock, Shares Authorized Estimated Fair Value Total estimated fair value Debt Securities, Available-for-Sale Aggregate offering amount authorized per agreement Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement Annual license maintenance fee, years two and three Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three Accrued Liabilities [Abstract] Accrued Liabilities [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Accounts payable, accrued liabilities and other liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Outstanding stock threshold Outstanding Stock Threshold Outstanding Stock Threshold Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Net operating loss carryforwards, prior to write down Operating Loss Carryforwards, Before Write Down Operating Loss Carryforwards, Before Write Down Common stock, value, outstanding Common Stock, Value, Outstanding Warrants, Weighted Average Exercise Price Warrants Weighted Average Exercise Price [Roll Forward] Warrants Weighted Average Exercise Price [Roll Forward] Conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Additional paid-in capital Additional Paid in Capital Annual license maintenance fee, after first sale Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale Value of shares issued Stock Issued During Period, Value, Restricted Stock Award, Gross Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from option exercises Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Milestones, Royalties Collaborative Arrangement, Accounting Policy [Policy Text Block] Options, Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid and other current assets Prepaid Expense and Other Assets, Current Expected amortization, year three Finite-Lived Intangible Asset, Expected Amortization, Year Three Accounting & tax consulting liabilities Accrued Grant Funding Accrued Grant Funding Options, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Lisata transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Share-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Other assets Increase (Decrease) in Other Operating Assets Expected amortization, year two Finite-Lived Intangible Asset, Expected Amortization, Year Two In-process Research and Development Expense In Process Research and Development, Policy [Policy Text Block] Warrants, Vested and expected to vest, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants vested and expected to vest Aggregate Intrinsic Value, Warrants vested and expected to vest Warrants, Forfeited (in dollars per share) Weighted Average Exercise Price, Warrants Canceled Weighted Average Exercise Price, Warrants Canceled Non-controlling interests Equity, Attributable to Noncontrolling Interest Warrants, Granted (in dollars per share) Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Warrants Granted Sanford Burnham Prebys Sanford Burnham Prebys [Member] Sanford Burnham Prebys Document Period End Date Document Period End Date Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Clinical and R&D related liabilities Clinical and R&D Related Liabilities Clinical and R&D Related Liabilities Massachusetts Institute of Technology Massachusetts Institute of Technology [Member] Massachusetts Institute of Technology Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Total share-based compensation expense Share-Based Payment Arrangement, Expense Benefit from income taxes Income Tax Expense (Benefit) Warrants, Vested, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants vested Aggregate Intrinsic Value, Warrants vested Asset Acquisition [Abstract] Income Tax Authority [Domain] Income Tax Authority [Domain] Salaries, employee benefits and related taxes Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Acquired in-process research and development Asset Acquisition, Acquired In-Process Research And Development Asset Acquisition, Acquired In-Process Research And Development Net proceeds from issuances of common stock Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted average remaining lease term for operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Revenue excluding taxes Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Money market funds Money Market Funds [Member] Asset acquisition costs, net of cash acquired related to merger with Cend Payments for Asset Acquisition Costs, Net Payments for Asset Acquisition Costs, Net Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted average discount rate for operating leases (percent) Operating Lease, Weighted Average Discount Rate, Percent Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Useful life Property, Plant and Equipment, Useful Life Leasehold improvements Leasehold Improvements [Member] Diluted shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Operating Expenses: Operating Expenses [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Asset Acquisition, Cash and Cash Equivalents Asset Acquisition, Cash and Cash Equivalents Options, Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Proceeds from sale of NOLs Proceeds From Sale of NOLS Proceeds From Sale of NOLS Australia Research and Development Tax Incentive Research and Development Tax Incentive [Text Block] Research and Development Tax Incentive Cover [Abstract] Cover [Abstract] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Recurring Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Total lease payments Lessee, Operating Lease, Liability, to be Paid Operating Lease Liabilities: Operating Lease, Liability [Abstract] Total purchase price Asset Acquisition, Consideration Transferred Total operating expenses Operating Expenses Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Equity Component [Domain] Equity Component [Domain] Marketable securities Marketable Securities State State and Local Jurisdiction [Member] Basic shares (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Agency bonds Bonds [Member] Operating loss Operating Income (Loss) Qilu Qilu [Member] Qilu Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block] Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Statement [Line Items] Statement [Line Items] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Options, Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Stock Options, Weighted Average Contractual Term and Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] Number of shares authorized to be repurchased (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Non- Controlling Interest in Subsidiary Noncontrolling Interest [Member] EX-101.PRE 8 lsta-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 9 lsta-20230930_g1.jpg begin 644 lsta-20230930_g1.jpg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ⅅ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

(?#7B/R] M@6..X3S!;X91*[3A&W!FRM=1110 4444 %%%% %;4/\ CSD_#^8K%K:U M#_CSD_#^8K%KHI[%QV"BBBM2@HHHH **** "BBB@ HHHH **** /GK]M[_DE M&D_]AN+_ -$3U\0U]W_MA^'=6\3?#/3+71]+O-6N4U>*5H;&W>9U00S@L54$ MXR0,^XKX]_X5'XZ_Z$OQ#_X*I_\ XBOV+A>O2IY@_M'!?\ /Z/_ ($O\SDJ*ZW_ (5'XZ_Z$OQ#_P"" MJ?\ ^(H_X5'XZ_Z$OQ#_ ."J?_XBCZU0_P"?B^]!_:."_P"?T?\ P)?YG)45 MUO\ PJ/QU_T)?B'_ ,%4_P#\11_PJ/QU_P!"7XA_\%4__P 11]:H?\_%]Z#^ MT<%_S^C_ .!+_,Y*BNM_X5'XZ_Z$OQ#_ ."J?_XBC_A4?CK_ *$OQ#_X*I__ M (BCZU0_Y^+[T']HX+_G]'_P)?YG)45UO_"H_'7_ $)?B'_P53__ !%'_"H_ M'7_0E^(?_!5/_P#$4?6J'_/Q?>@_M'!?\_H_^!+_ #/GGX]?\P/_ +;_ /M. MOK#_ (41X"^+7P5^$OA?0M&TW2?BP/#UKXDMW2VAMUUV 2;+F"63CS)-J[QO M]#R 7(\)^-'P'^)>L_V/_9_P[\5WWE^=O^S:)"[6SU=>%_!_@OX:?'KPC MIEW!#\2=+OY;9%BNKNR6".:2X" R"QO+M)%4#)C:1"V[YEVXW8_CCX1_'?XD M>+-2\2^(_AQXUU'6]1D\VZNO^$8N(O,; 7.U(54< = *G\"_"OXZ?#G6/[4T M3X5>)!?#:4EU'P0;_P IE8,KQBXMI C@@890&]Z5-2AAU2GB8OW;6NEK:WQ+ MWOP/D8W4.5U$]+?T]SU'Q3JD?P__ &F_B]X2\!?#'3]=\6ZK?'3?#K0VL3Q: M*N096AM#$T>2IQO)4( 2>-P/J_C2U\%Z;\(_&7C*TTSPKXI^,/@G0M/TS6KV MSTJ"?38KR>X*M-Y.SR99HD7;YFTJ",<@%1X]%XT_:RAU#6+^/P%K<=]K*&/4 M[I?AG:"6^4]5G;[#F0'T;-8VD']I;0=0ENM-^&.KZ"VM;V! MR"T=Q#'9JDP^7C>"5R=I&3GR9X653D;J03BHW]]^]:R:=UI%I6LM+OF=WH6ENN_\ P/+YE7]IC1]*UCX-_!;XBQZ-9:'XC\365]!JT>FV<=G!=-;3 M*B7 AC 16<,22H /' KYQKW7XC> ?V@OBMJ%C=>(OASXQG73[9;*QM+7PI/: MVMG OW8XH8H51%'L.>]C_ /#-?Q=_Z)7XU_\ "=O/_C='_#-? MQ=_Z)7XU_P#"=O/_ (W7?]C_ /#-?Q=_Z)7XU_\ M"=O/_C='_#-?Q=_Z)7XU_P#"=O/_ (W1]@]I#^9'G%%>C_ /#-?Q=_Z)7XU_\ "=O/_C='_#-?Q=_Z)7XU M_P#"=O/_ (W1]@]I#^9'G% M%>C_ /#-?Q=_Z)7XU_\ "=O/_C='_#-?Q=_Z)7XU_P#"=O/_ (W1]@]I#^9'G%%>C_ /#-?Q=_Z)7XU_\ M"=O/_C='_#-?Q=_Z)7XU_P#"=O/_ (W1]@]I#^9'G%%>C_ /#-?Q=_Z)7XU_\ "=O/_C='_#-?Q=_Z)7XU M_P#"=O/_ (W1]'KO/'1ES'U&3]03]:^D+'X>^,+^S2Y M7P9XE@1OX;K1KF%P?0JR US3Q6'O?VD?O1_%WB3P]F-'/:V/C!U*56S4DKVT M2Y7;9JVG=6MUMS6H0PW-CK72_-UUT]#SVBO0O M^&=?BO\ ]$Q\9?\ @@N__C='_#.OQ7_Z)CXR_P#!!=__ !NM?K>'_P"?D?O1 M^[>TA_,CSVBO0O\ AG7XK_\ 1,?&7_@@N_\ XW1_PSK\5_\ HF/C+_P07?\ M\;H^MX?_ )^1^]![2'\R//:*]"_X9U^*_P#T3'QE_P"""[_^-T?\,Z_%?_HF M/C+_ ,$%W_\ &Z/K>'_Y^1^]![2'\R//:*]"_P"&=?BO_P!$Q\9?^""[_P#C M='_#.OQ7_P"B8^,O_!!=_P#QNCZWA_\ GY'[T'M(?S(\]HKT+_AG7XK_ /1, M?&7_ ((+O_XW1_PSK\5_^B8^,O\ P07?_P ;H^MX?_GY'[T'M(?S(\]HKT+_ M (9U^*__ $3'QE_X(+O_ .-T?\,Z_%?_ *)CXR_\$%W_ /&Z/K>'_P"?D?O0 M>TA_,CSVBO0O^&=?BO\ ]$Q\9?\ @@N__C='_#.OQ7_Z)CXR_P#!!=__ !NC MZWA_^?D?O0>TA_,CSVBO0O\ AG7XK_\ 1,?&7_@@N_\ XW1_PSK\5_\ HF/C M+_P07?\ \;H^MX?_ )^1^]![2'\R//:*]"_X9U^*_P#T3'QE_P"""[_^-T?\ M,Z_%?_HF/C+_ ,$%W_\ &Z/K>'_Y^1^]![2'\R//:*]"_P"&=?BO_P!$Q\9? M^""[_P#C='_#.OQ7_P"B8^,O_!!=_P#QNCZWA_\ GY'[T'M(?S(\]HKT+_AG M7XK_ /1,?&7_ ((+O_XW1_PSK\5_^B8^,O\ P07?_P ;H^MX?_GY'[T'M(?S M(\]HKT+_ (9U^*__ $3'QE_X(+O_ .-T?\,Z_%?_ *)CXR_\$%W_ /&Z/K>' M_P"?D?O0>TA_,CSVBO0O^&=?BO\ ]$Q\9?\ @@N__C='_#.OQ7_Z)CXR_P#! M!=__ !NCZWA_^?D?O0>TA_,CSVBO0O\ AG7XK_\ 1,?&7_@@N_\ XW1_PSK\ M5_\ HF/C+_P07?\ \;H^MX?_ )^1^]![2'\R//:*]"_X9U^*_P#T3'QE_P"" M"[_^-T?\,Z_%?_HF/C+_ ,$%W_\ &Z/K>'_Y^1^]![2'\R//:*]"_P"&=?BO M_P!$Q\9?^""[_P#C='_#.OQ7_P"B8^,O_!!=_P#QNCZWA_\ GY'[T'M(?S(\ M]HKT+_AG7XK_ /1,?&7_ ((+O_XW1_PSK\5_^B8^,O\ P07?_P ;H^MX?_GY M'[T'M(?S(\]HKT+_ (9U^*__ $3'QE_X(+O_ .-T?\,Z_%?_ *)CXR_\$%W_ M /&Z/K>'_P"?D?O0>TA_,CSVBO0O^&=?BO\ ]$Q\9?\ @@N__C='_#.OQ7_Z M)CXR_P#!!=__ !NCZWA_^?D?O0>TA_,CSVBO0O\ AG7XK_\ 1,?&7_@@N_\ MXW1_PSK\5_\ HF/C+_P07?\ \;H^MX?_ )^1^]![2'\R//:*]"_X9U^*_P#T M3'QE_P"""[_^-T?\,Z_%?_HF/C+_ ,$%W_\ &Z/K>'_Y^1^]![2'\R//:*]# M7]G+XLNV%^%_C-CZ#P_=_P#QNI/^&:_B[_T2OQK_ .$[>?\ QNCZWA_^?D?O M0>TA_,CSBBO1_P#AFOXN_P#1*_&O_A.WG_QNC_AFOXN_]$K\:_\ A.WG_P ; MH^N8;_GY'[T'M(?S(\XHKT?_ (9K^+O_ $2OQK_X3MY_\;H_X9K^+O\ T2OQ MK_X3MY_\;H^N8;_GY'[T'M(?S(\XHKT?_AFOXN_]$K\:_P#A.WG_ ,;H_P"& M:_B[_P!$K\:_^$[>?_&Z/KF&_P"?D?O0>TA_,CSE69&#*2K*<@C@BOMGX ^. MM4\=>!4GU6WD%Q:O]G%XP^6Z 'WA[CH>V?Q ^==-_9K^*/\ :%N;_P"%?CO[ M$'!F%OX=NO,*]PN8\9/J>GO7O]AJ_P 4=&BT_3-)^ 7C*PTBW*1?/HUXS+$" M,X40CYL9ZDY->-F56CB(*%.46^_,M/QZGT638W#X6I*I5K**VMW_ .&/5J^N M_P!FSPS8Z9\.;'5XK66'4-44RW#7&PR* S*$&QF 7C/7//(!^4>&?!_X1-\3 M+W58[JXFTV"QC4%Q'EO-8G"D''0*V1UZ5]!?"OX::S\,IKBR_MJ'5=#FRXB> M)HI(9/[RC+#![C/H?K^4YUB:4Z3P\9VDK-K77ROMYE\79AAZU"6"A6M.+3<; M/WEO:]K=G:XS]IKQEJ'P]_9W^)'B727\K5-+\/WMU:R9QLE6%BK?4'!_"OS= M^-'@>QTKX(?L'Z-8:-IVKQZEJ-I=2Z;JAV6M_-=&UEE2X;RY/DD>5@QV/P3\ MK=*_5;QAX5T_QUX3UGPYJT7GZ7JUG-8W4?\ >BD0HP^N":^=_AG^Q?IEW\&_ M ?@WXOPP>*M4\ 74M"T+1S*BQKM!<*8P58U\,?C)\ MH>$_B%;?LN_'S]IBUU._T[X(WO\ 8UA?:?I/AO33K6A6BDV\7VB&$&W,D[-, MH53'$H,C%LJ,'MO"/[3'QWC^.T_@?2KCQ!XA?5OA]/KVBZ;\0-)TFQNY+]8W M,,B?8"JI$[*!LF;<.0V,;J^M=,_8^^$&FP^*TD\&Q:S+XJ1(]:N_$%[=:K=7 MJH5*!I[J620!2B$888**>J@C/TW]B#X):7KG]KQ>!HI;XZ8^C.UWJ%W<))9N MI0PO'),R.H4X&X$J NTC:N #Y*\'_M'>.[K1?$?@KXO>+O%VD^+M5\#ZJ&\* M^,/!=I8P7EXEM,[S:=?6OEYB"+C;*C9VMALD"O%?V?\ ]M[Q1X+^"?P\\":! M+>^!])\.Z%K&M7&KW6G1S/XFN+9YYO[.LVE1XTCP1OEQO!4JH4@;_P!)?#O[ M%WP=\+S1RV?A.6XD@TR71K5M2UB^OC967%G$S,68PV\ MTSQPDECGRU7/&>@H ^ /V6? OA;P]X]_;,UZP\*Z!%J_@K5[RX\-73:3;2-H M[Q?;6C-J&0B(*8TP% 'RCCBN>O\ XY?'S4O^"?\ J'QH\6?$;3=?.J7]O::7 MI%SX6TV1+8)>M%).Y:$H[-M90ICPH"L#DFOT9\.?LX_#OPG-\0)M*\/?99/' MTDDOB-OMMR_VYI!('/S2'R\^=)_J]N-W'08R[C]DOX4W7P3M?A'+X5W?#RVF M\^+1_P"T;L;7\YIL^=YOFG]XS-@OCG'3B@#XE^.'[8GQ#TGP?\1_%7P[\?\ MB75X/"6HV=DYL/".E6OAW3V,BQR6D\ERSW=Q+U!D@"H"1A55@1PG]F1_%*X_ M;9U;4C'::E#HVC>)+>Y@)C^S7D-LURCQMDE#N4J#G.&(S7W[XJ_8;^!OC0ZQ M_:G@"U9-8D2:_BM+RZM8[B5#E962&55\S)/[S&X[FR3N;/(?&/\ 8GTO5O W MBC0?A=;6/A#4/'4EAI_BK6KZ^N[F5M+MQM(@CIN1+<****R)"BBB@ HHHH **** ,7PWX M4L?"[:HUDFTZA>/>R\?QL!D#VX_4UM4454I2F^:3NS2I4G5DYS=V%%8?_%2? M]0O_ ,B4?\5)_P!0O_R)4F9N45A_\5)_U"__ ")1_P 5)_U"_P#R)0!N45A_ M\5)_U"__ ")1_P 5)_U"_P#R)0!N45A_\5)_U"__ ")1_P 5)_U"_P#R)0!N M45A_\5)_U"__ ")1_P 5)_U"_P#R)0!N45A_\5)_U"__ ")1_P 5)_U"_P#R M)0!N45A_\5)_U"__ ")1_P 5)_U"_P#R)0!N45A_\5)_U"__ ")1_P 5)_U" M_P#R)0!N45A_\5)_U"__ ")1_P 5)_U"_P#R)0!N45A_\5)_U"__ ")1_P 5 M)_U"_P#R)0!N45A_\5)_U"__ ")1_P 5)_U"_P#R)0!N45A_\5)_U"__ ")1 M_P 5)_U"_P#R)0!IZA_QYR?A_,5BT7W_ D7V5]W]EXXZ>9ZBLC_ (G_ /U# M?_(E=%/8N)KT5D?\3_\ ZAO_ )$H_P")_P#]0W_R)6ERC7HK(_XG_P#U#?\ MR)1_Q/\ _J&_^1*+@:]%9'_$_P#^H;_Y$H_XG_\ U#?_ ")1<#7HK(_XG_\ MU#?_ ")1_P 3_P#ZAO\ Y$HN!KT5D?\ $_\ ^H;_ .1*/^)__P!0W_R)1<#7 MHK(_XG__ %#?_(E'_$__ .H;_P"1*+@:]%9'_$__ .H;_P"1*/\ B?\ _4-_ M\B47 UZ*R/\ B?\ _4-_\B4?\3__ *AO_D2BX&O161_Q/_\ J&_^1*/^)_\ M]0W_ ,B47 UZ*R/^)_\ ]0W_ ,B4?\3_ /ZAO_D2BX&O161_Q/\ _J&_^1*/ M^)__ -0W_P B47 UZ*R/^)__ -0W_P B4?\ $_\ ^H;_ .1*+@:]%9'_ !/_ M /J&_P#D2C_B?_\ 4-_\B47 UZ*R/^)__P!0W_R)1_Q/_P#J&_\ D2BX&O16 M1_Q/_P#J&_\ D2C_ (G_ /U#?_(E%P->BLC_ (G_ /U#?_(E'_$__P"H;_Y$ MHN!U&C_\MOP_K6E7*:5_PD/[W;_9G;KYGO5__BI/^H7_ .1*YI_$0]SBLC_ (G_ /U#?_(E'_$__P"H;_Y$HN!K MT5D?\3__ *AO_D2C_B?_ /4-_P#(E%P->BLC_B?_ /4-_P#(E'_$_P#^H;_Y M$HN!KT5D?\3_ /ZAO_D2C_B?_P#4-_\ (E%P->BLC_B?_P#4-_\ (E'_ !/_ M /J&_P#D2BX&O161_P 3_P#ZAO\ Y$H_XG__ %#?_(E%P->BLC_B?_\ 4-_\ MB4?\3_\ ZAO_ )$HN!KT5D?\3_\ ZAO_ )$H_P")_P#]0W_R)1<#7HK(_P") M_P#]0W_R)1_Q/_\ J&_^1*+@:]%9'_$__P"H;_Y$H_XG_P#U#?\ R)1<#7HK M(_XG_P#U#?\ R)1_Q/\ _J&_^1*+@:]%9'_$_P#^H;_Y$H_XG_\ U#?_ ")1 M<#7HK(_XG_\ U#?_ ")1_P 3_P#ZAO\ Y$HN!KT5D?\ $_\ ^H;_ .1*/^)_ M_P!0W_R)1<#7HK(_XG__ %#?_(E'_$__ .H;_P"1*+@:]%9'_$__ .H;_P"1 M*/\ B?\ _4-_\B47 UZ*R/\ B?\ _4-_\B4?\3__ *AO_D2BX'0:?_Q^1_C_ M "-;5<98_P#"0?:DV_V;GGKYGH:U_P#BI/\ J%_^1*PJ;D2-RBL/_BI/^H7_ M .1*/^*D_P"H7_Y$K(DW**P_^*D_ZA?_ )$H_P"*D_ZA?_D2@#FW>HZ ME=P:?I]I$]QQ7<'F+@LF^-BNX9&1G/(K=H ***KZAJ%KI-C%4 $DG@ 4 6**PO!OCSPU\1-'.K>%/$6D^)]+\QH?MV MC7L5W!YBX+)OC8KN&1D9SR*W: "BBB@ HHHH **** "BBB@"MJ'_ !YR?A_, M5BUM:A_QYR?A_,5BUT4]BX[!65XI\5:5X)T"\UO6[U-/TNT7?-<2 D*"0 M"222 !DD@"M6OG']L;4-&@7P+9>+(M0?P?=WMRM^^GR!)(I?*"PR<@[MF]V MV]]O?H>3,,4\'AIUHVNN^VKMKY:ZGG9EBW@<).O&UU:U]KMI:^2OKY'/WG_! M0?PW%JIBMO"NIW&G!P/M+SQI(5[D1\CZ#=^5?2/@?QEI_P 0/"VGZ_I:W*V% M]$)8A=P-#)CIR#UY!&1E3C@D,+W6+CS+.;3$;[/"-MO;% M)E$,4:=%4(\@'?CO7QN69QC%BHT,;*[F]$DKKSNNG9:W6NUK_#93G>.6,CAL MPDG*H[**2O'S;71]%JVM=K7^P:***_0C],"BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** /$_B)\>/$GA_XY:9\,O"WA#2M=U&\\/R^(&OM8 MU^3388XXYO*,8V6DY+9(.3@=>F.?-/AO^W)KOQFUKPQHW@KX<6$^JZMH=YK$ MZ:SXE-K#"UM=M;20Q2Q6DPF!< K)A00><8KN_B%^S'9_$[]IK1/'?B?1_#?B M7P=8>&)M(;2M:M5NI/M;7 D258I(VCVA=PW;@P)QC!K/\6? WQAX:^/WAWQ[ M\-M%\'_V)I/A.;PW%H=_J$VE1P,]P)5:-8+29=BA0-H"]3TJ=1:F%XB_;QLM M'^!=[XSMO!&H7GC.S\1?\(G/X%^U#[4-45\20)+&DF\! SJRH=P &!GC9D_; M"7Q%X)^$=SX+\-)K?B[XE([:=I%U?F"VL1#'NNWN)UB<[83\IVIN8C@#MYWX M"_85\3S?$+2=;^(GB*TU*P:^U+Q5JL?AW4KVPF.O73(B?9WC\N1((84PK^8K MEF.5P:CT7]C#QU\*?&]CXF\$WVBZE!X6\37^I^'-'U;4+C=/IM_"BW=I-.T3 MM'(DB%HY,R;M[%SDTO>%J?1?PC^(WC#Q3K_BOP]XV\#R>%M4T*:(0ZE9RRW. MEZK!(I99+>=XH\LN"KQD94X]<#TVO,OA+8_%*7Q!XKUGXB7VDVFG7TT2Z'X9 MT=Q<)IL**0[RW)AC>661CDCE5"C'4X]-JT4%%%% &CH__+;\/ZUI5FZ/_P M MOP_K6E7+/XF9O<****@04444 %%%% 'E'Q._:"L? 7C[0_ >D^'=6\:^.=8M M9-0AT71VMXS!:1L%:XGEGEC2./=E1R2S# %97@K]KSX>>(_ ]YXBU_4E^'TF MGZO+H&H:7XKFAM;FVU"/&Z# =ED)!#*4+94YXP0.5^)'@SQ=\/?VLM+^,&A> M%[_QOX>U#PPWAC5M.TB6$7UBZW'GQ7")/+&DB,3M8*VX8S@UYYKVA?&_Q3\7 MOA7\9/%OPVCFT_PSJ>M6\?@[1KF"35+&PN84CM;J0O<^1+/E6+B-QM5EP"0V M #Z US]IWP/I5]\-(;"\?Q+9_$#4'T[1]3T-X;FT\Q$+,TC^8,*,$?*&(((( M&*U;7]HOX6WWB:]\.P?$/PS+K=D)C<62ZK#OB\E=TP/S8S&N2XZJ 2<8-?&G MA']D_P"*7]M> M=E\/?V+!/\3]:\7W6FK?6Y?0+"ZA6.$-B7:SY7<5A+8W>N M<"];O-2O/%;7UH+"\B N63[.XG\UGN/ M.12'1=I!W[0* /T7\(_$[P=\0))8_"_BS0_$DD4:S2+I&I0W12-ONN1&QPI[ M'H:\D^*_[;/@/X/Z+XZUC5[#7;W2O"-]:Z5=7FGV\+Q7=],,FVMB\R^9)$OS M29VA>F200/E'Q-X"^(_[.NK?LP/X9\*VMCXN?PE<^"WBADM7\K5;B,/YDL:/ MNECB823R.@9?E.6^?GV;5?V/=;E\3_"#P)I=UJ&C_#[P;!<>)=2\7VKV4EYJ M7B%VVJ[17"S;G)>:4L\3+APH8$# ![GH_P"U-\*M0\%^&O$U_P"._#_AFS\0 M:9%JUE;^(-5MK*X,#X&61Y.S90X) 8$9-;&J?M _"[0]0AL-2^)/A'3[Z987 MCM;K7;6*5UE7="55I 2'7E'(S7YQ_#_X2^//@/^VL/!,O@-?B=I.E>'=8 MD\*1WU_8P,^FW%P'#L&VQIMEEEB90J<2.53: #SOP+_9R\?_ _\1?'#X3+X M+T[X@^*[[P98Z;)?2W]O#;:&UVLKJBF4;GC3>#E 3NMUP,%2H!^G^H?'SX;: M5XXC\'7GCOP];>*I)4@72)-1B%QYKC,<93=D.P^ZIY/& XDVH2'.U')PI!!/;!S7Y\>!_V%_B?X$^'NN?"?5[ M7Q)XGTC6-M=!\9V_BC6;K5[\WEJ&@M;H3QK++*CYD5XVB5@FYPN/E^ M7% 'VN?VPOAE??$JU\$:#K]GXLU6;2[W59+C0=1L[BUM4M@"\<\OG@1.<_+N MPO!+,H&:Z30_VB/AYJUCX:DN_&'A_1-1\10)<:=I-_KM@US.'8JHC\F>1)?F M!7,3NI(P":^0/"?[/_Q*U#QWX'NI?@__ ,(9;>&_AC?^$KR__M739$OKUK,_"&M?"?2?&%]XWL-$BBU# M4M9A6WT-K8A9$N3%J@'(.>+/VN?A5X<\ ^*?%>F^,='\:6W MANS^W7]AX4U2TO[Q8MZID1K* /F8#+$#WKXITW]C/XO:5\(_#7PX;POJ&NW7 MA+4KC5;"?5-5T%/"T]PIE:.3RULWU"=9A)L>"8H#N(,B@*1D?$3]EW]H+XEQ MQ_:/!&LF6W\ 7&@G^T;SPY9P"\D:)_LMI#8,NRV5D;89F8_[O< _4#P[K<'B M7P_IFKVJ21VVH6L5W$LP <)(@8!@"1G!&<$UH5S_ ,/=+NM#\ ^&=-OHO(O; M/3+:WGBW!MDB1*K#()!P0>0<5T% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% 'YY>(?C]\8]8U3XTQ>$?%/C;5/&'ASQHVD>&O#.D>#(+ M[1IK99(?W5W=BQ_=?*\FYFNHV50&P>,]%I_Q(^-/BOPC^T)XOL_B9/HNJ?#O M7KZ*P\/RZ7ILNE26]M;I.UO*QMQ.=V702"<$<'G!S]7?"_X,Z+\)M4\;7VD7 M5_+=O->7Z[^Q#X?UW_A.;,^/O'%AX M<\;:N^LZ]X?L+JQBMKR1]HDB,HM/M"Q,J!2BS#*Y&>+X/$' MPWUCPAXAT3PSH=EX;TWQ5XLT'4)K47&II=2Q;K*U\U2[R)%O?$95MK9Y(4'W M&'QUXL_:8^.7Q&\/^'?'^H^"O!'A"QTT6$F@6]LT^I75[;-.MS(\\+GRE4@+ M&FT-U)KV'P#^R]X(^'>B_$#2K&&ZO+#QM*W]I0WK1L([?[.+:.TBVHNV".(; M45MQ )RQKSVP_8ETKX=Q6%SX%^(/BWPGJ:Z-!X?O[^%K*>34[6!66W:826Y4 M31(0B2(JD*H!S51W&MSTGX0V/CC2_AYI%G\1M0TS5_&%NC17NHZ0I6"ZPY"2 M[2B;69-I90H4-G'&*[*N-^$/PIT/X)?#S2/!OAT7+:9IR,!->R"2XGD=R\DL MK@ ,[NS,2 !D\ # KLJZS0**** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "N'^.GC#4?A[\%_'7B?2(EFU31]$O M+ZU1EW+YL<+,I(SR 0"1Z"NXJ.XMXKNWE@GB2:"52DD M471F(E=3%EP8U!W8&WBO;_#O['_PQ\,:QH=]::7J4UOH%V]_HVDWNM7EQIVF M3MG,D%J\IC0C)(&W"DY4 U+X9_9)^&7A'Q)INKZ=HUXJZ5?2ZEI>E3:I"/A]IFNQSZ_XK\3^ M)&G\2>*/.U(V=E9.&6**,S(68[@H!?:H!P#VO_#W]MCXN>//BIX@^'5K8^#( MM5\*6>L?VKJES:7317DUC*%5X42?Y%D#Q@J2=IW,&( 0_2TW[(_PP_L72]/L M=$N]&.DZG<:OI]]I>JW<%[:75P?](>.X$OF 2#ADW;2,<<#%KP7^RO\ ##X? MW\=_HGAK[-J(T^YTR2\>^N99IX;B3S)S*S2'S'=^3(V7X # "BS#4\:A_:* MU+]ISP7\,O#7A2>X\,:KXNT]=>\47VF7S13:#I4,NR7RY@ 5DFE0Q1GKM#MQ MC=7SQH7[5GC?P?\ %K5_BU=:_P"(KWX>>*)]6T?1=%U:QU'^QK7R8O\ B6W$ M<[@6\AG>W96$3[QER2=QV_:'P%_9)\+? [P#XJ\+1RR:K;>))K@7;*\\'E6; MADBLX6,SRI'%&Q4'S"VYF;()XW?B)^S/X'^('P';X3RZ5%:>&+>R2UTV$/*W MV%XEQ!*")%=RAP3E_GY#$[C19AJ?(?Q%_;^^+WPA^$_@/Q=X@TCP5J4WCW0Y MM1TFUTVSO$.GS1^4_P#I :X;S8WCD_A,91CR6"Y.W\6/VW/BU\'_ !]X<^&^ MLZ7X5U#Q3XLM=/O=/U71-,O[B+38IY'29)+))))KJ1-AV>45W<'9VKTB;_@G M=X&C^ WEN711*DLKQ6\DY6$2,I)6-E'S'DUZ1I7[ M'?PCTSP]J>,?!'@_3/"_A[Q)X4T34[K6M0U!;F>*YG@F:%$M%26- MHMPVOYC,^TMC!QD_4GAW]E?X8>%_$>D^(;#PW(=?TN\EO[?5KS4[NZNS/)%Y M3-+-+*SS?N_E D+!1]T"L2Z_8E^#%U]J(\(26DUV]VUS"))FN-:U>^) MENWO!#&\X\_RG W EWC:3"[5= V&CZ1)H5C;W5W%YUO M6NUO?[8_MF^.JK*L?E*5O_/^TJ!'\NT2!<<8HLPLSY^L?VR/BC-'?Z/J"Z#X M=\1Z3!?R"UOO!/B"\U#68H6'V>]73HA&]E:R*0#+*[X?< !M(K6_8_\ CUXB M^.G[0GB#5]1O+RUTN_\ VCZDF@B\DDLK2X=B)7BC8[5W$'G&2,9)KUZ?]B# MX+S0RI'X1FL6N+62RO)]/UO4+2;4(9'WR+=RQ3J]UN;DF8N>!SQ76_#+]G7X M>_!S5&U+PAX?_LB];3H=),OVVXG_ -%B),<>)9&'!)^;&X]R:+2#4]1T_P#X M_(_Q_D:VJQ=/_P"/R/\ '^1K:K*IN3+<****R)"BBB@ HHHH **** "BBB@# M@?C]XFU?P7\#?B!K^@$KK>F:#>WEDRQ^85F2!V0[>^" <>U?G_\ !OX(_"KQ M%^PUX3^*_BOQJ_@?QU<:HVK7?Q1$C2ZI%>_:WB\II<[V!4!-A..=V,Y-?IXZ M+(K*RAE88*L,@CTKPNU_8;^"%GJ4-W%X&C$$.HG5HM);4KQM*2[(QYJV!F^S M!L<<18':@#XY^ OP_P#^%D_M:?M+R_\ "MOA]\6/)U2P?[1XVG^S+!O28[[< M?8+O_68RP^3&U?O=N3^-!\2? _\ ;O\ %_Q*\":3:VVD?#C1=%EUGPWI46V) MM(EACAN(X54*-L8PP^4!0H<@!,5^@\G[)?PU'C+Q'XKL[+Q!HFO^(IUN=6O- M#\6ZOIOVR1<[2Z6]TBG&YL#&!N..IK9T']G?P!X=U_7=;MM&GNM7UW2X]%U2 M\U34[N_DO;2-=BQRF>5]QV\%C\S=R: /Q]L7TSQM\._@.\MM%J&CZM\9-49K M>[B#QS02S6.5=&!!!5L%3ZD5ZS^V=8Q? 7X]?$3P'\,K./2?!7BSX=76H^(O M#FFKLL+.=$F"7*0+\D+'R8%RH /FG^]7WC'^P7\#8/"N@^'(/!DUKI.@ZC+J M^F1VVNZC%+:W<@C#S),MP)-W[J/'S84KD8.:W]/_ &1?A-IND>+]/7PH;K_A M+H&MM=OK_4KN[U"_B.,H]Y+*T^WY5X$@Z#TH _,[]GW0=+\2?M6_#JSU?X=P M_$ZT/PHTM_[#N(+*9 PM8<2E;QTC^7D9!+?-P,9(]O\ A?X!\.?%;]O[QAX# M\9_#O3M \%>$_#<=]X?^'\UE;QZ?%++]G\V[:W@)MY929I%,GS=5&(].\0^(]!>3Q%I\306VLZ9J%UIM\D3!@8_M%K+'(4P[?(6*_ M,>.: /R+UFXC\%P_$>30=5U6W\0?"[XC1Z7\+&L]U]/,TMQ.)=+'):2 )"C[ M!]8\)ZIH?@BUL+SPKYIT@I]N1: M7%S+#(B2R0[FC0[I"2T<>[YF/.3D ^ _$/[OX-_\$^)F^6)/$5MND/"C_2K< M\G\#^5:7[3WP-^(/Q^_;2^-?AWX>:M#I]]'X=TBXO;.ZN)+>#4[=5BS:O(G( M#':VTD [.2,9'V/\)OV3K&[_ &8?!WPK^,7A_0]=D\-;5MYM)U"X=0Z$E+B* M;RX)89/F883H/XCG Z2;]BWX,W5GJ$5YX,74;R_O(M0GUC4-2O+G53<1KMCD M6_DF:Y1E'"[9!CM0!\46O[3WAC]D;Q5X@C\:?L_-\$/B=/X9E?3O^$;U83:' MJLBQMY6^VA<6ZLTB;=^V5QT9A7%?L*ZOJ_[-?[4G@RT\1-KD=I\6]$SJEQX@ MT>[TY5U@O),L<;3Q1B;!9$WQ[U)N>#TK[Y\3?L&_!#QQ>?;?$_A&\\4:CNB8 M:AKWB'4[^Z CW;$$TURT@C&]B8PVPYY!P*[OXP? WPA\8K/19_$7ARWUW4_# M=U_:>A^9?W%CY%VHRA\Z [E4L%SPPX!VL5% '@O_ 3#_P"2&^,?^QZUC_T. M.OK^O _V+_@3XE_9]^%^LZ#XKN-)N-4U#Q#?:S_Q)KB6>"..^4 %%%% !1110 4444 %%%% %;4/\ CSD_#^8K%K:U#_CSD_#^8K\] M=0\ _P#">?MZ?&2+_A6_@CXC?9]%T9O(\;7/DQVN8B-T/^A766;&#PO ')[; MP=D6MC[PKD_BA\,]'^+7@^Z\/:VC_9I662.>' E@D7[KH2#@\D>X)'>OD#XG M_%CXC?#WQ9\&-*U'2?#%EH]H]F)'BW/#O,2N(<(PPNT\ MJ5*@%2W4_P!H/XHZYXP^+'B32_%EQ8>'?!O@33?%%EX6MM-M'CN;JXL3.4EE M>%YO*!5BRJX8@\,N*56,*T'3J*Z>C1G5ITZ].5*JKQ>C1-?_ /!/WQ(PC*.23C?U)KZ>^!OP-T?X&^&Y]/T^=[^_O'62]U M"5 C3,HPJA1]U!EL+D_>/)S7R9=?%+QUX?A^&=C>^/[SQ_8_$[P%J^HZQ:WM MO;*EE-'IYN%GMO(A0QQ[G,6UBPP/49KY,^'OBB^\(VFD7VGQV,EPVC>#X?\ MB8:=;WJ*&O'!94G1U5QV< ,IY!!KQ<'D^!P%7VU&'O>;O;T/"P.0Y?EU;V]" M'O>;;MZ'[7T5^:L_[7GQC\#?!7P;\0[SQC;^(9_$>N:SHITV]T*+R+=81,+> M4?9HQ*S*\0+8R"IQMR"Q] _8C^)GC+XQ?%B#Q!XH^(O_ D%HGA*W_XDTWB/ M3#*NH.^Z>1-/TV78(0K8#74?G*2!QCCW^;H?17/NJBBBJ&%%%% !1110 444 M4 %%%% !1110 4444 %%%% !39)%CC9W(5%&2QZ 4ZH[BWCNK>6"5=\4BE'4 M]P1@B@#Y@TO]J[Q_XP\$2_$GPC\*?^$C^'*ZD;2"*UU&5M=OK59C#)>0V:VY M4J""1%YFY@K?=[=[J7[7GPQTGQ%=:3CWVK#2KHZ;8WSXVVT]WY M?E1R9*@@M\I8!B#7E_@7X-_'CX/?"Y?A/X&OO"]GI%GJ+?V7XYNKIGN[33I+ M@RNC6#6S1O<*&902^PY!.,5RWB+]C[XDWG@/XA_"6TF\/S^"?&/BT^(G\57% MVZ7UI;R3QS30FU6#:\P:+"L)%4AN=O2HU%J>N>"_VTO!FM^//&7A/Q$1X4O] M"\3'PW;2SF::"\/2[E],LKY^%MYKP1^2CY*@Y;"E@&(KR#Q!^QOXOU+PC\2=*MM1T)+C MQ)\1+7Q9:223S +9Q20L8Y2(!OB/\)[%_#K M>"/&GBYO$9\337DBWME;RSQSRP&U$!$DJM$%5O,"D-SMZ47D&IWFO?\ !0;X M>+KWA*R\*6^L>,K/5]0?8U\9^%_V._'O@?X7?"73]-O/#5_XD\#>+KOQ#);7% MY<06E[!,\Y">>MNSI(%D7DQ$9![ 9^Q[%[F2QMVO8HK>\:-3-%!*98T? W*K ME5+*#D!BJDCG Z4U?J,GHHHJ@-'1_P#EM^']:TJS='_Y;?A_6M*N6?Q,S>X4 M445 @HHHH **** "BBB@ HHHH \H^)W[05CX"\?:'X#TGP[JWC7QSK%K)J$. MBZ.UO&8+2-@K7$\L\L:1Q[LJ.2688 K*\%?M>?#SQ'X'O/$6OZDOP^DT_5Y= M U#2_%+OA[^UEI?Q@T+PO?\ MC?P]J'AAO#&K:=I$L(OK%UN//BN$2>6-)$8G:P5MPQG!KSS7M"^-_BGXO?"O MXR>+?AM'-I_AG4]:MX_!VC7,$FJ6-AY\B6?*L7$;C:K+@$AL 'N MWBK]K3X:^$[KX>&;7[:\T7QQ-(OC/X"\(^%['Q)K/C/0M/T"_D$5GJ4VH1""Z]-+U[6[*VOH&SCRY M8O..UQD?+D_>'K7RG^SW^QK\1=*_:(\2>/?$WA*WT?1?$%AXAN].M+F\MY3H MEQ>W"B"!E21R',>]BT895#D;MV16#X/_ &;_ (L^&/!$%E%\&?$VC>,['P8W MADZYINO^'-0T_6&5W:.&[L+YG46V2I+H1(<8*]Z /TYCD66-71@Z,,JRG((/ M0@TZN4^$^EZUHGPQ\*:=XCMM,LM>M-+MH+ZVT6,1V44RQJK)"@ "H", # MCBNKH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\^^/6 MJ>,=%^%/B'4/ ]UI=AK=K9S7'VS58WE2WC2)V9TC7B208&U6(7/7(X/H-*M:\*6]RKQ74VB1V;2W$+HR-$WVFWF4*0V7"Z9IMD\JDO=7D\4#K!$,?P MQ$?2N;\:?M9?%7Q#JWP9N?!^C^%+#3?$'BJ;1;M;3Q=;:K::J8XY&V+2RQV:QW,; C*W*2_=&-O.%=7T>]O(/$27N MX?;[91(UB8C&.9(S^[??EV^39GFO!KO_ (*97H36R_A'PKX:O/#NC6NKZGI' MBCQE'9WMX\\0N!:6"&#,\JPED:K::OK.J:I,7U2]: .#!';I;B%1)E=\@=>&=1&!C/0>+OV8-*\0>-->\3: M)XR\7^ ;[Q##!#K,ZE_P48M- M+ET/4+CPUX>A\/ZQJ%A;6UH_C>TD\1&UNU0QWATR&.0",;QE3.'QR5%=-\-? MVP-6^('P5\8?%7Q%X"A\*^!O#ZWSPS6^MF_O;XVI99-L'V:-44E& )DSN&,8 M^:HIO^">/@2XL;G3+'QOXYL/#$_B,>)YM"M]2M98)M05ERTLTML]S,-T8R)9 MFY!/!YKTOPO^S?X0\ _ V]^%L8OM9\*7YO4N4U256FE2Z>1Y5+1JF!F1@" " M!CG(S51W0^I\KZE^V'\68?BSX*GN? UKHWAC5_!MUXBM]"_X2"SV7^=AB>XN M[B&(6AB5@7 9EPW&\C%87Q;_ &_/&NHVFI:+X'M/"-KJVE7^D/<:YX?\5QZW M93075PD?DQM]AV[B=R29"L@PR[\UZAXF_P"";O@+QQ!I=OXE\:^.]?M-(TH: M-I5M>W]GLL+=75T$86U4LRE%YD+Y"@-N &-O5OV#?"?B:^\4ZEXA\;^-M?UC M7XK*.34;N[LXY+/[)*LL!MTBM4C3:R_=*%>3\N3FM[2*U,7Q?^W!J7PU\26^ ME^+_ GX4TV7^VK71[C3;'Q[;WFL*)F5?M4=BMN&: ,?XWCDVX8QKR!]8U\L M1_\ !/CPLNFS:9+\1/'L^DW/B+_A*KRP\_38X[O4-ZN9)3'8JS+E1\F[:,?* M >:^IZM7ZE!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** /EVXOO&&B_M]>'M)O\ QKJ6I^'M4\*ZA?1: M%&/L]C;!)XUC_=*2)9 "V97R><#:!BL-OVEOBOI_Q#.C>*;3PS\.[>^\1R:' MI=MXB\/ZJ\4\+*1;7$>J0N;2:5F&?LY\DL!M\Q2-%\77*>) MV\2()$CU%/&6LI)#'(^]XH]MV!'$6P?+4!. ,8%16O[)/PIL_$$&KP^&)%D@ MU4ZY%8?VK>'38[\_\O*V)F^S"3G.X1\'GK4V8M3S3]B?7/B3XH^$?CJ\U?Q9 M9:_J:>(-7L]+DU*TN7,$\Z+X*L/[:\):4L'C"VO;6Y\NUUJ6\%G!;P[7SY>X23$?.S* @8,&(^R/"O MP2\._#6?Q)?^![>3P_J>M//=21S7MY=::MW*=QG^PF=8E)8 MY8C8@$;AFN9 M^&O[,FC>&?!OC?2/&$UKX[O?&^ISZIXANKBP%O#=/)@+&D.]_+2-54)\Y8$; MMV>:5GL&IX+J'[6WQ/\ !NN#0]7GTE+*_BLWL?%WB+P+K^DQ"Z>3RY]/AL"G MFWTY&'C6-TR"V2=IQEZ1^VQ\6?%GQ*T?X=Z)9^%8]&0*7RCNO:C- MJ5H8O-%F%F<%\9?C9\2_P#A96M?"_P.?#=KJ^D> M!Y/$NHZSJUO<$7,A9HEBMHHYU:'YE+;V>3;D#!QD^5?#?]J#QOHOP/\ AK:V MGB[0[_7YO!LFM74>K:/K'B;6KR59'"O+%9E3! < &XE=N3]WY>?K#XG?LZ_# M_P",.J1:GXIT.2ZU*.RDTW[;8ZC=6$\EI)G?;R26TL;21')_=N2O)XY-ZM+2STG^P473]XDXE+=:+.X:G MR+X!_:L^*&M>,?$WQ!O?&WA'0-*D\$:;JXTGQ%!?II%J9KB2-518[EV$P8#+ MK&3-A4"QD[A]+?LZ_M&>)?B/\7O&'@3Q$EG>+I.EV>JV>J6OAS4= >5)BRNC MVE\[2<,/ED!VL/TV=7_89^">N:;I^GW/@Z5+2QT^+2XH[76M0M]]M%*98HY3 M'.IFV2''-+O8O$.M1)#J&IZCK-[J,]R MB$%0S7,TAXP.>N!BA)AJ>DT4458RSI__ !^1_C_(UM5BZ?\ \?D?X_R-;5<] M3R\_9O\OS(V3=MR,XW9QD9QUK@/V6_@3_PS5\#?#OPZ_MS_A(_[(-P?[2^ MR?9?-\VXDF_U>]]N/,V_>.<9XSB@#Q'X]?M^:E\ Y=>EUGP+X>2WTFXMXAIM MYX]LXM(_L!^QM!',4\L6LH\P>:J@;R"0>0*I>/O\ @FJ/$FC_ M !2T70?B5+H>C?$#5DUJ_CO= AOKF*X$WFE%N/,C,/'^O2>.5W^+/ 4?@AH5T? MBMO%";H'S_ )\^5N\OC&[&\XR0!^F_MW1> M/-:^%OAKX>^#/^$A\7^.-#/B%[#5=5_L^VTJU"ODS3I#,S,7B=5"Q\\$XR*Y MSXH?M]>//AEXX\">!KGX WDWCCQ18270T5_%5H/(D5Y%P)HXY(VBQ&6,C-'M M7)91CG5\+_L%:A\-]0^&7B+P3\18]'\:^#] ?PWU3XZ?#7XH>,/BG/XQUCPGIMWI]Y':-IWB:Z\(Z79>%;C5TTJ>'_A,+63 M7[=2@+77]F"/+0!R5W"7) W8 -=+\1/^"C&H?#;6M.LM2\!^&S-J&M_V+'H\ M/Q M+G6K8MD13W5G;PRK%&QP#B9RN>1G /9_#/\ 8[\9?!GP_)X*\$?&2XT# MXXU6&"4'?:)>2R-&(RQW;C;%QV:O.9?^"8$EGX'T'P9HWQ2 M:S\,:'XG7Q-9PW?AN&:Y>0?P3SI+&TO' ;"X!.01MV@'D4?[8GQ.U[]EWXI> M,?'D%QJ>C:3XW?2H+GPKXK?0=4M,/!Y=I&\%AAX%#L3*[[WZ%,1J MZ8C YB!Z'(YSW7A7]C7Q?\)O$'C.;X7?%S_A"M#\6ZA#JE]93^&H=1N+:Y!_ M?M:S23!$$H.,212[>,=* />?B9\0O^%;_"7Q-XVN--FD.BZ/<:J^G.Z"0F.( MR>464LH.1M)!(],U\A_"7Q)^T_\ %S]GOPY\8?#GCJPU/Q)J^HM>)X#N-+LH M-(;3Q,\1A$YC^T*X"E]YF/\ =P3R?>/@G\/_ (B:U\-_'7AKXXZRWC"'5=2O MK"S%S:6=K*^D,OE)Y@M,(&D&]^NX!QG!X'E>E_L"^)M+^&-C\)T^-.H1_"BS MU0WR:=:Z,(=7-OYAD%H=06XVA-YW;A ">G X _Q5_P4"O["#XE:WX<^&,GB M+P9\.;RWT_Q%JTFN+;3_ &AI-EPEI"('6<0GJ6EC#<8X(->'^"OV\AX#^,GQ MY\43ZCKWCO1=3O-"MO!?A=K^39)->0/(D<*.66W5E&6*KV'!.!7NGB7_ ()] MRSV_Q)\.^%/B+)X5^'GQ"O8;_6M!;1Q=W,#35:30)M/B:*%BS2D7(*L05(3\\$ % M?XQ?\%-+_P"!.I^)O#'BSX5I'X]T>:R:+2+'Q'Y]I?6MPF?.CN3:JP9&*J4, M0SNR&XKVGX!_M2:E\5OBQX]^&WB?P4O@WQ;X2@M+J:*TU8:E;SQSQJXQ)Y,1 M#+N4$;2.3SQ7CWQ8_P"":5S\;M\FSM;2V'_' MO%;&Y9LNP5F=I3R.%&:]N\"_LOKX-_:,^)OQ3?Q(UZGC:PM;!M(6R\HV8AC1 M"PF\P[RVS/W%QGOB@#R/QO\ \%$I_AOXLT?3?$7@C0;:+4/$"Z')IECX[LK[ M7[)6.$N+BP@C=$4_W?M!() )&1G,\>?\%(M<\':W\7C;_"./4_#/PSU6#3=5 MU8^)O)FF\Z. V%P"<@C;MZ?QA_P $]/\ A*_#_P >],_X3[[+ M_P +4U>TU7S?[&W_ -E^1.9?+Q]H'G;LXW93'7!Z4 9/[0G[:&K^)='^*_@[ MX6>&;B_N/#O@MM9U;Q/)K1TN32_M%N)(OLZK$[23+'()/OQC*, V<9]K_8C\ M1:KXL_9/^&6KZWJ=YK.K7FDK)1R68^Y->7>*/V!-1D\0>, M=2\(?$E/#47C3PK!X9\16=YH ODN?*@6$7,)%Q$8F*)C:=X^9^>1M^@?@#\* M?^%&_!OPGX"_M3^V_P"P;(6?]H?9_L_GX8G=Y>]MO7IN- 'H%%%% !1110!P MGQQ^*FD_!/X6ZUXTURWO+K2],\CSH=/1'G;S)XXEVAV53\TBDY8< _2OA7Q5 M^VO^R[XZUJ75_$OP;G\0ZM*JK)?ZKX7TNYG<*,*#)),6( YX%?2_\ P41_ MY,Z^('_@W=U=:;\/==TZYN[>*SN)K71=/B>:")=D43LMP"R(ORJIX M4< "M?7/V=?AM\2_C!X'A\)>'-&L/$'@U]+G\3>'OL4$-KJFF7$:R&X$>-DK M(S$-D9(.#G]V#\E:A^S[X.U[7==O)O&D>@,VJWJ#389- C2W5+F1%55N-9MY M5&U1@-"GL",$]6%R_(L0O>C*&B>K?6]MEU6J?9FE.CA)[IH]^\)_MJ?LO^ [ MG4+CP[\(]0T6;4(7MKI[+0-/C,L+DEXCBX_U9))*?=/I3X_VV?V7HXT1/@Y< M(B+"BJOA?2P%6%MT*@>=P$))4?PDY&*\=\*7?PA^$_PY\7Z!?^)]/D\7KK5M M+8ZG/X-TSQ'<269@3>B?Z1/:*N]VSMN2P\OID[1Z+\8_AK<_LW_ :X^(%O!X M2\4^)?$6LV<-AK\?A.RAAM=+:V,L96Q,/DP32-D.=K$@@9)P1I/*,IC4C35* M7O.T;N2YMM?AM;7NWY#>&PRDH\KUVWU_ N^.OVP/V7OB'\/9_!.J_"S64\/M MYS06]IHFGPFSEESOGMRL_P"ZE)8G>O))._%K MQEJGA739-*T0:];:1LLH70(^!;F$R,54#=(7/X\UX_\ MG^$]#T'QEX+UK1- M&M_#I\5>$]/UZ]TJSA$,%OG_"C_H7_ !E_X!6G_P E4?\ #T_X4?\ 0O\ C+_P M"M/_ )*K\LJ*Z_\ 5'*^TOO-/[-P_9_>?J;_ ,/3_A1_T+_C+_P"M/\ Y*H_ MX>G_ H_Z%_QE_X!6G_R57Y944?ZHY7VE]X?V;A^S^\_4W_AZ?\ "C_H7_&7 M_@%:?_)5'_#T_P"%'_0O^,O_ "M/_DJORRHH_U1ROM+[P_LW#]G]Y^IO_#T M_P"%'_0O^,O_ "M/_DJC_AZ?\*/^A?\9?\ @%:?_)5?EE11_JCE?:7WA_9N M'[/[S]3?^'I_PH_Z%_QE_P" 5I_\E4?\/3_A1_T+_C+_ , K3_Y*K\LJ*/\ M5'*^TOO#^SG_"C_H7_ !E_X!6G M_P E5^65%'^J.5]I?>']FX?L_O/U-_X>G_"C_H7_ !E_X!6G_P E4?\ #T_X M4?\ 0O\ C+_P"M/_ )*K\LJ*/]4?J;_P /3_A1_P!"_P", MO_ *T_\ DJC_ (>G_"C_ *%_QE_X!6G_ ,E5^65%'^J.5]I?>']FX?L_O/U- M_P"'I_PH_P"A?\9?^ 5I_P#)5'_#T_X4?]"_XR_\ K3_ .2J_+*BC_5'*^TO MO#^S[,?M6 /?"\:9E0X6RF6.A#FFVHQ3>G,[O7R23?GMIN?>TW[86E+=%8O#EX M]MGB22=%?'KM (S[;OQKFO&'_!1;P!X'OEMM5\+^,4#Y\N>*SM6BEQUVM]I' MY$ ^U> 5QWQ;T&VU[P!JXG0%[6![N)\?K'_ ,/9/A%_T+GC7_P!L_\ MY*H_X>R?"+_H7/&O_@#9_P#R57Y.44?ZFY5_++_P(/[,P_9_>?K'_P /9/A% M_P!"YXU_\ ;/_P"2J/\ A[)\(O\ H7/&O_@#9_\ R57Y.44?ZFY5_++_ ,"# M^S,/V?WGZQ_\/9/A%_T+GC7_ , ;/_Y*H_X>R?"+_H7/&O\ X V?_P E5^3E M%'^IN5?RR_\ @_LS#]G]Y^L?_#V3X1?]"YXU_\ &S_ /DJC_A[)\(O^A<\ M:_\ @#9__)5?DY11_J;E7\LO_ @_LS#]G]Y^L?\ P]D^$7_0N>-?_ &S_P#D MJC_A[)\(O^A<\:_^ -G_ /)5?DY11_J;E7\LO_ @_LS#]G]Y^N6A_P#!4?X9 M>)-0CL=-\)>.;NZ?HD=A9\#U)^U8 ]SQ7>R?MO\ A".V,H\,^*9'QGR5AL]_ MTYN<9_&OS^^"?A2V\.^![*Y1 ;S48UN9I>Y!&47Z!2/Q)KOZPEPCE=](R^\_ ME?B7Q%KX;,JF&RJG%4Z;<;RNW)IV;W5E?;K;6_1>_P"H_P#!5+X6Z1>2VE[X M4\$_[; M"!;W3V13(.K1NP7:?HS C\?6OFNM8\'Y5)7Y9?\ @1^Y\(9CA.*GDTT_G8_6/\ X>R?"+_H7/&O_@#9_P#R51_P]D^$7_0N>-?_ !L M_P#Y*K\G**K_ %-RK^67_@1]K_9F'[/[S]8_^'LGPB_Z%SQK_P" -G_\E4?\ M/9/A%_T+GC7_ , ;/_Y*K\G**/\ 4W*OY9?^!!_9F'[/[S]8_P#A[)\(O^A< M\:_^ -G_ /)5'_#V3X1?]"YXU_\ &S_ /DJORR?"+_ *%SQK_X V?_ ,E4?\/9/A%_T+GC7_P!L_\ Y*K\G**/]3R?"+_H7/&O\ X V?_P E4?\ #V3X1?\ 0N>-?_ & MS_\ DJORR?"+_H7/&O_ ( V?_R51_P] MD^$7_0N>-?\ P!L__DJOR-?_ &S_P#DJORR?"+_H7/&O M_@#9_P#R51_P]D^$7_0N>-?_ !L_P#Y*K\G**/]3401^%_&H MN7.V-);&T4%NV3]I.![XK\FX9GMY4DC8HZG(8=J](T743JVGQSO'L?H>."1W M'M7YOQE@\/PO1CBJ>']I2E[M^=IQEK:ZL[I_+:W5'Z%PCP5E7$E:6&J5I0J1 M]ZUKJ4=+ZW5G]^_DS[4^!?\ P4.T7X3^$]1T_P"(.GZ]J][>:M_?[57Y\U MY[XFU>74KYHR&CAA)58VX.>Y/O7R? ?+GTX8&6'O[-7G4]M&_ M)_:>('!&49=5JYJZC4JS]VG%65[+F;=]NMK;NWFOTU_X>G_"C_H7_&7_ (!6 MG_R51_P]/^%'_0O^,O\ P"M/_DJORRHK]X_U1ROM+[S\*_LW#]G]Y^IO_#T_ MX4?]"_XR_P# *T_^2J/^'I_PH_Z%_P 9?^ 5I_\ )5?EE11_JCE?:7WA_9N' M[/[S]3?^'I_PH_Z%_P 9?^ 5I_\ )5'_ ]/^%'_ $+_ (R_\ K3_P"2J_+* MBC_5'*^TOO#^S']FX?L_O/U-_X>G_"C_H7_&7_ (!6G_R51_P]/^%'_0O^,O\ MP"M/_DJORRHH_P!4?J;_P]/^%'_0O^,O\ P"M/_DJC_AZ? M\*/^A?\ &7_@%:?_ "57Y944?ZHY7VE]X?V;A^S^\_4W_AZ?\*/^A?\ &7_@ M%:?_ "51_P /3_A1_P!"_P",O_ *T_\ DJORRHH_U1ROM+[P_LW#]G]Y^IO_ M ]/^%'_ $+_ (R_\ K3_P"2J/\ AZ?\*/\ H7_&7_@%:?\ R57Y944?ZHY7 MVE]X?V;A^S^\_4W_ (>G_"C_ *%_QE_X!6G_ ,E4?\/3_A1_T+_C+_P"M/\ MY*K\LJ*/]4?J;_ ,/3_A1_T+_C+_P"M/\ Y*H_X>G_ H_ MZ%_QE_X!6G_R57Y944?ZHY7VE]X?V;A^S^\_4W_AZ?\ "C_H7_&7_@%:?_)5 M'_#T_P"%'_0O^,O_ "M/_DJORRHH_U1ROM+[P_LW#]G]Y^IO_#T_P"%'_0O M^,O_ "M/_DJC_AZ?\*/^A?\9?\ @%:?_)5?EE11_JCE?:7WA_9N'[/[S]3? M^'I_PH_Z%_QE_P" 5I_\E4?\/3_A1_T+_C+_ , K3_Y*K\LJ*/\ 5'*^TOO# M^S&O&DK*,E4L;0 MG'T^TU^5E36=W+8W"3PMMD0Y'^%&C^\MIS-VOYVUU[]-]=CIPV M6X'VT5B>;DOK9ZV\KZ?+KY'Z7^/O^"D'@WQ=X+U[0O#6A>*;'7KZRDM[>XU& MTMXHH2XVER5G9@0"2,*><5%\.?\ @HUX.\$^!/#_ (?\3Z'XHO\ 7=/LDMYK MC3;6"6*4)E48,\ZL2552?5O;.SG[7GY? M>Y>6W+:]]M>]^A]_7'_!43X76943^&O&D3,,A7L;0'\OM-0_\/3_ (4?]"_X MR_\ *T_^2J_+F]O)=0NGGF;<['\!["H*_IS"\)8-T(/%1_>6UY6[)]E?73O MUWTV/YFQ66X%5IK#EE:>G_7U6C_P]D^$7_0N>-?\ P!L__DJOR?K'_P]D^$7_0N>-?_ !L_P#Y*H_X M>R?"+_H7/&O_ ( V?_R57Y.44?ZFY5_++_P(/[,P_9_>?K'_ ,/9/A%_T+GC M7_P!L_\ Y*H_X>R?"+_H7/&O_@#9_P#R57Y.44?ZFY5_++_P(/[,P_9_>?K' M_P /9/A%_P!"YXU_\ ;/_P"2J/\ A[)\(O\ H7/&O_@#9_\ R57Y.44?ZFY5 M_++_ ,"#^S,/V?WG[ ^!/^"G/P@\<>+-.T)K?Q#X>-])Y*:AK5M;QVD;'[HD M=)W*@G W$8&>2!DU]; A@"#D&OYR*_3/_@F3^TCXS\9_:/AOK>GWFO:-I-KY MMIKW7^SXQPMO,Q/S*<$1XRPP1@J,I\IQ!PK2P6'>*P3TC\2;_%/]/N/.QF7Q MI0]I2V6Y^@M?.W@']NSX:_$C]HS6?@QI"ZL?$VFO,M8^'_ ,'_ !=K_A[2-0U[Q!9Z=*VFZ=IEG)=SSW3# M;"%BC5F8;V4GC 4$G@&OS1U+]C_XM_ OX3?!/XKZ-9MXJ\8^&-7CUS4O#>D: M!<#69/MK))'IKHVK_ &EGVSRJA^S%>'Q(5'[L]QBMM+*;P#^TU\0O#/BWP?K/C_Q)_P * M=L]$:WT719-6E^W?V?;1MN$2L45F!3S/NY89(!H _4OQ9\4_!?@'2++5?$WB M_0?#FEWQ M;[5M3@M8)R5W#RWD8*V5YX)XYJAK7QR^''AO0=)US5_B!X6TK1 M=74MIVI7NM6T-M>@8R89&<+(!D?=)ZU^:OPV_9V^*OPO\3? /7?'EOXTM_#V MF^$KO33<^$]%AUJ]T&ZEGN91'+:/;76T-#)'&76(D<+E0I%;6I?LS?8(?V:[ M3PEX"^)$WA)?B#-K.HV/C32X&N-/A=K7<\L5FGEVUNQC9@DH4CY\@# H _0_ M_A>?PW_X0\^+?^%@^%?^$5\_[+_;G]M6WV'SO^>?G[]F_P#VH7TVF6FA7$^4E/[B_AME0M-&NW=OC M5@-H[LH-&'X)?$75/%$E_I'PV\7:1977QKAUJT%QX$&\=^&5\6&7R1H)UBW^W^9C.SR-^_=CG&,XH;XT M?#U/&8\(-X[\,KXL,ODC03K%O]O\S&=GD;]^['.,9Q7P[^RGX;D^%_PKE^&7 MQ(^"'BSQ;\09?&%U=R:A+X534-/-RX_=:I]NN-ML$4<;_,\P'.%YKR_X:_LW M:HGPK;X=?$OP]\9;KQI%XOFU$6OA70=.-A-=$%H]3&KW%IM"$85BUUNSQLQP M #]*H_CU\,Y?%@\+)\1?";^)C?#_P 0]9O]%B\(V/@[7KS1IYIM0$Z21VZAFN&8QH(Q@DE><8^\:_/3Q[\. M_C'XE\">"+#7/ASXETK5M)\?Q7MQX3\*^![6WT'3+8$YN(9K6%I9BW.Y_,9> MNX9V,WT9^RG\#?%VJ_ ']IOP=JFBZAX7U'Q7XDUN+3'UNREMEF2> )',N]06 MC)/WER.#C- 'I]O_ ,%%/A[-X=MO%S^&/&EO\-[C53I$?CN;3(1I9D!*B0@3 M_:!$6&W>80-W!P&&"),EQZ8->&^//AU\8O$G@/P1I^M?#?Q%H^JZ3X^BO;CPCX1\"VMM MX?TNV!/^D02VL32S%NN-GDZ7 MJ6L6]O=2;SA-L3N&.X\# Y[5^9WQ8_9_\8ZQX;_;2NH?AUKU]JVM>)=,DT*1 M-%GDEOH%O6>1K7Y"9% (9C'D8P3VKKOV=?"FL?!>R^,>C?%WX/\ C#XB:]XN MO+"YLI;;PH=8M=1MRG[A'>1?(B,#$,R3NFS QRM 'Z!M\:?A['XS'A!O'?AE M?%AE\D:"=8MQ?^9C.SR-^_=CG&,XK%D_:@^#4)D$GQ;\"QF-F5PWB2R&TJ0& M!_>\$$C/ID5^<'P5_9DN;3X.Z=\,?B5X3^,UCXEMO%9O5TOPCX>TO[#'-M!C MU!-5EM3&JA0$;_2SR,!"M8?PO_8_5O@7K^N>,?A[\1=%\;P_$,S:?K6A^&5O M-0M;9(T,4TEI/LDFM=\DC-Y*L2R D$+B@#]:_!_COPU\1-'_ +6\*^(=*\3: M7YC1?;M'O8KN#>.J[XV*Y&1D9[UNU\E_L(CXBPZA\38O&?AFUMM);5$ETWQ> MWA)?#-_XC<[Q+<7-EM5P>$(=U!.\\MV^M* "BBB@ HHHH \2_;1^'^O_ !2_ M9I\8^&/#%A_:>N7WV/[/:^='#OV7L$C_ #R,JC"(QY(Z8ZU^7/\ P[_^/?\ MT(?_ )6+#_X_7[5:A_QYR?A_,5BU]?D_$&*RFA*A0C%IN^J?9+HUV/2PV,J8 M>#A!+<_+JR^"/[8>F_$R'X@VNDRV_BZ&U6R74([[20# L8C6-HO,\M@% ^\I MY /4 UY_JW["?[0NNZM>ZE?>"//O;R=[B>7^UM.7?([%F; G &23P!BOV%HK MUJ?%N+I.].C33LEI%K1;+XMET1TK,:D=5&/W?\$_*KP7^S?^U;X!\.W/A_2? M"MM)H-Q<+=OI>JRZ+J-J)EZ2+%*/"TFJZO9]6TU%"J JHB M),%10!@*H %_\ H0__ "L6'_Q^OV0HH_UTS#^2'W2_^2#^ MU*W9?C_F?C?_ ,.__CW_ -"'_P"5BP_^/T?\._\ X]_]"'_Y6+#_ ./U^R%% M'^NF8?R0^Z7_ ,D']J5NR_'_ #/QO_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ MZ$/_ ,K%A_\ 'Z_9"BC_ %TS#^2'W2_^2#^U*W9?C_F?C?\ \.__ (]_]"'_ M .5BP_\ C]'_ [_ /CW_P!"'_Y6+#_X_7[(44?ZZ9A_)#[I?_)!_:E;LOQ_ MS/QO_P"'?_Q[_P"A#_\ *Q8?_'Z/^'?_ ,>_^A#_ /*Q8?\ Q^OV0HH_UTS# M^2'W2_\ D@_M2MV7X_YGXW_\._\ X]_]"'_Y6+#_ ./T?\.__CW_ -"'_P"5 MBP_^/U^R%%'^NF8?R0^Z7_R0?VI6[+\?\S\;_P#AW_\ 'O\ Z$/_ ,K%A_\ M'Z/^'?\ \>_^A#_\K%A_\?K]D**/]=,P_DA]TO\ Y(/[4K=E^/\ F?C?_P . M_P#X]_\ 0A_^5BP_^/UZW\+/V ;A?!?A2;54OOW#7$EU!;(L?\17SI$WY^[\N1R? M2OT(G\ ^&+J[-U-X_\ H0__ "L6 M'_Q^OV0HH_UTS#^2'W2_^2#^U*W9?C_F?CG#_P $]_C_ '&?+\ [L=?^)SIX M_P#;BI?^'=W[0?\ T3__ ,K6G_\ R17[,:/_ ,MOP_K6E6,N-\Q3M[.'W2_^ M2)>:U^R_'_,_%7_AW=^T'_T3_P#\K6G_ /R11_P[N_:#_P"B?_\ E:T__P"2 M*_:JBI_UXS+_ )]P^Z7_ ,D+^UJ_9?C_ )GXJ_\ #N[]H/\ Z)__ .5K3_\ MY(H_X=W?M!_]$_\ _*UI_P#\D5^U5%'^O&9?\^X?=+_Y(/[6K]E^/^9^*O\ MP[N_:#_Z)_\ ^5K3_P#Y(H_X=W?M!_\ 1/\ _P K6G__ "17[544?Z\9E_S[ MA]TO_D@_M:OV7X_YGXJ_\.[OV@_^B?\ _E:T_P#^2*/^'=W[0?\ T3__ ,K6 MG_\ R17[544?Z\9E_P ^X?=+_P"2#^UJ_9?C_F?BK_P[N_:#_P"B?_\ E:T_ M_P"2*/\ AW=^T'_T3_\ \K6G_P#R17[544?Z\9E_S[A]TO\ Y(/[6K]E^/\ MF?BK_P .[OV@_P#HG_\ Y6M/_P#DBC_AW=^T'_T3_P#\K6G_ /R17[544?Z\ M9E_S[A]TO_D@_M:OV7X_YGY;Z/\ "#X@_"OP1I%MXZ\,RZ%-&#;12?:8+F.1 M5QM^:%W"G! PQ!.TD4ROU!U32[/6K":QU"UAO;.9=LD$Z!T8>A!KSZ']F[X; MP7@NE\,0F0-NVO<3-'G_ '"Y7'MC%>KA>-:;@_KE)\W]W;\7=?B?S?G_ (=U M\=F%3%X"I&,:C4?\.[OV@_\ HG__ )6M/_\ DBOVFM[>*SMX MX((D@@C4(D<:A551P .@J2O-GQOCE)^RIP4>E[M_?S+\C]CX7P2X7RV. H6 MEJY2;3UD]WOIHDEY(_%7_AW=^T'_ -$__P#*UI__ ,D4?\.[OV@_^B?_ /E: MT_\ ^2*_:JBH_P!>,R_Y]P^Z7_R1];_:U?LOQ_S/Q5_X=W?M!_\ 1/\ _P K M6G__ "11_P .[OV@_P#HG_\ Y6M/_P#DBOVJHH_UXS+_ )]P^Z7_ ,D']K5^ MR_'_ #/Q5_X=W?M!_P#1/_\ RM:?_P#)%'_#N[]H/_HG_P#Y6M/_ /DBOVJH MH_UXS+_GW#[I?_)!_:U?LOQ_S/Q5_P"'=W[0?_1/_P#RM:?_ /)%'_#N[]H/ M_HG_ /Y6M/\ _DBOVJHH_P!>,R_Y]P^Z7_R0?VM7[+\?\S\5?^'=W[0?_1/_ M /RM:?\ _)%'_#N[]H/_ *)__P"5K3__ )(K]JJ*/]>,R_Y]P^Z7_P D']K5 M^R_'_,_%7_AW=^T'_P!$_P#_ "M:?_\ )%'_ [N_:#_ .B?_P#E:T__ .2* M_:JBC_7C,O\ GW#[I?\ R0?VM7[+\?\ ,_%7_AW=^T'_ -$__P#*UI__ ,D4 M?\.[OV@_^B?_ /E:T_\ ^2*_:JBC_7C,O^?,R_P"?,R_ MY]P^Z7_R0?VM7[+\?\S\5?\ AW=^T'_T3_\ \K6G_P#R11_P[N_:#_Z)_P#^ M5K3_ /Y(K]JJ*/\ 7C,O^?804E%-12BZGXL_#SX&?$/XO6U[/X'\+/XAAL72.Z<7MO;",L"5 M,SKN/RGAZ_P"__0UXG#L/[#E2 MQ-&"597N[R]Y/[+7-RM?);7WU/J>+?$K&9SB,1A,.HRPK:Y%*.JLOB3T=V[O MT=MC\6?^'?\ \>_^A#_\K%A_\?H_X=__ ![_ .A#_P#*Q8?_ !^OV0HK]3_U MTS#^2'W2_P#DC\L_M2MV7X_YGXW_ /#O_P"/?_0A_P#E8L/_ (_1_P ._P#X M]_\ 0A_^5BP_^/U^R%%'^NF8?R0^Z7_R0?VI6[+\?\S\;_\ AW_\>_\ H0__ M "L6'_Q^C_AW_P#'O_H0_P#RL6'_ ,?K]D**/]=,P_DA]TO_ )(/[4K=E^/^ M9^-__#O_ ./?_0A_^5BP_P#C]'_#O_X]_P#0A_\ E8L/_C]?LA11_KIF'\D/ MNE_\D']J5NR_'_,_&_\ X=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O_H0__*Q8 M?_'Z_9"BC_73,/Y(?=+_ .2#^U*W9?C_ )GXW_\ #O\ ^/?_ $(?_E8L/_C] M'_#O_P"/?_0A_P#E8L/_ (_7[(44?ZZ9A_)#[I?_ "0?VI6[+\?\S\;_ /AW M_P#'O_H0_P#RL6'_ ,?H_P"'?_Q[_P"A#_\ *Q8?_'Z_9"BC_73,/Y(?=+_Y M(/[4K=E^/^9^-_\ P[_^/?\ T(?_ )6+#_X_1_P[_P#CW_T(?_E8L/\ X_7[ M(44?ZZ9A_)#[I?\ R0?VI6[+\?\ ,_&__AW_ /'O_H0__*Q8?_'Z/^'?_P > M_P#H0_\ RL6'_P ?K]D**/\ 73,/Y(?=+_Y(/[4K=E^/^9^-_P#P[_\ CW_T M(?\ Y6+#_P"/T?\ #O\ ^/?_ $(?_E8L/_C]?LA11_KIF'\D/NE_\D']J5NR M_'_,_&__ (=__'O_ *$/_P K%A_\?H_X=_\ Q[_Z$/\ \K%A_P#'Z_9"BC_7 M3,/Y(?=+_P"2#^U*W9?C_F?C?_P[_P#CW_T(?_E8L/\ X_1_P[_^/?\ T(?_ M )6+#_X_7[(44?ZZ9A_)#[I?_)!_:E;LOQ_S/QO_ .'?_P >_P#H0_\ RL6' M_P ?H_X=_P#Q[_Z$/_RL6'_Q^OV0HH_UTS#^2'W2_P#D@_M2MV7X_P"9^-__ M [_ /CW_P!"'_Y6+#_X_1_P[_\ CW_T(?\ Y6+#_P"/U^R%%'^NF8?R0^Z7 M_P D']J5NR_'_,_&_P#X=_\ Q[_Z$/\ \K%A_P#'Z/\ AW_\>_\ H0__ "L6 M'_Q^OV0HH_UTS#^2'W2_^2#^U*W9?C_F?C?_ ,.__CW_ -"'_P"5BP_^/T?\ M._\ X]_]"'_Y6+#_ ./U^R%%'^NF8?R0^Z7_ ,D']J5NR_'_ #/QO_X=_P#Q M[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\ 'Z_9"BC_ %TS#^2'W2_^2#^U M*W9?C_F?C?\ \.__ (]_]"'_ .5BP_\ C]7-+_8'^.=I=+-*6@NFU.TMS)ABI(624,!E3U'/4<5^LGB M;P_:>+/#FJ:)?IOLM1MI+69?]AU*G'O@TSPCX9M/!GA;2-!L%VV>FVL=I%Q@ ME44+D^YQD^YK\P_LG ?7?;?5H>RY;W]X_5/^(L9W_93I>T_V MGVE^;E5N3EVM:U^;RV/R2U;]@CXYWET9[?X?-!OY>,ZSIY /J/W]4O\ AW_\ M>_\ H0__ "L6'_Q^OV0HK].PO%>-P="&'IPCRQ5E?F;LMM7*[^>I^68G/,3B MZTZ]2,>:3N[*ROUT3LOD?C?_ ,.__CW_ -"'_P"5BP_^/T?\._\ X]_]"'_Y M6+#_ ./U^R%%=7^NF8?R0^Z7_P D_P#H0_\ MRL6'_P ?H_X=_P#Q[_Z$/_RL6'_Q^OV0HH_UTS#^2'W2_P#D@_M2MV7X_P"9 M^.,?_!/OX^S.$3P%ECT']L:?_P#'ZG_X=W?M!_\ 1/\ _P K6G__ "17[(:? M_P ?D?X_R-;592XVS&+LJ,R_Y]P^Z7_R0O[6K]E^/ M^9^*O_#N[]H/_HG_ /Y6M/\ _DBC_AW=^T'_ -$__P#*UI__ ,D5^U5%'^O& M9?\ /N'W2_\ D@_M:OV7X_YGXJ_\.[OV@_\ HG__ )6M/_\ DBC_ (=W?M!_ M]$__ /*UI_\ \D5^U5%'^O&9?\^X?=+_ .2#^UJ_9?C_ )GXJ_\ #N[]H/\ MZ)__ .5K3_\ Y(H_X=W?M!_]$_\ _*UI_P#\D5^U5%'^O&9?\^X?=+_Y(/[6 MK]E^/^9^-W@[_@FO\;]=\3:=8ZUXSA^>>XDP9KN8@!I96Q\S''T MKNZ*\#->(,;F\8PKV45TC=*_=W;./$8RKB4E/1>04445\V<)Q'@7X+^#?AIX MH\7>(O#>C_V;K'BR[6^UFY^U32_:IEW8;:[LJ??;A HYZ4:9\%_!NC_%C5_B M79Z/Y/C;5K)-.O=4^U3-YMNFS:GE%S&N/+3E5!XZ]:[>B@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K:A_QYR?A_,5BUM:A_QY MR?A_,5BUT4]BX[!1116I04444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110!HZ/_P MOP_K6E6;H_\ MRV_#^M:5BM;(9D?\(KIW]VY_\#)O_BZ/^$5T[^[< M_P#@9-_\76O119 9'_"*Z=_=N?\ P,F_^+H_X173O[MS_P"!DW_Q=:]%%D!D M?\(KIW]VY_\ R;_ .+KQ;XT?M > _@WJ)TB2#4-;U]0&DL;2]E58 0"/,'UK\XX?@RWQN-WJN@ZP/^$PAOY?^$GT[69DB-N&E8M> M1L<9A7.&'+ K[@5\QGF-Q.%A"G@U[\K_ (6V75Z_OW)GT)\)OVH/ OQ*UM-'N]-U3P]?RL%@::]EF@&9O 7P]E\VRDPNM^)-NV M75Y%YV)W2!23@=6P"??]%_ 5Y>ZAX%\-W6I;O[1GTRUEN=W7S6A4OG_@1-89 M%F53&.="O)2E%)W2T]/.W?\ X=\W#V;5L=*>'Q$E.4$FVEIK?331V[JR>MKK M5S?\(KIW]VY_\#)O_BZ/^$5T[^[<_P#@9-_\76O17UUD?:F1_P (KIW]VY_\ M#)O_ (NC_A%=._NW/_@9-_\ %UKT460&1_PBNG?W;G_P,F_^+H_X173O[MS_ M .!DW_Q=:]%%D!D?\(KIW]VY_P# R;_XNC_A%=._NW/_ (&3?_%UKT460&1_ MPBNG?W;G_P #)O\ XNC_ (173O[MS_X&3?\ Q=:]%%D!D?\ "*Z=_=N?_ R; M_P"+H_X173O[MS_X&3?_ !=:]%%D!D?\(KIW]VY_\#)O_BZ/^$5T[^[<_P#@ M9-_\76O119 9'_"*Z=_=N?\ P,F_^+H_X173O[MS_P"!DW_Q=:]%%D!D?\(K MIW]VY_\ R;_ .+H_P"$5T[^[<_^!DW_ ,76O119 9'_ BNG?W;G_P,F_\ MBZ/^$5T[^[<_^!DW_P 76O119 9'_"*Z=_=N?_ R;_XNC_A%=._NW/\ X&3? M_%UKT460%?2_".F2>;N6ZXQTO9AZ_P"W5_\ X0S2_P"[=?\ @=/_ /%U:T?_ M );?A_6M*N6?Q$/[UB"\UZX>UTRTTZWU/4;B[E1-[(D5LLCDA>>G8TOAWQEX,\43VD5GIO MC6%KJX-K&=1\.Z]8J'";\NT\""-,#_6.0F?ESGBO-?VN/ /B3QS\7OV>VT Z MY816'B&\EO=7^L7MA;LUC"UL%'FFSMH8HX\@X9USEC\QX /IW_ (0S2_[M MU_X'3_\ Q=4]8T/0/#^D7VJ7[W4%C9027-Q+]LN&V1HI9FP&). "< $U^>/P M>^#'C'X:^&?@-XAT;P)XBT[Q;+X]U1/$3+9W4,YTV62=5%SQ^[MRHC92P" G M<.6)/"-X)\:ZAXA\!WVC?!O5/!NNR7>MG6X-)\%:P+JWAFAGC\N^UNYE<:CY MI*L-J;06X8< @'Z:^ +KP;\4?!ND^*_#%Y=:GH&JPBXL[O[1=Q>;&21G9(59 M>0>" :Z#_A#-+_NW7_@=/_\ %UY7^Q'X>U7PG^R?\,M(UO3+S1M6L])6.YL- M0MW@GA?>WRO&X#*?8BO<* ,/_A#-+_NW7_@=/_\ %T?\(9I?]VZ_\#I__BZW M** ,/_A#-+_NW7_@=/\ _%T?\(9I?]VZ_P# Z?\ ^+KQPKXYC-G)J(TA-9_LV\_LEKLKN$(U#R?LN[&3_K<8!H$>[45PVJ_ M%3^Q_&6I:'/X3\2&QL=*?57\1):Q'3'"C)@23S=QFQD[2@7C[U4OV?OCKH/[ M2'PMTOQ[X9M-2L='U"2:.*#5HHX[A3%(T;;EC=UZJ<88\8Z4 >C445Y/XK_: MD^'/@WXBWG@.^U+5KOQ?9V:ZA<:3HWAS4M3EBMVQB5OLMO( OS+DYX) .,T M>L45\_77[/=7;1--O-(A79;7*F,,MTDKQR0X\U#M*% ML'.WD9^@: "BBB@ HILDBQ1L[L$11EF8X 'J:\ET3]J[X8>+HO'Y\,>)HO%, MW@:T:]UJ+28GD5$".^(Y6"Q2DB-Q\CD C!(H ] MM;^ST?6$D>"#4XT2X4)(\9WJCNHY0]&/&*I>)/CWX;\,_OAO/'>7.NW^E M7.MW-Q (A:Z78P\&>[=Y%,:,WR*55N>N!S0!Z117BOA7]LKX/>-=?TC2-)\7 M^;/K%S+9:7=W&F7EM8ZA/&VUX[>[EA6"9MW "2$DD8SFO:J "BO)/%/[26A^ M%_C_ *!\(3H>N:CXDUC3/[86[M%MELK:U$CH\DKRSHWR^6Q(1&.", GBL2U_ M;D^"%YJ4-I%XYC,$VHG28M6;3;Q=*>[ SY2WYA^S%L<\2X/:@#W:BO+?#O[3 MGPT\5_#WQ;XXTKQ+]J\+>$Y[BVUF_P#L%RGV62!%>9?+:,.^U64Y16!SQFLK MX>_MC?!_XJ>-M-\(>&/&4>H^(M2L!J=G8O875N9[-@&5U.00>A!]*^+?AS^S#J'Q2U;X]Z3XQU;QCX:\(ZUXZN+AM$ MM8;>TM=9M@(7$GFR6S3M&Y7:3#*JD*1UR:\Q\1_LHZWK7@/]IS4=!\%75IXU MOO%;0:/=S631W-SHZM"TT=F[E24DC,RGRV'F#*9.<55V/4^^_&'Q-\,> _!. MK>+M:UB&W\.Z2ADO;Z!6N!"H(!^6(,Q/S#@ GFK6@^-=+\37A@T\7TH^R0WJ MW,NFW,5M)%*NY#'.\8C=L=45BRY&X"OSN\1?!W7=3^'?QEO/"7AK6+6UOO!= MOI/]@:-\.+OPW:7MREPC1.EO/>2S3W*1[U9TAV[2/GR,-B_&CX#^+?&?QFL( MKGP%K^J>'KJ#P7:WCKI5PT#11Y6Z5G5< (I(?GY<\XHYF%S]2*S/#OB*U\4: M>;VSBOH81*\.W4=/N+*7UC MXE7?_"9?#O7?[+AT'Q,T#:EIES##]IDOF, R5 +LK%D!R>C+R 0@ZKJ&[[;:7 9;>:L6EF(*FY=I9LD ME6S@]A>?"GQ!\-/ 'Q*^.\^FW?ACXK>'?&UOJ&D7^O6DT3:I;O#'%);*C &1 M)FN)0=O+%<9'4<&,P=#,*?LZ\;K?S1YN.P&'S*E[+$QNM^S7HSW/3_V3=!^" M.EW7CSXO^*+-?#&AE+BY@TRWGN(W&]0OF?N][*25!54).>H%>XZI^VM\'] N M?LFK>(=3T?4"L#Q:;J7AK5+6\N%F$/^"=/B?PC#8WWB3Q[J]HNJ:M'86[W%S>:E<74L>-O'?CJVU;1;"WN)[>UD?1K,7 >:2*WMK2.-=IP6>5' MP%&>,@Q@LOP^6P<,-&U]^K9GE^5X7*X.&%C:^_5L^B]2_:Z^&^CZOINDZA+X MJL-6U,N+#3[KP1K<5S>%!E_)B:S#2;1RVT' (SBN]^'7Q.\,?%GP[_;GA/5H M]7TX3/;2,J/%)!,AP\4L4BJ\4B\91U##(XYKY]^,7PML]%\8>$=7\3>(_C%X MAUJS:;^R_&GAK2[*Y?1@RCS8)(+"R#.DP"Y\RVE7Y0-R9(+_ /J'QK^(/[+ MOQ6M=3_M2/Q8YU2R\(:IJ5@FC:G?6OE8MII8 %$$IL?0 M.H_$GPYI/C_1_!-UJ/E>)]7M)KZRL?(D/FPPD"1MX78N-PX9@3G@&CXA?$GP MY\*]!CUGQ1J/]EZ;)=P6*S^1)-F:9PD2[8U8\L0,XP.Y%?EIXH^&,^DZGX.U M#P/^SWXQU&[M_ ;Z=XJLKW1]3TV&[OF>,2&2:-4>Z?\ UC.(F/G*0H+<@,\8 M? C6O$WB+Q_>Z=\)+BYT.Q&@W%LNE_#F\T.VF\N[07AL[*Y:25F,6%DVX:0+ MEDP,F>9BN?KI17YA?M+^&[CQ=)\11X4^"%[I\*:9I]IX5O4\ :S?:A VOF\#>'6U,3#4CIUL;H7"D2^;Y2[]X/(;=G. M>]4G<9NT4450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH T='_Y;?A_6 MM*LW1_\ EM^']:TJY9_$S-[A1114""BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "N7\)_$WPUXX\0>*-$T34OMNI^&;M+'5H/(EC^S3,@D M5-SJ%?*D'*%A[YKP[]NWPCK_ (M\'> 5LM$U7Q/X1LO%UC=^+=#T:-YY[S2U MW[U,"?/.@RL1$VZ];2H/+GO;='SBW^Z-R;E&W /TE^(WQ-\-?";P_%K?BO4O[*T MR2[@L4G\B6;,TSB.)-L:LW+$#.,#/) KJ*_)MO@7X@\5?!/XJR2_"C4+BUT[ MQ_IVIZ%IH\$3Z8RV#20B^;3]/F,LL<4@C!:*-FR ,@?=&M^T_P"&KCQC)\21 MX2^!5]IT*:7IUGX3OD^'NMW^HW2H/E-DQ:&+15@9<&/RMSM^@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "J6K?\ 'NO^_P#T-7:I:M_Q[K_O_P!#51^) M#6YDT445UF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10!9T_\ X_(_Q_D:VJQ=/_X_(_Q_D:VJYZFY$MPHHHK(D**** "BBB@ HHHH M **** //?VAO"^M>-_@1\0?#_AQRFO:IH-[:6.UMI,SPLJKN[9)QGMFOS6O/ MB'X7OO\ @EW9?!.V4R?%Z2]715\"I;L^KK?+J1N'9K;'F*/+#-OQMR=N=W%? MK77!_%#X&^"_C'<:#<^*M*FNK_0;AKK2]0L=0N=/N[*1E"LT4]M)'(N0!D!L M' ]!0!\&>!_#NK^$?VT9-#U^;S]=TWX$PV=_)NW;IXXHUD.>_P P/-?/W[*7 MB+3OASXM_9G\6^)KN/1/#(T#Q)9_VK>92W\_S[[$6_IO.] %ZDLH')%?L?X+ M\8>&/%=C<1>&/$6G^(H-+F.GW,EAJ*WK03( &BF<.Q$@&,ASNYR>M=#0!^87 M_!-S6O!EKX-^$=EJWQ'\4:!XJNM8ULZ1X3TNYF72M:4$-;TG0=3_P"$ A+W6LZ3+J47E^9;958H[FW(;.TA MBY& 1M./O"_AW4H85N);/5M9MK69(F8*LC)(X M(4L0 Q&"3B@#\V_CU^Q[X>^">O?LW^!=3U.;QF/%'Q"GO]?N[N!;>.]DF:U6 M1%A4D1QE5 V[F/+<\@#S'PQX@M/#?C_QAX#N/!6EW_@:W^*6H1VNH^)A?7'A MGPX-VT+-86\B13;E'R+*0J[#C +$?M)'*DT:21NLD;@,K*<@@]"#Z4^@#\)? MA[I6G:WXDUJQN?B%X3T73O#_ (ZO)=*\*^-]&U&#P;?-(C8,GWTM !&VV.5M MV#UR/FZ_X?\ BB7X@>//AO8^,=#T'X8_!/3;34+/1F\70:CK7A*\U#YV>=/M M%U"0&C?$6Z4JA7Y1N8X_:NB@#Y-_9)T/P)X#_9-O;;Q#\1+'QW\+7NYO(U/Q M9HTVD:=#92&-5M@FH.^^W#DA'+%6W[1DCGY4^$_Q6^&_AWXJ?MJ%/&/A72]' MUG36M] VZG;0V]\!;W*JEI\P60#*@"//4#TK]7:* /Q'^"NO>"/A[X9_9D\1 M^!YX[/XA:1J6I:EX[N+!7%Q#HZRAYFO, ?NOL^-F[@@G&*SMXH((UA@B4)''&,*J@8 [ "@#\O/&WQ>^'G[7'CCP)H/AOQ%X+^%OP0 M^'FK)JMN;_5+/2]0UBYBSLALK$NK01GD!G5?]9NQE0M>%>//%EG?6/@GQ9:^ M'-#^&GBN/XCQ_:--2VU.7Q1:J6.Z2_U:ZF+.K\XC* <94C:ZC]O** /ST_:R M\,ZOXT_;L.@: "VMZG\'-6L[)5D\LM,YNU0;NV20,^]<9\&_C9\*?#W[#7A/ MX4>+/!M M4 ?D)^SOX*U6\_8'_:4U&U\6^(?#&GV.J:VDOABV73YK6;;:0DI-++;2SDX( M0F.9@>(-=UO2M(L;^+46M]&>V3[3+&0T?F-+!(P"G M/"%<[CG/&/5* "BBB@#%\8>(])\)^'+O5=YU5=SN M0HRS*!D\D@=Z\S_X:+^%'_13O!O_ (/[3_XY7+_\%$?^3.OB!_W#_P#TX6U? MBK7Z%P[P[2S?"RKSJ.+4FM/1/]3VL%@HXFFYMVU/W2_X:+^%'_13O!O_ (/[ M3_XY1_PT7\*/^BG>#?\ P?VG_P DM^S[X%\?\ A?5K[4-9NK.U MU'Q'HTTT3O!:3OL^TP(J!E1&# [MW&3D;#GSSXQ?LS3>$_BWXO\ #OA?5-'. MBZ/??8X7\1^*=+L;MOW:.2R330L1\_W@@4XQU!KT:/#^65Y.,<2TU>]TE;E: M3_-6[HVC@\/-V4WU_ _5W_AHOX4?]%.\&_\ @_M/_CE'_#1?PH_Z*=X-_P#! M_:?_ !ROR.^&G[-^K^,OB5:^']3U#2K/1K>V;5=:UO3-6M-1MM.L(R?-E>6W MDD17PI 1CDEEXP"_VF- \#0>+=8LO!VJ6%C>Q7UU +F\N6 MN' 6*,)&BH6!&&=0%Y)STJY\-Y="K[+ZQ)OEG7R&\#04N7G=[7V/TN M_P"&B_A1_P!%.\&_^#^T_P#CE'_#1?PH_P"BG>#?_!_:?_'*_&WX_P#P_P!. M^%7QG\7^$=)FNKC3='OWM8);UE:9E &"Y55!//8"O/Z[Z7!N%K4XU85I6DDU MHNIM'+*M^ ?&. MNZ0)+C2(I+NROKJ*; ;_ $<$LRL2B\I@_*/2OQR\ ^+D\'>((KNYT^WU;3G_ M '=U8W42R)+&>N P(##J#_0FOLGP7X+\#W3Z?XL\.Z5:0O+&6@N;<% P*L- M@. >H/&1R*XL5PMA\&TY3DT]M%:_9GOY;PS2QTDU5V>JZV\C[1\*_M">"K?P MWIP\5>-?#^A:UY7[ZVU35(+:5L$J)-CN#AL9SC'7TK5_X:+^%'_13O!O_@_M M/_CE?%?BSP'X7\27$>J>(--MKM[*)@)KAB%2,98[AG! Y//3FOCWXM^-],\4 MZU]E\/Z9::5H%FQ6!+6W6(SMT,KX )SV!Z#W)I8;AG#XV;Y9R7?167DCHS;A MFEA:DZRJ64F^6*_K9'[+?\-%_"C_ **=X-_\']I_\#?_!_:?_'*/^&B M_A1_T4[P;_X/[3_XY7X6T4?ZDX?_ )_2^Y!_94/YF?NE_P -%_"C_HIW@W_P M?VG_ ,#?_!_:?\ QRC_ (:+^%'_ $4[ MP;_X/[3_ ..5^%M%'^I.'_Y_2^Y!_94/YF?O%I?[2'PEC\W?\4?!:YQC=X@M M!Z_]-*O_ /#2GPB_Z*GX*_\ "AL__CE?@=16M7=O M8*)"2?8EZE'#>P6L:.IS\HQM8=L"O@ M^*,MPW#$(UJT:DZK MBU>[7:W;N?K]^R-\?)/COX1\07-X0NI:?JTX\DXW):RNTEOG'HI:/_ME7O%? MBA\/?BWXO^%,FH2>$]:_2']DGX6>,] M.T=/&WQ(\0:SJ_B/4HLV>G:E>R2)I\##.?+8[5D8=>/E''!+"ORS*Z_[_P#0U4?B0UN9-%%%=9H%%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 6=/\ ^/R/\?Y&MJL73_\ C\C_ !_D:VJYZFY$MPHH MHK(D**** "BBB@ HHHH **** .0^,7_)(_&__8#OO_2=Z^"/^"8/PX\(^*/@ M#X5N]9^!6F^([O\ M.[)\:WVG:3.8RLS%#NDD^T_(0%&$R".!@ U^C6L:3:> M(-(OM+OXO/L;V"2VN(MQ7?&ZE67(((R"1D$&N9^$OP?\(_ OP5;>$O ^D_V) MX>MY))HK/[3-<;6=BSG?*[LGQ@6GEL=C((-CMD#]XX+_[5=?XP^*W[47P/UW7!\4_'?BV M#PK!:VMSI_C/PGX%TO4]*B9BCSB^CVK(D2Y>($2(Q(#=P#]A:A^Q3\&-6\%Z MUX3NO!OF^']9UL^(KZS_ +4O1YVH$$&;>)MR\$_*I"_[-6?&7['?PC\>>(M9 MUO5_"LC7^MQPQ:L+'5KVR@U)8B#&+J&"9(Y\$#_6*V<#.: /C#]BGX@0/^T? M\?O',_CWQ9XHT>2_T@FXT#PU]O\ [;22WN?*>>WMK*6:%$5?E\OR@IPKEC@' MQG]NSXW7NC_M8^*/&7@Y+BQN5\'6-O&/$OAEHW -[&K9M-1MP?HQC]U-?J1X M9_9>^&?@GQ]_PF7AKPXWAK76@AMI#HNHW=E:SQ0IY<22VL4JP2A5X >,] >H M!K)^*W[&OP>^-WBJ\\2>-?"']M:U>6<6GSW/]IWD&^"-Q(B;8IE4890<@9.. M3B@#X4\:?M4_'?3],_:)\4:9\3'T[3/AOJ^FV>E:&FAZ<\$T<]P8V25VM_,V MA!QA@"_VHOVD/VFH_B+KGPSM=7L9]!U"WL-(T/3;/0SII9/FF^WR7 MTZ7691G:8,!/5CFOL:^_8Y^$&I:/XXTJY\(^98>-KF"[U^'^T[P?;987WQ-D M39CPW.(RH/?-5M<_8H^#'B&^O+J[\&[?M\=M%?VUIJM[;6VH+;D&'[5!%,L= MP5(!S*K$]\T >,_M4?&;XOZ#XN_9C\,:)KS?#76/'MXUIXD@MK.SOS;R8M-Z M(TR2KE#+* 5)!R,EABOGAOVO_CWH/PK\0>.[CXD+J8\+?$9/"']FS:'8)'J= ML#(SO<,D*LKD>6H,)CP%;J2&'Z/>*O@+X"\::YX&U?5O#T4U]X(E\[P\T$\M MO'I[80?+'$ZHR@11@*ZL %X%7D@87.-8?!'6_#7[5G[)_P\^,/V'QKJ,7 MAV\CU"TU(+J%OY>^]DA@?S01)Y2^6O((!0;<@ U^FW@CX)^"_AQXR\7>*O#N MC?V=KWBR:.XUJ[^U32_:I(]VP['=E3&]N$"@YY[5C?$C]F;X=_%CQQHWC+Q' MI%])XJT>W:UT_5M-UN_TVXMHR6)"-;3QXSO;GKAB,XH _-+XE?&O4_V4_BI^ MTK\*?AU]J?PEJ5K;6GA_2+/?-'IFKWHA#Q6R<["5FNV$:CDPH .*\_\ #_Q. M\3_L9^"/CE\*=!O]"(8KG1-5_MRTN&O[MY'OL@BXG=I2;EU(^4S%] MNYL8W-GI?B)^SC\-_BSXQT3Q5XM\+6VMZ[HT$UK9W,TLJJ(95*R121JX29&# M,-LBL,,W'S'(!\E>$_@'\'?AY\,_V=/'FG>-(?ACXLG-A(GB&T4O/XEFN8TD MFM;D@_O5D<\[L[1P,"OOZO%/!?[&/P=\ >(-#UG1_"+B\T%I'TA+_5KV^M]- M9VW,UM!/,\4)+#.44$'IBO:Z "BBB@ HHHH **** "BBB@#YQ_X*(_\ )G7Q M _[A_P#Z<+:OQ5K^B_4/^/.3\/YBL6OO,AXC_L?#2H>RY[R;OS6Z)=GV/7P> M.^K4W#EOK??_ (!^.GA;]LW6O!/C#X6Z]HNC_93X-T-/#]Y:M>%DU:VWEI W MR#R\Y&/O[656YQBN<^(W[5OCSQ5\1?$WB3PUXD\1>!M/UJ\^VMH^E:[.D4;F M-$))C,88D(/FV@]/2OVNHKT8\38.%3VJP2O:WQWTO?K'N;K'4D^;V6OK\^Q^ M(.E_M4_%/3;'5K.;Q;-KMOJT<<-\OB2TM]8,\<99HXV-Y'*=BL[,$SM!8G&3 MFNV\=_M8Z7\3_B9X:\5>(_!#K#X?M;-;.ST:]M+*5[B!E.^6X^PL[Q-MXAX" M9.TCG/[$44Y<3824_:?4DGKJI6>MD]HKHK>@/'TV[^RU]?\ @'X9_'SXGZ%\ M8O'^I>+M,\.ZAX>U'5KF2ZOX;O5H[Z%G;;@1!;:(H!@YW%\Y'(QSYM7]"M%= ME'C.%"G&E3PWNK1>^W^<;FLB\_\ @'X'> ="TK7?$$2:[JL.D:1# M^\N9I&^=U'\" T:]TZX'[FZA:)O;(QGZCK^%W8U\E_%S1?#%KK7]I>$=5M[W2;UBWV5,K):OU*[6 .P]N..GIG]L_ASX M5_X0SP?I^F/M^T(I>=E.09&.6Y[XZ?0"NEI4.*(8.;]G2;Z?%H_.W+I]YT9K MQ0L54G25).*;Y7?7U^9_/517]"M%>C_KQ_U#?^3_ /VI\Y_:W]S\?^ ?SU45 M_0K11_KQ_P!0W_D__P!J']K?W/Q_X!_/517]"M%'^O'_ %#?^3__ &H?VM_< M_'_@'\]5%?T*T4?Z\?\ 4-_Y/_\ :A_:W]S\?^ ?SU45_0K11_KQ_P!0W_D_ M_P!J']K?W/Q_X!_/517]"M%'^O'_ %#?^3__ &H?VM_<_'_@'\]5%?T*T4?Z M\?\ 4-_Y/_\ :A_:W]S\?^ ?SU45_0K11_KQ_P!0W_D__P!J']K?W/Q_X!_/ M517]"M%'^O'_ %#?^3__ &H?VM_<_'_@'\]5%?T*T4?Z\?\ 4-_Y/_\ :A_: MW]S\?^ ?SU45_0K11_KQ_P!0W_D__P!J']K?W/Q_X!_/517]$VC_ /+;\/ZU MI5E+CSE=OJW_ )/_ /:DO-_^G?X_\ _G'HK^CBBI_P!??^H;_P G_P#M0_MC M_IW^/_ /YQZ*_HXHH_U]_P"H;_R?_P"U#^V/^G?X_P# /YQZ*_HXHH_U]_ZA MO_)__M0_MC_IW^/_ #^<>BOZ.**/]??^H;_ ,G_ /M0_MC_ *=_C_P#^<>B MOZ.**/\ 7W_J&_\ )_\ [4/[8_Z=_C_P#^<>BOZ.**/]??\ J&_\G_\ M0_M MC_IW^/\ P#^<>BOZ.**/]??^H;_R?_[4/[8_Z=_C_P _G'HK^CBBC_7W_J& M_P#)_P#[4/[8_P"G?X_\ _G'HK^CBBC_ %]_ZAO_ "?_ .U#^V/^G?X_\ _G M'HK^CBBC_7W_ *AO_)__ +4/[8_Z=_C_ , _G-LX%N;A(WE6%"?FD<\ 5W&G MZYI-J(+*UD)R0BX0\D]R2*_?JHKFVBO+>6WGC66"5#')&XR&4C!!'H17Q'$F M94>)U&&*A.,(WM&,TH\W\TO<;=NFJMKW9]IP[Q]5X&PT7*35Y2;%='7P)\2_#-_:_8(O^)7K.]+B)HA_RPDDC9@"H^Z2>1\O4#=UG[,GP M&A^ ?A/6M-#+-2=[6;OI;5?>%%%%?3GX8%%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 52U;_CW7_?_H:NU2U;_CW7_?\ MZ&JC\2&MS)HHHKK- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@"SI__'Y'^/\ (UM5BZ?_ ,?D?X_R-;5<]3*J*-]N_W+ M4^D/^$ILO^>.I?\ @LN?_C='_"4V7_/'4O\ P67/_P ;K(^&OQ,TSXH>';;5 M=/MKZP\Z$3_9=0MS%*$+,JN/X70E6PRD@X['BNNKLI58UH*I3=TSNHUJ=>"J MTG>+V9D?\)39?\\=2_\ !9<__&Z/^$ILO^>.I?\ @LN?_C=:]%:ZFID?\)39 M?\\=2_\ !9<__&Z/^$ILO^>.I?\ @LN?_C=:]%&H&1_PE-E_SQU+_P %ES_\ M;H_X2FR_YXZE_P""RY_^-UKT4:@9'_"4V7_/'4O_ 67/_QNC_A*;+_GCJ7_ M (++G_XW6O11J!D?\)39?\\=2_\ !9<__&Z/^$ILO^>.I?\ @LN?_C=:]%&H M&1_PE-E_SQU+_P %ES_\;H_X2FR_YXZE_P""RY_^-UKT4:@9'_"4V7_/'4O_ M 67/_QNC_A*;+_GCJ7_ (++G_XW6O11J!D?\)39?\\=2_\ !9<__&Z/^$IL MO^>.I?\ @LN?_C=:]%&H&1_PE-E_SQU+_P %ES_\;H_X2FR_YXZE_P""RY_^ M-UKT4:@9'_"4V7_/'4O_ 67/_QNC_A*;+_GCJ7_ (++G_XW6O11J!D?\)39 M?\\=2_\ !9<__&Z/^$ILO^>.I?\ @LN?_C=:]%&H&1_PE-E_SQU+_P %ES_\ M;H_X2FR_YXZE_P""RY_^-UKT4:@9'_"4V7_/'4O_ 67/_QNC_A*;+_GCJ7_ M (++G_XW6O11J!D?\)39?\\=2_\ !9<__&Z/^$ILO^>.I?\ @LN?_C=:]%&H M%?2_%MC'YN8-3/3[NE71]?2.K_\ PF-A_P ^^J_^"B[_ /C56M'_ .6WX?UK M2KFG\1#W,/\ X3&P_P"??5?_ 47?_QJC_A,;#_GWU7_ ,%%W_\ &JW**@DP M_P#A,;#_ )]]5_\ !1=__&J/^$QL/^??5?\ P47?_P :K.I?^"RY_\ C='_ E-E_SQU+_P67/_ M ,;K7HKJU-#(_P"$ILO^>.I?^"RY_P#C='_"4V7_ #QU+_P67/\ \;K7HHU MR/\ A*;+_GCJ7_@LN?\ XW1_PE-E_P \=2_\%ES_ /&ZUZ*-0,C_ (2FR_YX MZE_X++G_ .-T?\)39?\ /'4O_!9<_P#QNM>BC4#(_P"$ILO^>.I?^"RY_P#C M='_"4V7_ #QU+_P67/\ \;K7HHU R/\ A*;+_GCJ7_@LN?\ XW1_PE-E_P \ M=2_\%ES_ /&ZUZ*-0,C_ (2FR_YXZE_X++G_ .-T?\)39?\ /'4O_!9<_P#Q MNM>OB_Q5J6L^(OVS/B-H-QIGQ&\7Z)I^A:5/:Z3X.\7/I$5E)('WR,IU&T5M M^!TW'*\@=2G= ?7/_"4V7_/'4O\ P67/_P ;H_X2FR_YXZE_X++G_P"-U\7? M$+]HSQ)\#?$OQC@T'2I ?"7@[1]3LK7Q3J^H:G*LLTRH\=QNO9(RRB1@7B(9 MB!F1P!76ZI^UOXO\%ZAX]\-^*YO ND:_HOAO3_$-EK-U)>0:6HN7$;12H!)+ M(R.?E"8,N0,(3PN85SZD_P"$ILO^>.I?^"RY_P#C='_"4V7_ #QU+_P67/\ M\;K\]/C5^UM\0-6_M#PB^JR6%UIVL>';VVUS1-&U3PQ-/;W-PR3026UW(92A M(X8'8Z]NP]8_:1\1?$#QQ^UYX*^%GAR&XD\.Q^'9M>O+=?$-WH4%Q(96B#S7 M%J#-(D>U-L28R\@+<"CF"Y]9_P#"4V7_ #QU+_P67/\ \;H_X2FR_P">.I?^ M"RY_^-U\1:%^UU=_"']F;X@"SM?%&H^/O!NK7>FR0^*+>^UW3H)XYT5HO[4B M@C0PA6.P3RK*,J"6RNZUXK_:M^//@O4OB-97=O\ #N]_X0?PY9^)KNX@TZ^C M%W'.J'[,BFZ)1A^^_>DL/E3Y!N.TY@N?:?\ PE-E_P \=2_\%ES_ /&Z/^$I MLO\ GCJ7_@LN?_C=?$:?MN?$C6/@WXL^.5C;>';/P1X<\11Z0WA*:UDDO;JV M#Q1RR&[\X!)2TX*J(L +SFJMO^V?\6/$'PM\(Z_LIK2QO M&FL6A\P1SL/M(W%O+==H8;25?<>4!S!<^YO^$ILO^>.I?^"RY_\ C='_ E- ME_SQU+_P67/_ ,;K\_? GQ ^,%YX1_9$>W\22V MF:,R1AOF56 !P22/4T)W"YZ'_P )39?\\=2_\%ES_P#&Z/\ A*;+_GCJ7_@L MN?\ XW6O15:C,C_A*;+_ )XZE_X++G_XW1_PE-E_SQU+_P %ES_\;K7HHU R M/^$ILO\ GCJ7_@LN?_C='_"4V7_/'4O_ 67/_QNM>BC4#(_X2FR_P">.I?^ M"RY_^-T?\)39?\\=2_\ !9<__&ZUZ*-0,C_A*;+_ )XZE_X++G_XW1_PE-E_ MSQU+_P %ES_\;K7HHU R/^$ILO\ GCJ7_@LN?_C='_"4V7_/'4O_ 67/_QN MM>BC4#(_X2FR_P">.I?^"RY_^-T?\)39?\\=2_\ !9<__&ZUZ*-0,C_A*;+_ M )XZE_X++G_XW1_PE-E_SQU+_P %ES_\;K7HHU R/^$ILO\ GCJ7_@LN?_C= M'_"4V7_/'4O_ 67/_QNM>BC4#(_X2FR_P">.I?^"RY_^-T?\)39?\\=2_\ M!9<__&ZUZ*-0,^Q\5V2W2$P:ECGII=T>Q_Z9UK_\)C8?\^^J_P#@HN__ (U3 MM/\ ^/R/\?Y&MJL*FY$C#_X3&P_Y]]5_\%%W_P#&J/\ A,;#_GWU7_P47?\ M\:K+O"FF^. M?#.HZ#J\'VC3K^(PRIW'<,I[," 0>Q -?&WB;_@G]XD;5-NA^*M-N=)0XA_M M3S8YHT))VX1&4D$GH5!)S@9KXC/L!B*E=8BC1]IIIY/S75=5V>^FC_/.(LNQ M5;$+$T:"JZ:?W7YK[2ZI='OHVGE_LQ_%'Q1\1/VGK34M1N3(EU974$UO -D% MM;+&62.-.BHKK$ /IR:^]*\:_9[_ &:]+^!=O=7;7AU?Q#>1B*>]\O8D<>2 3C))YVC@=*]EKV\BPF(P>%:Q3]^3;?6USWN'<%BL%@W'&.\Y2U[ M?Y7"BBBOH3Z<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** -'1_P#EM^']:TJS='_Y;?A_6M*N6?Q,S>X4445 M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6K?\>Z_[_\ M0U=JEJW_ ![K_O\ ]#51^)#6YDT445UF@4444 %%%% !1110 4444 %%%% ! M7,Z;\-?#FC^/M:\:VFG>3XFUFU@L[Z^\^1O.AASY2["Q1<;CRJ@G/)-=-7S1 M^WMXDUGPW\-?!;:+>ZW:2WOC32K&XB\/ZB]A=W<$CN'MUF26+;O''+J,X)(Q MD)]P/3/&/[-WPY\?:EXJU#7O#OV^[\46$&F:O)]NN8_M-O"X>),)( FUE!R@ M4G')-0>+_P!F'X8^/=2UC4-?\+1ZC>:OIL&D7DLEY<*7MH9!)"JA9 $9'56$ MB8?(^]7QU\9K7XN?#GP[XEU,S^//"W@C5O%OAZST30=2\8&\ULAFV7BI=QW< MABCE)"A&N3S\V4%>K_$+X8_$+6?"-O)\//#WQ*\+SVVKVDVL:5XB^(L: M>N]I(+*Y&HW:VSE@FYMT)*\;L9%3?R$>G+^Q-\'&U'4=0N/#%[J&HZC<6UU= MWNH^(-2NYYY;=M\#-)+<,QVD#OR!@Y'%=M\1O@?X0^*FK:-JVN65Y'K>C>8- M/U?2=2N=.O;99!B1%GMY$?:PX*DD'TKPSX=_'WPG\)_#?Q7?5;WX@6>H^%7@ MN+KPCX[ODU"YMI)T(MX;*Z#2O.D[@*NZ>7#8QM!YXK4K?X@3?$CX)?#[QQXM MU[2I_B#=:OXE\36^FZS/ T;10*\.E6TT9#0P1@@,L;#=ACG)S1H!]-1?LX?# MF'X3W_PT3PU&G@S4&9[RP6YG#W+LX=I))P_FNY95)IVUS9))8X'5CY;SH?F4$GM M[Y\-?CMHOA']FWXA^*-.N_&?B&;P-)J*WNC^.I8SJMG<0)YGV-YE4[T&5VR, MTK8;EVQ@.Z ZQOV,_A0=3DN%T&[CL)KR#4;C0TU:[&F7-W" (YY;3S/*D?Y5 MR64[BH+ GFMFV_9=^&%KH?AG1X_"Z'3/#>IRZQI=M)>W+K!=RLS22'=(3("7 M?Y7W+SC%?,%C\;OBO#\G>)-#1-5\&W>O1>(=$\*ZUH[Q& M$ LEG/=7">6YT: M&XUR_N8-/>5&23R899V1%8,V5"[*=2\ M,Z#8:A<6%CX7UJ^N9?-C5R+ZYBF:&P&E>3>5+G8&VK]O^%]:'B7PUI.KK M$8%U"TANQ$3DH)$#;<]\9IJW0#3HHHJAA1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% %G3_ /C\C_'^1K:K%T__ (_(_P ?Y&MJN>IN1+<* M***R)"BBB@ HHHH **** "BBB@"AK]^=*T'4KU98H&MK:282SJS1IM4G+!?F M(&.0.<=*^/E_;^F\.^!_@MJ<]IH?Q#D^(FOS:)_;'APWFDV=MMN$B\Q(+N)Y MF(WX(8KDH<'!&/K?QGI]QJW@_7;&UC\VZN;">&*/(&YVC8*,G@9)'6OS+M?V M.?C3HOP*_9FTL> IK[6_ OBN\UC6],MM5T\2Q6[7B3)L=[A8W9E4X ?@]<4 M?:'[4/[6FG_LWZMX$T(:/%K7B'QEJ'V&P2^U)--L(%5HU>6XNF1_+4&5.B,3 MS[9J^)_CM\8?"/A/Q9K^H_!K0[?3_#=C<:G-?-XX#VNH6\41ES9M'9-*SD*P M*SQ0@?+AFR<9GQJT_4/CEHNG:;XK_9AO_%OAM)V6YM]8UW2;?5K3)/"E]I/AOX>:QKL-[.] M]+ )R4GDAB&X.H+3,V)/F8 4 >GZ?\ MX:O#^RQ-\=M>\ :5IGAVZ@ T;2K M/Q++=7]]=FY,"P.IL46,$J[;U:0@+]WT]._9(_:@M/VJ?A;=>*8]$;POJUA? MSZ;J.A377VB2SFCP0&8I&?F4J>4&#D/5 S,ZO!$(L;FDGYCA"X:,=C0!J_L MU_M?:]XX_99\7?&GXD?V':6&CR7GEV.AV4UOM2WR-K/)/+O:1BH7"K@G'S9X MY3X=_P#!3:V\=? 7XH>/KGX>R:+KW@9;6>7PO<:P2]U;SE!'*)3;J4!+-_RS M;@+S\W'SW\!_A/XZ^/G["G@WX;^%K"X/AS7/'URWBO5X;N"'[%IL4Z,V%D<- M(Q;:RA4?F+D+/#WCOPNVB:_J6MW&GVC6$?A=I=S MX.]'C^Q7S;8+C+N/+D.U\(V< M'Y6X)X/2N1^,5OXC^ /P\T&Z\%>#_ OP8\2>(O&.DZ'/=^#+>#4$GM96=3YO MF6-MD@DX7:3Z.,FOK+XUV'@:\^'][-\1-(TK6?#-I)%-)#K&G+?0I(7"(_E% M'^;+XR!D;CVS7S_I'BC]EOP_SI?AWPAII\^*Y_T/PCY7[V(EHI/EMA\R$DJW M523C%>EAL#BL3!SH4I26UTF_R1ZV$RK,,=3=3"8>=2*=KQC*2OVND]=3QGXA M?M'_ !7TVV\:^"]*\9_9=?T3XCZ1X8M?$SZ5:/,]E>QL<2Q&,Q,RD?>5%R / M>M#Q?\1?B2NK_M"6[?%K5M'?X3:1:7&E![+3U;4Y7MFN6GO%%J%=78")5C"* M%QU;+'VVX^*_[/-Y>75W<0:#/=W=[#J5Q/)X)[#0=?U:!!$EYJ/A^6:38&W*A+0GO->B?L]_&GXG^*/%USX5T?QA:^$='M]+\2:R\&D M^'--C62:WOF2,[1 "N0>']0NMD4EQ? M7GAJ2:5E@^:(LQMRS>7U7^Z>EO'N]*N?#VF7;Q30-/9^$KB M*1HY6WRH66U!*NWS,.C'DYH649A>ZH3_ / 9?Y'#B,KQ^$:6(H3@W_-&2_-' MR1;_ +97Q8_: T^XT]_'UCX&EN;71A;Q0ZII_A^T):0F]DFFNG2];<$.TV+$ M $ ]>?U@T^..'3[:.&1I85B54D:5I2R@#!+L26R/XB23U)-?GOJ6N?LG>7XS ML/#OQ8\0>!O#'C!8TUKPQX;T8PZ=.%38=B2:=(\.Y20WE.F?:O>O#?[<'[.W MA/P]I>B:9XV^SZ;IMK%9VT7]D:@=D4:!$&3!DX ')JHY3F*WP\__ &7^1RK M#5_Y']S/I:BOGK_AX!\!/^A\_P#*/?\ _P 8H_X> ? 3_H?/_*/?_P#QBK_L MG,/^@>?_ (#+_(?U>M_(_N9]"T5\]?\ #P#X"?\ 0^?^4>__ /C%'_#P#X"? M]#Y_Y1[_ /\ C%']DYA_T#S_ / 9?Y!]7K?R/[F?0M%?/7_#P#X"?]#Y_P"4 M>_\ _C%'_#P#X"?]#Y_Y1[__ .,4?V3F'_0//_P&7^0?5ZW\C^YGT+17SU_P M\ ^ G_0^?^4>_P#_ (Q1_P / /@)_P!#Y_Y1[_\ ^,4?V3F'_0//_P !E_D' MU>M_(_N9]"T5\]?\/ /@)_T/G_E'O_\ XQ1_P\ ^ G_0^?\ E'O_ /XQ1_9. M8?\ 0//_ ,!E_D'U>M_(_N9]"T5\]?\ #P#X"?\ 0^?^4>__ /C%'_#P#X"? M]#Y_Y1[_ /\ C%']DYA_T#S_ / 9?Y!]7K?R/[F?0M%?/7_#P#X"?]#Y_P"4 M>_\ _C%'_#P#X"?]#Y_Y1[__ .,4?V3F'_0//_P&7^0?5ZW\C^YGT+17SU_P M\ ^ G_0^?^4>_P#_ (Q1_P / /@)_P!#Y_Y1[_\ ^,4?V3F'_0//_P !E_D' MU>M_(_N9]"T5\]?\/ /@)_T/G_E'O_\ XQ1_P\ ^ G_0^?\ E'O_ /XQ1_9. M8?\ 0//_ ,!E_D'U>M_(_N9]"T5\]?\ #P#X"?\ 0^?^4>__ /C%'_#P#X"? M]#Y_Y1[_ /\ C%']DYA_T#S_ / 9?Y!]7K?R/[F?0M%?/7_#P#X"?]#Y_P"4 M>_\ _C%'_#P#X"?]#Y_Y1[__ .,4?V3F'_0//_P&7^0?5ZW\C^YGT+17SU_P M\ ^ G_0^?^4>_P#_ (Q1_P / /@)_P!#Y_Y1[_\ ^,4?V3F'_0//_P !E_D' MU>M_(_N9]"T5\]?\/ /@)_T/G_E'O_\ XQ1_P\ ^ G_0^?\ E'O_ /XQ1_9. M8?\ 0//_ ,!E_D'U>M_(_N9]+:/_ ,MOP_K6E7S)IO\ P4(^ %OYGF>/MN<8 M_P")-J!]?^G>KO\ P\1_9\_Z*!_Y1=0_^1ZYIY1F/-_NT_\ P"7^1#PU>_P/ M[F?1U%?./_#Q']GS_HH'_E%U#_Y'H_X>(_L^?]% _P#*+J'_ ,CU']D9E_T# M3_\ )?Y"^K5_P"1_(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@? M^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_(_L^?]% _P#*+J'_ M ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_ M(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5 M_P"1_(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R, MR_Z!I_\ @$O\@^K5_P"1_(_L^?]% _P#*+J'_ ,CT?\/$?V?/ M^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_(_L^?]% _P#* M+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\ M@^K5_P"1_(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474/_D> MC^R,R_Z!I_\ @$O\@^K5_P"1_(_L^?]% _P#*+J'_ ,CT?\/$ M?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_(_L^?]% M_P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ M@$O\@^K5_P"1_(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474 M/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_(_L^?]% _P#*+J'_ ,CT M?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_(_L^ M?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1 M_(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z! MI_\ @$O\@^K5_P"1_(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@? M^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_(_L^?]% _P#*+J'_ M ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_3;Z7=0[F] \T:)GD$C=G':L:S_;9TB2[5;GPS>P MVQ.&EBN4D<#UVD#/YUTT\AS2JG*-"2MWT_!V9\EF'$>4Y57^JXRNH5.VK:]; M)V^=CZ4HKP'7/V\/@?X:O?L>J^,Y;"ZVAO*ET:_/![@B AAU&02.#6?_ ,/$ M?V?/^B@?^474/_D>N;^R,Q_Z!I_^ 2_R/IZ,)8BG&M17-&6J:U37=-'T=17S MC_P\1_9\_P"B@?\ E%U#_P"1Z/\ AXC^SY_T4#_RBZA_\CT?V1F7_0-/_P ME_D;?5J_\C^YGT=5+5O^/=?]_P#H:^?O^'B/[/G_ $4#_P HNH?_ "/574/^ M"A7[/\\*JGC[<=V?^0-J'H?^G>JCE&8W7^S3_P# )?Y#6&KW^!_ ? 3_ *'S_P H]_\ _&*/^'@'P$_Z'S_RCW__ ,8KJ_LG,/\ H'G_ . R M_P B_J];^1_ ? 3_H?/\ RCW_ /\ &*/^'@'P$_Z'S_RCW_\ M\8H_LG,/^@>?_@,O\@^KUOY']S/H6BOGK_AX!\!/^A\_\H]__P#&*/\ AX!\ M!/\ H?/_ "CW_P#\8H_LG,/^@>?_ (#+_(/J];^1_ ? 3_H?/ M_*/?_P#QBC_AX!\!/^A\_P#*/?\ _P 8H_LG,/\ H'G_ . R_P @^KUOY']S M/H6BOGK_ (> ? 3_ *'S_P H]_\ _&*/^'@'P$_Z'S_RCW__ ,8H_LG,/^@> M?_@,O\@^KUOY']S/H6BOGK_AX!\!/^A\_P#*/?\ _P 8H_X> ? 3_H?/_*/? M_P#QBC^R?)%Y=U"Q:*3,;*3M)^ZX->0?\/ /@)_T/G_E'O_\ XQ1_P\ ^ G_0 M^?\ E'O_ /XQ1_9.8?\ 0//_ ,!E_D'U>M_(_N9Z_P"/_AKX<^*.E66F^)]. M_M.RL[^#4X(O/DBV7$+;XGS&RD[6YP3@]P:K?$CX2^%/BUI]C:>*-+-^-/N5 MO+*X@N9K6YM)ATDAGA=)(VQQE6&1P:\I_P"'@'P$_P"A\_\ */?_ /QBC_AX M!\!/^A\_\H]__P#&*/[)S#_H'G_X#+_(/J];^1_7$> S[L\8KT7XF?"#PQ\ M7+72X_$-I<-7K^W]\!68!? M'98^@T;4/_C%)_P\ ^ F<_]@>__P#C%3_96/O;ZO/_ ,!E_D/ZK7M? MV;^YFS8?L:_"?3GBNH=!OX]<2ZEO6\1PZY?PZQ+-* )&DOHYEG<, /E+[?:N MV\&?!7P3\/\ P;J7A71/#]O#H6J23RZC;7+/=-?O,,3/<23,[S,XX+2,Q(P. M@KQC]F#]HO\ X6M\6/B/I4EPSV4]S_:.C*^1_HR!8" #T)587V^K.?6OI>XO M;>T:)9YXH6E;9&LCA2['H!GJ?:O PN)I8JG[6GM=K[G8]7.1XSZCBHVG MRQE_X%%2_"]GYIGB^B_L6_!S0M0-Y;^$Y9Y?[*FT-8]0UB_O(8["4$/;1Q33 MNB1X9L*J@+DXQ3+#]BCX.6%])>'PM=:A M%"@;?X<&O<:*Z[(\$^?)_P!@GX)76GZE83>&M7FL=3$ OK:3Q9K#17?DJ%@\ MU3=X?RU "[L[0 !BO>=*TNVT32[/3K*+R;.SA2W@CW%MD:*%49)). !R3FK5 M%.R0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!9T M_P#X_(_Q_D:VJQ=/_P"/R/\ '^1K:KGJ;D2W"BBBLB0HHHH **** "BBB@ H MHHH H>(-=L?"^@ZCK.IS_9M-TZVDN[J;8S^7%&I9VVJ"3A03@ GTKR>Q_;&^ M#VJ?"N#XD6OC*.?P9-J2Z0NHI871(NV;:L30^5YJDDCED P0 XV$AOA9BXS9' M2L#?MQG?Y78#=SFJGCCX>'QU\;/C-<_$[2XM5\7:)\$[?49A>*&-OJBV%L'F M'I(KE\$="30!^PU)UX/(KY/_ &/?%_Q;U+]F3X7S6/AOPSX@TQM$MT&JZSXM MN[:]=5&T[H5TZ9X+P0R)YD3O(GF=R$0!EY- '[A>"?AAX.^&L=Y'X0\):'X5CO M762Z71--ALQ.PSAG$:KN(R<$^IKIJ_'7XH_"GP!>S>(+WPK^T'X9TWPS-J6F MR:EX=\.^!M6A\$2W:A/)%S<13W-O'N!&\;L9SN"D$CC/ MQ9>(/VB;;3O%2? M#_P;\*[6>_ABO%MM2U;X?7FK[',D\$!M>^)6H?":YOX+_ ,5-HYU.[T*>SDDC>P=A$6=BGE,"6"E"V2#]W%?EQ\-M M!\+>$?C)\*]-^)?C^3QY^S:NFZC<^'+_ ,4:'=:;H?VXJ^;?RKQGWJB^BC2Z"0LZ ML"JNRY)C;'S=QTK\>?$VM:;!K/PBU?0[+POX/N]2TK7+;4=)\+Z??6MW;JT# MC[-J-W01LW?*03C.30!^O?[/WQUT']I#X6Z7X]\,VFI6.CZA)-'%!JT4< M=PIBD:-MRQNZ]5.,,>,=*]&K\.OV?X+W4M+^!5GX^U30-#^$?]E:P=/N_&FE MRW_A\ZH;RZ$@N(UN;=/.\K;L9Y,+A=H).:^D_'_A:Q\(_P#!)_XB66B^/;SX MA^&FNX)=(U&ZT2[TI(+4WUIMMX([IWD>%6W%7#%2&(!.TF@#],J\S^(_[1W@ M'X4^--$\(^(=3U!?$^MP27.G:3I>B7^I7%S&F=Y1+6"0\!6)'7 )Z5^7^E_! M#P3!\8M2\-IH-N-"7X%Q^(7T\9$,VHBS 6[D7.'E!D=@YY#'<,'FK/P*O_%/ MB?XI?L52:;KEK!XA_P"$8UJ&WU'7+234(8TC>^15>)9X6<"-=B@2+MPO4#! M/T.OOVX/@EIO@G5/%=WXV6UTC2M371]06;2[U+NSNVWXBFM##Y\9/EO@M&!E M&&>*Z3P/^TS\.?B#XV/@[2];NK3Q7]D%]'HNN:1>Z3=30'.)(H[N&)I5PK'* M X )Z5^>O_!0#]E__A2/[/?COQKK'B=O%?C'QQXRL+S4KR&P%A:1(BW)CBA@ M\R0J!YC LTC$@+[DW/VT_CAHGB?XG?!CQC\,=5M/$DOPOLY=;\0:]I,OG6-M M"1 8K22Y3Y-\S1O$(PV29@N/FH ^_/#7[4'PP\8?OA;I'BJ*\\=Z4)#=Z M2+6X7R_+V^8!*T8B8KN&0KD]?0XPO$W[:_P8\(Z[K6DZCXR_?:)JW5II M=[=66GS.VQ8[B[BA:")MV5(=Q@@@XP:_,J7X5_$7]FGP+\'?VD]1TC3X+AM7 M;5?$6JV.I32ZA?6^ID.!<0&V180L9=.)I/GF' KU#]DKXO\ P\^ _P"RQ\4_ MA_\ %;3%N_%LNL3R3^$+@-]L\21W4<2V_P!G&,S+(0<.N0 0V<$$@'ZFZ?J% MKJUA;7UC<17EE';J3S)=.0J"(&.3RH.,=L8XQBNUH **** /'?VN_P#DWCQ9_P!N MG_I7#7YMU^DG[7?_ ";QXL_[=/\ TKAK\VZ_9^"_^1?/_&__ $F)_4?A;_R) M:O\ U]E_Z1 ****^^/V(R?%W_(IZU_UY3_\ HMJ^8Z^G/%W_ "*>M?\ 7E/_ M .BVKYCKHI['XGQ__O-#_"_S/KS]E/\ 9]^''Q@^ _BN;Q3*FC^+KS7(]#\/ M:Y)<3*D-U)")(8F16\LJ[*5.Y2?FP"#MJ#Q]^QK>0Z'\,]%L-'E\.>,KC1[Z M[U\366J:@TLL5V(E/EVD%P4&UEPP14((.22,^ :9\7-:TGX4W_@"VBM$TF\U M>'6FNPKBZ2>.,HH1P^T+@Y^[G/>M[XY_M(^+?VAD\,'Q:MA)=:#9&RBN[2)T MEN0=NZ2;+L"Y*Y)4*.3Q7SKP>8_6W.-6U-R;WO;W;*R[-[KHTFC\<]G7]I=2 MTO\ H=!XD_9YNO@?-H_B/QM8R>)?#QODMY]+BL-9T4W!978*;J\T^*-!E>=K M%\9P!RR_2/PB_9)\"?&?P[IFI:OX3TGPO<1>('21/!'B.36;>:P2!I3'M']V*1KFXF(BY(V M(5&&/K4YAA,QJ4U'#U'S_P U^5>C2=OGRN_E85:G6DK0EKWV_K[F=#=>&O G MQ@_9_P#B;XMT;P99>!=<\$7]F]NNEW=U,EU8W$IB6*;SY7S(I!/F+MW8^Z*^ M9Z]?\;_M):AXH\#ZOX3T;PMH/@K2-H;A1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 ?:OA#P_;>%_#=AIMJBJD,2[F'\;D99C[D MY-;%>>_"+XDV?C#0;6SGGCCUFV01R0,V&E"C D7UR.OH<^U>A5QNZ>I_G!GN M#QV!S*O1S%/VO,VV^MW\2[I[IGE_[0GA^VU'P+)J3H!=:?(C1R=]KNJ,OTY! M_"OF*O=/C]\2+2^LU\.:9.ESEP]Y+&3Z8 ]<>%UT4[VU/[$\+ ML'CL%P[".-37-*4H)[J#M;3I=\TEZWZA1116A^MA1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% "QR-&ZNC%64Y##J#7H&@ZA%KUGOG@1IXB M%(N6U M\SPM*C@,-*IB$[QE'3D76\MGS?RW\^FOZQP!F%'+<35JXW$1IT&K.,M>9]+1 M\OYK>7IW&CZ[J7AV]%YI6H76F784H+BSF:&3:1@C2K,6R?WI(8$=5&1U) ^0?@3\$]5^/7BN?1=)NH; M%8+1KN6\N%9HT4%54<=R6'ZGM7VO^S3\'OBI\ =:ET74I=,\0>"KYR[?8KMO M,LI>TJK(J\'@,HSV(Y&&_F?(<-45>-:K3;A?1]%+NU_5OD??^)V;89Y;6R_" M8N%/$63E%Z2G3U]U2VUWM?5:==?I^BBBOU$_B@**** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"SI__'Y'^/\ (UM5BZ?_ ,?D M?X_R-;5<]3S'VD_YF>>?\,Z_"C_HF/@W_P $%I_\;H_X M9U^%'_1,?!O_ ((+3_XW7H=%'UO$?\_)?>P]I/\ F9YY_P ,Z_"C_HF/@W_P M06G_ ,;H_P"&=?A1_P!$Q\&_^""T_P#C=>AT4?6\1_S\E][#VD_YF>>?\,Z_ M"C_HF/@W_P $%I_\;H_X9U^%'_1,?!O_ ((+3_XW7H=%'UO$?\_)?>P]I/\ MF9YY_P ,Z_"C_HF/@W_P06G_ ,;H_P"&=?A1_P!$Q\&_^""T_P#C=>AT4?6\ M1_S\E][#VD_YF>>?\,Z_"C_HF/@W_P $%I_\;H_X9U^%'_1,?!O_ ((+3_XW M7H=%'UO$?\_)?>P]I/\ F9YY_P ,Z_"C_HF/@W_P06G_ ,;H_P"&=?A1_P!$ MQ\&_^""T_P#C=>AT4?6\1_S\E][#VD_YF>>?\,Z_"C_HF/@W_P $%I_\;H_X M9U^%'_1,?!O_ ((+3_XW7H=%'UO$?\_)?>P]I/\ F9YY_P ,Z_"C_HF/@W_P M06G_ ,;H_P"&=?A1_P!$Q\&_^""T_P#C=>AT4?6\1_S\E][#VD_YF>>?\,Z_ M"C_HF/@W_P $%I_\;H_X9U^%'_1,?!O_ ((+3_XW7H=%'UO$?\_)?>P]I/\ MF9YY_P ,Z_"C_HF/@W_P06G_ ,;H_P"&=?A1_P!$Q\&_^""T_P#C=>AT4?6\ M1_S\E][#VD_YF>>?\,Z_"C_HF/@W_P $%I_\;H_X9U^%'_1,?!O_ ((+3_XW M7H=%'UO$?\_)?>P]I/\ F9YY_P ,Z_"C_HF/@W_P06G_ ,;H_P"&=?A1_P!$ MQ\&_^""T_P#C=>AT4?6\1_S\E][#VD_YF>>?\,Z_"C_HF/@W_P $%I_\;H_X M9U^%'_1,?!O_ ((+3_XW7H=%'UO$?\_)?>P]I/\ F9QFE_LX?"63S=_PN\%M MC&-WA^T/K_TSJ_\ \,U_"+_HE?@K_P )VS_^-UVNC_\ +;\/ZUI5RSQF)YOX MDOO9#J3O\3/./^&:_A%_T2OP5_X3MG_\;H_X9K^$7_1*_!7_ (3MG_\ &Z]' MHJ/KF)_Y^2^]D^TG_,SSC_AFOX1?]$K\%?\ A.V?_P ;H_X9K^$7_1*_!7_A M.V?_ ,;KT>BCZYB?^?DOO8>TG_,SSC_AFOX1?]$K\%?^$[9__&Z/^&:_A%_T M2OP5_P"$[9__ !NO1Z*/KF)_Y^2^]A[2?\S/./\ AFOX1?\ 1*_!7_A.V?\ M\;H_X9K^$7_1*_!7_A.V?_QNO1Z*/KF)_P"?DOO8>TG_ #,\X_X9K^$7_1*_ M!7_A.V?_ ,;H_P"&:_A%_P!$K\%?^$[9_P#QNO1Z*/KF)_Y^2^]A[2?\S/./ M^&:_A%_T2OP5_P"$[9__ !NC_AFOX1?]$K\%?^$[9_\ QNO1Z*/KF)_Y^2^] MA[2?\S/./^&:_A%_T2OP5_X3MG_\;H_X9K^$7_1*_!7_ (3MG_\ &Z]'HH^N M8G_GY+[V'M)_S,\X_P"&:_A%_P!$K\%?^$[9_P#QNC_AFOX1?]$K\%?^$[9_ M_&Z]'HH^N8G_ )^2^]A[2?\ ,SSC_AFOX1?]$K\%?^$[9_\ QNC_ (9K^$7_ M $2OP5_X3MG_ /&Z]'HH^N8G_GY+[V'M)_S,\X_X9K^$7_1*_!7_ (3MG_\ M&Z/^&:_A%_T2OP5_X3MG_P#&Z]'HH^N8G_GY+[V'M)_S,\X_X9K^$7_1*_!7 M_A.V?_QNC_AFOX1?]$K\%?\ A.V?_P ;KT>BCZYB?^?DOO8>TG_,SSC_ (9K M^$7_ $2OP5_X3MG_ /&Z/^&:_A%_T2OP5_X3MG_\;KT>BCZYB?\ GY+[V'M) M_P S/./^&:_A%_T2OP5_X3MG_P#&Z/\ AFOX1?\ 1*_!7_A.V?\ \;KT>BCZ MYB?^?DOO8>TG_,SSC_AFOX1?]$K\%?\ A.V?_P ;H_X9K^$7_1*_!7_A.V?_ M ,;KT>BCZYB?^?DOO8>TG_,SSC_AFOX1?]$K\%?^$[9__&Z/^&:_A%_T2OP5 M_P"$[9__ !NO1Z*/KF)_Y^2^]A[2?\S/./\ AFOX1?\ 1*_!7_A.V?\ \;H_ MX9K^$7_1*_!7_A.V?_QNO1Z*/KF)_P"?DOO8>TG_ #,\X_X9K^$7_1*_!7_A M.V?_ ,;H_P"&:_A%_P!$K\%?^$[9_P#QNO1Z*/KF)_Y^2^]A[2?\S/./^&:_ MA%_T2OP5_P"$[9__ !NC_AFOX1?]$K\%?^$[9_\ QNO1Z*/KF)_Y^2^]A[2? M\S/.HOV')X&&#%) MI-NRD>A!3%=?11];Q'_/R7WLYZM*%>2E5BI-;75[>AYQ_P ,U_"+_HE?@K_P MG;/_ .-T?\,U_"+_ *)7X*_\)VS_ /C=>CT4?7,3_P _)?>SH]I/^9GG'_#- M?PB_Z)7X*_\ "=L__C='_#-?PB_Z)7X*_P#"=L__ (W7H]%'US$_\_)?>P]I M/^9GG'_#-?PB_P"B5^"O_"=L_P#XW5/4_P!F_P"$D=NI7X6^"U.[MX>M!V/_ M $SKU.J6K?\ 'NO^_P#T-5'&8FZ_>2^]C52=_B9Y-_PSK\*/^B8^#?\ P06G M_P ;H_X9U^%'_1,?!O\ X(+3_P"-UZ'177];Q'_/R7WLT]I/^9GGG_#.OPH_ MZ)CX-_\ !!:?_&Z/^&=?A1_T3'P;_P"""T_^-UZ'11];Q'_/R7WL/:3_ )F> M>?\ #.OPH_Z)CX-_\$%I_P#&Z/\ AG7X4?\ 1,?!O_@@M/\ XW7H=%'UO$?\ M_)?>P]I/^9GGG_#.OPH_Z)CX-_\ !!:?_&Z/^&=?A1_T3'P;_P"""T_^-UZ' M11];Q'_/R7WL/:3_ )F>>?\ #.OPH_Z)CX-_\$%I_P#&Z/\ AG7X4?\ 1,?! MO_@@M/\ XW7H=%'UO$?\_)?>P]I/^9GGG_#.OPH_Z)CX-_\ !!:?_&Z/^&=? MA1_T3'P;_P"""T_^-UZ'11];Q'_/R7WL/:3_ )F>>?\ #.OPH_Z)CX-_\$%I M_P#&Z/\ AG7X4?\ 1,?!O_@@M/\ XW7H=%'UO$?\_)?>P]I/^9GGG_#.OPH_ MZ)CX-_\ !!:?_&Z/^&=?A1_T3'P;_P"""T_^-UZ'11];Q'_/R7WL/:3_ )F> M>?\ #.OPH_Z)CX-_\$%I_P#&Z/\ AG7X4?\ 1,?!O_@@M/\ XW7H=%'UO$?\ M_)?>P]I/^9GFWPJ^!NA_"7Q)XRU/1[>WM8M>NXI8;6WB$<=K"D8_=*H& /,: M5L# P5':O2:**X*=.-*/+!66K^]W9TXS&5\?5]OB9\TK)7?:*45^"04445H< M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% % MG3_^/R/\?Y&MJL73_P#C\C_'^1K:KGJ;D2W"BBBLB0HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH K:A_QYR?A_,5BUO7$/VB%H\[<]\9[U2_L?_IM_P"._P#UZVA)):EI MF=16C_8__3;_ ,=_^O1_8_\ TV_\=_\ KUISQ'=&=16C_8__ $V_\=_^O1_8 M_P#TV_\ '?\ Z]'/$+HSJ*T?['_Z;?\ CO\ ]>C^Q_\ IM_X[_\ 7HYXA=&= M16C_ &/_ --O_'?_ *]']C_]-O\ QW_Z]'/$+HSJ*T?['_Z;?^.__7H_L?\ MZ;?^._\ UZ.>(71G45H_V/\ ]-O_ !W_ .O1_8__ $V_\=_^O1SQ"Z,ZBM'^ MQ_\ IM_X[_\ 7H_L?_IM_P"._P#UZ.>(71G45H_V/_TV_P#'?_KT?V/_ --O M_'?_ *]'/$+HSJ*T?['_ .FW_CO_ ->C^Q_^FW_CO_UZ.>(71G45H_V/_P!- MO_'?_KT?V/\ ]-O_ !W_ .O1SQ"Z,ZBM'^Q_^FW_ ([_ /7H_L?_ *;?^.__ M %Z.>(71G45H_P!C_P#3;_QW_P"O1_8__3;_ ,=_^O1SQ"Z,ZBM'^Q_^FW_C MO_UZ/['_ .FW_CO_ ->CGB%T9U%:/]C_ /3;_P =_P#KT?V/_P!-O_'?_KT< M\0NC.HK1_L?_ *;?^.__ %Z/['_Z;?\ CO\ ]>CGB%T9U%:/]C_]-O\ QW_Z M]']C_P#3;_QW_P"O1SQ"Z#1_^6WX?UK2JM9V?V7?\^_=CMBK-82=W=$/<*** M*@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+5O\ CW7_ M '_Z&KM07=M]JC";MN#G.,U4=&-&'16C_8__ $V_\=_^O1_8_P#TV_\ '?\ MZ]='/$NZ,ZBM'^Q_^FW_ ([_ /7H_L?_ *;?^.__ %Z.>(71G45H_P!C_P#3 M;_QW_P"O1_8__3;_ ,=_^O1SQ"Z,ZBM'^Q_^FW_CO_UZ/['_ .FW_CO_ ->C MGB%T9U%:/]C_ /3;_P =_P#KT?V/_P!-O_'?_KT<\0NC.HK1_L?_ *;?^.__ M %Z/['_Z;?\ CO\ ]>CGB%T9U%:/]C_]-O\ QW_Z]']C_P#3;_QW_P"O1SQ" MZ,ZBM'^Q_P#IM_X[_P#7H_L?_IM_X[_]>CGB%T9U%:/]C_\ 3;_QW_Z]']C_ M /3;_P =_P#KT<\0NC.HK1_L?_IM_P"._P#UZ/['_P"FW_CO_P!>CGB%T9U% M:/\ 8_\ TV_\=_\ KT?V/_TV_P#'?_KT<\0NC.HK1_L?_IM_X[_]>C^Q_P#I MM_X[_P#7HYXA=&=16C_8_P#TV_\ '?\ Z]']C_\ 3;_QW_Z]'/$+HSJ*T?[' M_P"FW_CO_P!>C^Q_^FW_ ([_ /7HYXA=&=16C_8__3;_ ,=_^O1_8_\ TV_\ M=_\ KT<\0NC.HK1_L?\ Z;?^._\ UZ/['_Z;?^.__7HYXA=&=16C_8__ $V_ M\=_^O1_8_P#TV_\ '?\ Z]'/$+HSJ*T?['_Z;?\ CO\ ]>C^Q_\ IM_X[_\ M7HYXA=&=16C_ &/_ --O_'?_ *]']C_]-O\ QW_Z]'/$+HSJ*T?['_Z;?^._ M_7H_L?\ Z;?^._\ UZ.>(71G45H_V/\ ]-O_ !W_ .O1_8__ $V_\=_^O1SQ M"Z,ZBM'^Q_\ IM_X[_\ 7H_L?_IM_P"._P#UZ.>(717T_P#X_(_Q_D:VJI6^ MF_9YED\S=CMMQV^M7:QFTWH2PHHHK,D**** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **\H\5_M)^&/!_P ??"/PBO;#6Y?$OB:SEO;. MZMK'?91I&')$DF[(/[MONJP&1N*YKU>@ HKYQ_;R^*_BCX._!73];\):S<:# MJ5QXBT[3Y;RTLHKR86\LA60)%)%(&8CIA" M(^*^K>%M M=\7:OX#T?P@E_:>*?'7A*'2+RSU?[2J^5!$]E;"X0Q$EMT!"G^+H& /T"HKX MND\??%35O@GJ.M_#+Q?\0_&_Q'_L2"ZAT;Q?X.@TK32\AB$TD$SZ5:K-)&KN MT<8G(;:#B0<%_P &_CMXYN?BU'X7/C:?Q#>7V@O=1>#_ (J:&_AC6DOD).ZW MEMK 0RVY4-N*B5EVY&X4 ?9U%?,G[;/Q<\<_"/\ 9^T/7](U!?"?B6ZUW3+" M^DT>--4\F.:0K,D'G6Y\TX^Z?)#' ^7G%>-^.OVM/BG^S_XFU[Q!;Z3XO^*W MPJM].LH5NO'.BKX7O4U6>Z\I8;=OL$!F38=QS 0#_&.C 'W_ $5\;W7[:7Q0 M:;XG1P?"/089OAGIT&H^)+:3Q9)(S>9#]H-O;L+(!I$B#[F(V;EPI888\[\6 MO^"F<>APZO;^"?"^F3W47AJQU[3YO%FL&PDU%KR-7ACL[1(W:\9"X#HLD9W* MZ@\;J /NJBOSVU__ (*<>+_!.LS>']6^&.F37%GJ>GZ'=>(M2UQM$M([R\@\ MY#-;213M;I&H?S TS[=A^;G U5_X*AQ6OCF?P7-X;\+7VHVU^MO/XNL_%^?" M:P20^;%*VH):R,CLP,?EF+ 93\_4 ^]**^+-0_X*)WEEJ.AZ=-X&\/:/)J. MFW%^NM:[X[MH= N9(Y2BV]GJ<$$\4TC!2V)/)*_Q!:PM>_X*!:KX?^,47AFU M\,7^J:[XDL]$AT30+C7M/?2X;N]SEOM-M;.VQ0I8R>?,'R-J)D[0#[PHKXJU MK_@H!XJ\-?%B/X1W/PPTW4/B;_PD$.C-:V_B1H-/:"> 3P7:S/:%]NW<&0QY M7:""Q8*.ND_;DTNST'XC:7KS^#? _P 3/"-Y)8#0O$7BV.&ROV"+(LMO<-"L MLBE&SM\@'=A3MSN !]3T5^=7P!_;0^,BZ7\,[37- @^).O?$>QN]5M+BZU^W MTVTTVVM7<2NT<&E!T& 25+W#$(NTY8K5ZR_X*R:=:^#]&\;ZWX?\,Q>&=3O9 M[(Z)I/BQ+OQ'9;%D,<\UD84Q'(\17EEP)(V.)_A[\/K338I?"_B#PSX5AU[3I)1"6GEU4BWGGA59,+A%C^52 M<]&8 ^TJ*^3OA+^VM<>+K?Q5IUYI^A^(;[PKX(A\4W.O>&]3D;3]4E*.7BA2 M2$/$NZ,C+9(.05XKF-%_X*#^+_&NH6MGX1^#,.MR_P#"$1^-[TS>*?LXMX65 MCY"C[&QD$_!T^@?#4:KXNU<: ML=7\/7/B6WL$T(6$@CD:>ZG18]K,R8+;.&XR<*0#[2HKX2\>?M_:GKWPS^-% MAX<&@Z1XT\(^'H=;L-<\)Z_!XDTV1'E2-@)6@11(A8 HT9'.<]*^S?A[JEUK MG@'PSJ5]+Y][>:9;7$\NT+OD>)68X &23P!B@#H***\V_:,\7ZOX#^#7B'7 M="N_L.JVOV?R;CRTDV[KB)&^5P5.59AR.]=&'HRQ-:%"&\FDK^;L=F"PL\=B MJ6$IM*522BK[7D[*^^FO8])HK\V_^&N_BU_T-G_E-M/_ (U1_P -=_%K_H;/ M_*;:?_&J^V_U+S#^>'WR_P#D3]6_XA;G7_/VE_X%/_Y _22BOS;_ .&N_BU_ MT-G_ )3;3_XU7I/[.?[1GQ#\>?&7P]H6N^(?MVE77VCSK?[%;Q[MMO*Z_,D8 M8895/![5SXCA''8:C.O.<+13;LWT5_Y3CQOAOFV!PM7%U*M-QIQXM=.Y]MT5YAXD_:2\"^%O'6H^#;B?7=0\3:=;PW5YI^A^%]4U5K>*4$QN[6 MMM(JAL'&3V-=7X5^(&E^,+AX;"UUNW=;>.Z)U70;[3UV/G: UQ#&"XP(/%&B:)J7VW4_#-VECJT'D2Q_9IF02*FYU M"OE2#E"P]\T =1115?4=0@TG3[J^NI/*M;:)II9,$[44$L<#DX /2@"Q17%> M!_C%X6^).GZ!J'ANYO\ 5-,UVQ;4;#4$TF\2UDA#;3NF:()&^>D"0. P[9!Z\C\Z +-%W%NURDJ: M=<-:A%(!#7(0PH^3PC.&(Y (% &I1110 4444 %%%,FF2")Y9&"1HI9F8X MY)- ;:L?17PK\:/VAM:^(&L75GI-[-IWAN)RD,5NQC>X4<;Y".3GJ%Z 8XSS M7G_AGX@>(O!^I1W^DZQ=VLZ$$@2%D?V93PP]B*_0J'!N*JT%4J5%&3^S;\WT M^YGXWB_$S T,4Z-*BYTT[I.BP:E;M MY%]!&"%60#.Y<_PL.1ZZ=I#W%U;E=52.*1#!, M\4C-L=E"Y1B#NZ8SCI7PN(P]3"U94*JM*+LS]8P>+HX_#PQ6'E>$U=/^OQ._ MHKB/"WQR^''CF2_C\-_$#PMX@?3X#\9Q^/O#WB33-'4>;;^']9L[JXED8,R01KYP#2L$?4(%MH,D*5DF#F-65CL8;N M&!'6JUO\?OAA>:%J6MP?$?PE/HVF2I!?:C'KEJUO:2,<*DL@DVHQ/ #$$T = M[17@WC/]N+X+>"]5\)63^/=!U=/$5Z;..\TG6;*>WL@%8F>Y?SAY<.4*[QGY MN,5LVG[67PN3PS:ZYK?C#0_#-K=W-S;6T>H:Y83--Y#8D=&MKB9"H&"?FRH8 M;PIXH ]@HKB&^.7PW2^AL6^(/A9;V9(9(K8ZU;>9(LR[H65=^2)%(*D?>'(S M7+Z'^U9\./$'QVU;X2V>O6K^*M/MUE;_ $RV,,\NYP]K%B4NT\>QB\>P%0,F M@#U^BO,X_P!HKP%;ZWK>EZUXET7PS=:7?OIVW5M=TY#<2)&)&*(EP[IA3DI* ML;@#)3&"?0-'UG3_ !#IEMJ6E7UMJ>G7*>9!=V5U)##W!H N4444 M %%%% !6=JWB+3=!4-?WL-KNY57;YC]!U-5/&GB+_A%_#MU?* TP 2)6Z%SP M/RZ_A7BWAGPGJGQ$U"YN9+G:H;,UW-EB6/0 =S[< #\*_-^)>*J^5XNEE65T M/;8JHKI=$M=7]SZJR5VSZ#+\MAB:4L3B9\E./7JSVK3?&VA:M.(;74X))CP$ M8E2WL <9_"MNO"_%?PEO?#>G/?6]VM_!$-TH$91U'KC)R/7FNP^$/B^?6K.? M3;V0RW%JH:.1CEFCZ8/K@XY]Q7%DO%N82S..39_A51K35XM.\9>6[[/52>NF MC-L9E=!8=XO!5.>"WONOR_(]$HKRGP_^TUX$UC4?&MK?ZI'X6C\*:Z/#EW>> M(;B"SMY[MHUD58',GS AN =K$@_+6?\ %K]KSX7?![P5IGBC4O$^GZMIFI7R M6%I_8^H6LSS,9$21TW2J&2+>K2$$[%.2*_53YD]FHKS;7/VE/A/X9GTN+5/B M1X6LGU2WCN[+S-7@Q/!(0L(K+[1$=NXJR"4\@9)QD<9SCFNM\'^//#7Q$T?^UO"OB+2?$VE M^8T7V[1[V*[@WC&5WQL5R,C(SWH W:*^>_A#^W5\*?C%JWQ!L[#5)=!M_!,P MCU'4O$+P6EG)&97B$T4OFD&/>@&7V'YTXYKU%OC5\/8_#U]KS>//#*Z%8RK# M=ZF=8MQ;6\C'"I)+OVHQ[ D$T =G17B/C;]LGX4^!_\ A"[F7Q3I^K:)XIU. M32K?Q!I.H6DVFVDT:!W-S<><%10"!QN.2.*[?QE\?"?7%FBNX=5T&Z\<#Q3*8XM16:.9%CSL0Q@;0 3T^7]37TN"RB59> MTDTXM.UN_P#P#]#R?A:>,BZ\Y1E3E%\K3^ULKJRVZ^:/NVBOG#P3\6/B#\5_ M$B:=ITEGH]HOSW-U;6H;R8_K(6!8] .Y]@:]6^,GQ7TCX"_"O6_'&OP:A?Z3 MHD"27$=@B27,@+K&-H=D4G+ \L.]>/BL)/"24*C5^RZ>I\IF65U2YG MK9.]O72VIW-%>->$_P!J#0]:^(5EX)\0>&O$7P_\0ZAI[ZIIL7B6.U\G4+=! MNE,,]M<31%D4AF1F# '.,5KO^TY\)&T+6]7L_B7X1U2TT6V^U7QT_7K28PIN M"KNQ)A=SE47<0"S =37$>.>G45XW\/\ ]KSX3>/OA;I/C_\ X371/#FAZ@_D M[?$&JVEK+;3[=WV>;]Z52;;AMFXG!!KU+P[XETCQAHMKK&@ZK9:WI%TN^WO] M.N$N()ER1E)$)5AD$<'M0!I4444 %%%% !7F?[17Q<7X(_"G4_$ZQI/>1R10 M6MNYXED=P,?@N]O^ UC_ +3+?$C0_!__ D_PVU9H[_25:6\T9[6.=+Z#J2H M92P=.3A2-PR.2 *_.KXW?M5>,?CYX(Z]#'.<)X>,_P!Y&[YDEK9J MRTELFF]'W3M^MNC:M:Z_H]CJEC()K*]@CN8)!T:-U#*?Q!%7*_+?X7_MB_%C M3_#/AGX<^$;/3;BZB L+*9K5IKJ3 N2:_0_P -R:S\.?A7 M+J/C;6)O$FL:?92ZAJ=U!#&FXHA=XX44(NU0NUH76B0P+;["XD=3J7F(,#NG&><#)'3:9^T1\/+K0- M$U/4_&'A_P .MJ]B-0MK/4]=L/-,);;O#13O'(H;Y=\;NF> QKUS\\/2**X[ MQA\9O 'P\2P?Q5XY\-^&4U",RV;:QJ]O:"Y08RT?F.-XY'(SU%8_A7X^>&?& M?Q>UWX=Z4MWX_U9BD60LQQS]T#!X)H ])HKQKQ=^U MQ\,/"?Q \-^"AXEL-;\1ZUJC:4UEH]_:W$FFR*C.SW:>:'B0;2"=I.<#%5O' M7[:7P6\#^"=;\2CXC>&?$,6DPF633]!URRN;R=N<111^<-TC8;"Y&<'TH ]N MHKS"V_:>^$TGA/0?$=W\1_"FD:7K<> M+?VC?AMX'U)M/U?Q=I\-]&S+);PN9GB8'!5P@.T^QP:\B_;J^-VH?#WPKIWA M?0;I[35M;#O<7,+8DAMEP"%(Y4N3C=Z*W?!K\[*^+S?B!X&M]7H13DMV]O0_ M/<]XH>6UWA<-!2DMV]EY:?YG[)^"OB1X7^(UD;KPUKMEK$2@&06TH9X\YP'3 M[RG@\$#I72U^8OPG^&NL?#7PLWQ8UCQ$_@B.%,Z'&8R\VJ3$;@ACR"86 Y]0 M<]J^O_B9^V-X/^$/[/\ H'Q8\06&JWFBZH]O;_9='CBFGBFD5B5(DDC7"E&! M.>HX!KULKS*>-CRUXVZ^9[N39M4S"'+B(VZ^?JCWNBO M#/C-^V1\/O@CI/P^U#57U#5XO'-Q%#HR:/'%([I(J$3L))$Q&/,CR1DY<<5/ MX]_:S\(_#K3=9O=3LK^YCTOQ':^&9H],N;"[E^T7! C=DCNBT29/*S".3C(0 MC!KWCZ4]LHK@M0^/GPVTGQQ'X-O?'?A^U\522I;C2)=1B6X$KC*1E-V0[ ?* MIY/& B7LOQ,\+6@UBW2YMX9]8MMX5F"?/M(FT"V\;>'+C75N&M#I<6K6[70G49:(Q!]V\ C*XR,T M =?17!:+\>_AOXC\:R>$-*\=>']1\3QO)$VDVNHQ23^9&,R(%#O]IL]+U#4X(+JYW':OEQ.X9\G@ M8!R:X7X3_M9?#SXQ^$KC6M#U:&WO(/MA?0-1O;2'4@+9G61C%YQ"J=A8,S!= MI!8J,X /9**\EA_:L^%<.EZ!=:SXX\/>'+G6K6.\M[#4-;LGE$;ML5F>":2( MKN^7>KLA(.&.*ZZ3XN>!H]!.N/XT\/)H@O?[-.I-JL MOM6[;Y'F;]OF[OEV M9W9XQ0!UE%>=^%_VBOA=XUFU.+0?B'X9U9],MVN[S[+JD+B&!6*M,2&QY8(P M7^Z.YK+^'/[3W@'XM_%#7?!'@_5X?$ESH^G0ZE/JVE7-O=:)_A7X3\&:1X*NK/3/%/C?Q/9^%[ M/5;Z$31Z=Y^[=<"-OE=E"\*W!)Z'H?/?B%\1OB_\!OC9H'@+2/$DWQ8?QKX< MU:?1+?Q':V5K<6>JV:#';V\$4J3F*ZB:#:89DD3!61616W 9R,8)%<5;_LG6L?$ M?QOXE\4:#836&@ZMJLNGM)I/G+LDFB2.S2.25D^4M.DN1VS@UX5\(?CU\2=- M^(GPRTGQWX]U32M9UIGLM?\ "?Q$\++I44UQL7!T:]M;013%9#M"2S-O5AT: MOISX@?$[Q)\,?@_\0?&GB/0=)M9O#MC>7]C:Z;JDMXEU%%$7C,K-;PF)F88* M*' '1S0 OQ4^ >D_&?X?:+X3\4ZYK5Y'IE_9ZG_:<+6T5U, MXZ$5\H^*/BQ\9/A1^R_X-^/^I_$9_$US?/IVHZOX..E6*:9)97LBA;>U>.); MA)(UF3$C32;BG((K:^(7_!2RQ^&7@WQ+>ZSX!F/BS0?%TGAJX\-6VJ[Y'MTA M,YOUD, _=F)6;:4'3E@.: /4OB-^QMHOCKQ=XVUJP\8^)/",'CJRAL/%6FZ. MUL8-3CC78K#S87:&0QY1F0C(/3.2?)=0_8I\;^$?B)X_U3P2^ER:)KFG6%AH MHMO&>L>%I]'2UMS!$DJ6$3K>A!M*M,V[@CN:P&_X*F1:+H>FZKJOA_PEJ0UK M0+S6K#3/#?C%;V\L9H(Q,+/4$%N/(=XR<-@X9&7;Z=O??MP>/= \+Z+KWB7X M8^"_!]AK&B_VY8MXB^*%K9O.A&Y+=(VM/,:=EPP 4H P!D#94 &I\-?V =)T M;P->1^-?&GB#Q-X_U34;#7[SQ5#<1Q36FJ6B,D,]H3&>BN5/G"3?R6 S@>A+ M^S#=1ZA#JL?QG^*B:\DS2MJ!UNW>*12FSRVL6MC8A0.?EMPV>2Q-?%WC+_@H M%\0O&'B:76/!6N3>'_#%]!X9GM=+N+"TF>V-U+OBOX7U7P)_P@]IKL7@J:YN/^$IU?PCI=OJNLVJA!]G6"UG1PR,Y;>RQ MNP"\8XW %;PE^PUH7P]M=2C\*?$GXA>'GU=[J;66M]0LYHM4FN&S)-+;3VLE MNDF,*'ABC(4 5R-A_P $N_A-X?%K/X>U3Q1H>JZ>EDVEZC!?122V%S;2/*ER MF^$Y=WD?>K90AL*JX&,;X1_MGZKI_BKP[X+U?7M-^)\VO>+YM!M]4$,VC:OI M=N(C(@U*PDM8P)P59?W81&"Y!R#5[QM_P4&UC0?$>J>'_#_PK_X276X/'C^! M;.T_X2%;7[7*(1(L^YK:/^PQX/M?B1IWQ#U?Q%XBU_QU M;ZXNO7&LW,EM&;R5(/(BA>.. *L,:$[50*W99'=Q&%#1A-^&7_!2F:3X1ZY>Z]X M,OKGQ9IEAI-UHVGW6LP2W/B07\QBC(>&S@CC97PK;(<#' H ]]^'?[&?@GX: M:K\-+_3=2UVZD\ :7>Z1ID=[/ Z3PW3,TAG"PKN8;CC:4'J#5?2_V*_"FE:. M?#,7BSQI_P *\$MPZ>!4U9(=+5)BYDA+11+G QPOAK]OB:; MXF^"_"'B?PIX;TBZ\3:K)HXL]#\=6FM:GIDXR(S>6L$6V-7('*ROMSSSQ7<_ ML/\ Q4\4?�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end GRAPHIC 10 lsta-20230930_g2.jpg begin 644 lsta-20230930_g2.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 02, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-33650  
Entity Registrant Name LISATA THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 22-2343568  
Entity Address, Address Line One 110 Allen Road, 2nd Floor  
Entity Address, City or Town Basking Ridge  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07920  
City Area Code 908  
Local Phone Number 842-0100  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol LSTA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   8,139,449
Entity Central Index Key 0000320017  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
ASSETS    
Cash and cash equivalents $ 32,428 $ 32,154
Marketable securities 21,966 37,072
Prepaid and other current assets 2,839 2,650
Total current assets 57,233 71,876
Property and equipment, net 204 296
Acquired license - intangible 281 334
Other assets 371 528
Total assets 58,089 73,034
Liabilities    
Accounts payable 1,312 2,655
Accrued liabilities 3,820 3,728
Total current liabilities 5,132 6,383
Other long-term liabilities 253 327
Total liabilities 5,385 6,710
Commitments and Contingencies (Note 14)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,140,187 and 7,866,799 shares at September 30, 2023 and December 31, 2022, respectively; and outstanding, 8,139,449 and 7,866,061 shares at September 30, 2023 and December 31, 2022, respectively 8 8
Additional paid-in capital 576,474 574,548
Treasury stock, at cost; 738 shares at September 30, 2023 and December 31, 2022 (708) (708)
Accumulated deficit (522,716) (507,241)
Accumulated other comprehensive loss (100) (29)
Total Lisata Therapeutics, Inc. stockholders' equity 52,958 66,578
Non-controlling interests (254) (254)
Total stockholders' equity 52,704 66,324
Total liabilities, non-controlling interests and stockholders' equity $ 58,089 $ 73,034
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in usd per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 33,333,333 33,333,333
Common stock, shares issued (in shares) 8,140,187 7,866,799
Common stock outstanding (in shares) 8,139,449 7,866,061
Treasury stock (in shares) 738 738
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating Expenses:        
Research and development $ 3,380 $ 3,335 $ 9,721 $ 9,853
In-process research and development 0 30,393 0 30,393
General and administrative 2,584 3,992 9,962 10,815
Total operating expenses 5,964 37,720 19,683 51,061
Operating loss (5,964) (37,720) (19,683) (51,061)
Other income (expense):        
Investment income, net 714 337 2,053 496
Other expense, net (11) 0 (175) (149)
Total other income (expense) 703 337 1,878 347
Net loss before benefit from income taxes and noncontrolling interests (5,261) (37,383) (17,805) (50,714)
Benefit from income taxes 0 0 (2,330) (2,479)
Net loss (5,261) (37,383) (15,475) (48,235)
Less - net income attributable to noncontrolling interests 0 0 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (5,261) $ (37,383) $ (15,475) $ (48,235)
Basic and diluted loss per share        
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) $ (0.65) $ (7.88) $ (1.92) $ (11.28)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) $ (0.65) $ (7.88) $ (1.92) $ (11.28)
Weighted average common shares outstanding        
Basic shares (in shares) 8,141 4,747 8,050 4,276
Diluted shares (in shares) 8,141 4,747 8,050 4,276
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (5,261) $ (37,383) $ (15,475) $ (48,235)
Available for sale securities - net unrealized gain 0 5 1 5
Cumulative translation adjustment arising during the period (50) (25) (72) (25)
Total other comprehensive loss (50) (20) (71) (20)
Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders $ (5,311) $ (37,403) $ (15,546) $ (48,255)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2021     3,986,000          
Beginning balance at Dec. 31, 2021 $ 92,000 $ 92,254 $ 4 $ 546,044 $ (70) $ (453,016) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (48,235) (48,235)       (48,235)    
Share-based compensation (in shares)     100,000          
Share-based compensation 1,899 1,899   1,899        
Net proceeds from issuances of common stock (in shares)     4,000          
Net proceeds from issuances of common stock 29 29   29        
Issuance of common stock in connection with Merger (in shares)     3,773,000          
Issuance of common stock in connection with Merger 26,098 26,098 $ 4 26,094        
Unrealized gain on marketable securities 5 5     5      
Foreign currency translation adjustment (25) (25)     (25)      
Common stock, ending balance (in shares) at Sep. 30, 2022     7,863,000          
Ending balance at Sep. 30, 2022 71,771 72,025 $ 8 574,066 (90) (501,251) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2022     4,038,000          
Beginning balance at Jun. 30, 2022 82,137 82,391 $ 4 547,032 (70) (463,868) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (37,383) (37,383)       (37,383)    
Share-based compensation (in shares)     52,000          
Share-based compensation 939 939   940        
Issuance of common stock in connection with Merger (in shares)     3,773,000          
Issuance of common stock in connection with Merger 26,098 26,098 $ 4 26,094        
Unrealized gain on marketable securities 5 5     5      
Foreign currency translation adjustment (25) (25)     (25)      
Common stock, ending balance (in shares) at Sep. 30, 2022     7,863,000          
Ending balance at Sep. 30, 2022 $ 71,771 72,025 $ 8 574,066 (90) (501,251) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2022 7,866,061   7,867,000          
Beginning balance at Dec. 31, 2022 $ 66,324 66,578 $ 8 574,548 (29) (507,241) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Proceeds from option exercises (in shares) 1,227,776              
Common stock, ending balance (in shares) at Jun. 30, 2023     8,133,000          
Ending balance at Jun. 30, 2023 $ 57,714 57,968 $ 8 576,173 (50) (517,455) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2022 7,866,061   7,867,000          
Beginning balance at Dec. 31, 2022 $ 66,324 66,578 $ 8 574,548 (29) (507,241) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (15,475) (15,475)       (15,475)    
Share-based compensation (in shares)     114,000          
Share-based compensation 1,474 1,474   1,474        
Net proceeds from issuances of common stock (in shares)     76,000          
Net proceeds from issuances of common stock $ 297 297   297        
Proceeds from option exercises (in shares) 82,500   83,000          
Proceeds from option exercises $ 155 155   155        
Unrealized gain on marketable securities 1 1     1      
Foreign currency translation adjustment $ (72)       (72)      
Common stock, ending balance (in shares) at Sep. 30, 2023 8,139,449   8,140,000          
Ending balance at Sep. 30, 2023 $ 52,704 52,958 $ 8 576,474 (100) (522,716) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2023     8,133,000          
Beginning balance at Jun. 30, 2023 57,714 57,968 $ 8 576,173 (50) (517,455) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (5,261) (5,261)       (5,261)    
Share-based compensation (in shares)     7,000          
Share-based compensation 301 301   301        
Foreign currency translation adjustment $ (50) (50)     (50)      
Common stock, ending balance (in shares) at Sep. 30, 2023 8,139,449   8,140,000          
Ending balance at Sep. 30, 2023 $ 52,704 $ 52,958 $ 8 $ 576,474 $ (100) $ (522,716) $ (708) $ (254)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (15,475) $ (48,235)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 1,565 2,168
Depreciation and amortization 142 22
Loss on disposal of fixed assets 3 0
In process research and development expenses 0 30,393
Amortization/accretion on marketable securities (709) 893
Changes in operating assets and liabilities:    
Prepaid and other current assets (314) 29
Other assets 130 178
Accounts payable, accrued liabilities and other liabilities (1,305) (150)
Net cash used in operating activities (15,963) (14,702)
Cash flows from investing activities:    
Purchase of marketable securities (77,355) (68,481)
Sale of marketable securities 93,171 93,865
Asset acquisition costs, net of cash acquired related to merger with Cend 0 (3,320)
Purchase of property and equipment 0 (259)
Net cash provided by investing activities 15,816 21,805
Cash flows from financing activities:    
Proceeds from option exercises 155 0
Tax withholding payments on net share settlement equity awards (91) (267)
Net proceeds from issuance of common stock 297 29
Net cash provided by (used in) financing activities 361 (238)
Effect of exchange rate changes on cash 60 (34)
Net increase in cash and cash equivalents 274 6,831
Cash and cash equivalents at beginning of period 32,154 24,647
Cash and cash equivalents at end of period 32,428 31,478
Supplemental disclosure of noncash investing activities:    
Issuance of common stock in connection with merger 0 23,580
Incremental fair value of Cend's fully vested stock options assumed $ 0 $ 2,136
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
The Business
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Business The Business
Overview
Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment (“TME”), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it is seeking to partner while incurring no additional capital outlay.
The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company’s current development pipeline includes:
•LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including, metastatic pancreatic ductal adenocarcinoma (mPDAC) and other forms of pancreatic cancer, cholangiocarcinoma, esophageal cancer, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.
Merger with Cend Therapeutics, Inc. and Name Change
On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (“Caladrius”), completed its acquisition of Cend Therapeutics, Inc. (“Cend”), a Delaware corporation (the “Merger”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (“Merger Sub”).
Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the “Effective Time”): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (“Reverse Stock Split”) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata’s common stock based on an exchange ratio of 0.5338, after taking into account the Reverse Stock Split (the “Exchange Ratio”). In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.
Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the “Cend Plan”), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata’s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock.
Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team provided a vast majority of the individuals on the management team and holds the chief executive officer (“CEO”), chief medical officer (“CMO”) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend’s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The
Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). Cend’s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&D with no alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.
Reverse Stock Split
On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company’s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company’s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.
Basis of Presentation
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). Accordingly, actual results could differ from those estimates and assumptions.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.
Foreign Currency Remeasurement
The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Cash and Cash Equivalents
Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.
Concentration of Risks
The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Marketable Securities
The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.
Property and Equipment
The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:
Furniture and fixtures10 years
Computer equipment3 years
Software3 years
Leasehold improvementsLife of lease
Long-lived Assets
Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Share-Based Compensation  
The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.
Loss Per Share
Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.
Treasury Stock
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.
Research and Development Costs 
Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.
To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.
In-process Research and Development Expense
Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.
Intangible Asset
The Company’s intangible asset consists of a single asset, Cend’s license agreement with Qilu Pharmaceutical, Co., Ltd. (“Qilu”) acquired in the Merger, with a value of $0.4 million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18 thousand for the three months ended September 30, 2023 and $53 thousand for the nine months ended September 30, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable. The projected amortization expense is $71 thousand per year for the next five years.
Revenue Recognition
The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September 30, 2023 and 2022.
Milestones
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September 30, 2023 and September 30, 2022, the Company has not recognized revenue related to milestones.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Merger
 9 Months Ended
Sep. 30, 2023
Asset Acquisition [Abstract]  
Merger Merger
The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&D. Cend’s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&D being expensed. The fair value of total consideration was $36.1 million. The following table is a summary of the purchase price calculation (in thousands except per share data).
Number of common shares of the combined company owned by Cend stockholders3,772,768 
Multiplied by the fair value per share of Lisata common stock on September 15, 2022$6.25
Total$23,580
Carrying value of Lisata's cost method investment in Cend10,000 
Incremental fair value of Cend's fully vested stock options2,136 
Lisata transaction costs382 
Total purchase price$36,098
The allocation of the purchase price was as follows (amounts in thousands):

Cash and cash equivalents$7,062
Net working capital (excluding cash)(1,690)
Other liabilities(22)
Acquired in-process research and development 30,393 
License355 
Net assets acquired$36,098
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Available-for-Sale-Securities
 9 Months Ended
Sep. 30, 2023
Debt Securities, Available-for-Sale [Abstract]  
Available-for-Sale-Securities Available-for-Sale-Securities
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):
September 30, 2023December 31, 2022
CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueCostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate debt securities$28,828 $— $(16)$28,812 $44,308 $— $(17)$44,291 
Commercial paper1,978 — — 1,978 7,953 — — 7,953 
Money market funds13,572 — — 13,572 4,871 — — 4,871 
Agency bonds1,987 — (1)1,986 — — — — 
Treasury bills3,996 — — 3,996 — — — — 
Municipal debt securities725 — — 725 7,626 — (1)7,625 
Total$51,086 $— $(17)$51,069 $64,758 $— $(18)$64,740 


Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):
September 30, 2023December 31, 2022
Cash equivalents$29,103 $27,668 
Marketable securities21,966 37,072 
Total$51,069 $64,740 
The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):
September 30, 2023
Amortized CostEstimated Fair Value
Less than one year$51,086 $51,069 
Greater than one year— — 
Total$51,086 $51,069 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment
 9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
Property and equipment consisted of the following (in thousands):
September 30, 2023December 31, 2022
Furniture and fixtures$— $25 
Computer equipment589 589 
Leasehold improvements72 99 
Property and equipment, gross661 713 
Accumulated depreciation(457)(417)
Property and equipment, net$204 $296 

The Company’s results included depreciation expense of approximately $89 thousand and $22 thousand for the nine months ended September 30, 2023 and 2022, respectively.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Income (Loss) Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Income (Loss) Per Share Income (Loss) Per Share
For the nine months ended September 30, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September 30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):
 September 30
 20232022
Stock options1,321 1,399 
Warrants1,422 1,424 
Restricted stock units202 48 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
Level 3 inputs are defined as unobservable inputs for the assets or liabilities.
Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires
judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands):
September 30, 2023December 31, 2022
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$29,103 $— $— $29,103 $27,668 $— $— $27,668 
Marketable securities - available for sale— 21,966 — 21,966 — 37,072 — 37,072 
$29,103 $21,966 $— $51,069 $27,668 $37,072 $— $64,740 

The carrying values of accounts payable and accrued expenses approximate fair value as of September 30, 2023 and December 31, 2022, due to the short maturity nature of these items.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Liabilities
 9 Months Ended
Sep. 30, 2023
Accrued Liabilities [Abstract]  
Accrued Liabilities Accrued Liabilities
Accrued liabilities as of September 30, 2023 and December 31, 2022 were as follows (in thousands):
September 30, 2023December 31, 2022
Salaries, employee benefits and related taxes$2,366 $2,586 
Clinical and R&D related liabilities915 785 
Accounting & tax consulting liabilities230 — 
Operating lease liabilities — current164 180 
Other145 177 
Total$3,820 $3,728 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Leases
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Operating Leases Operating LeasesThe Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.
Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):
September 30, 2023December 31, 2022
Right-of-Use Assets:
Other assets$348 $487 
Total Right-of-Use Asset$348 $487 
Operating Lease Liabilities:
Accrued liabilities$164 $180 
Other long-term liabilities181 305 
Total Operating Lease Liabilities$345 $485 
    
As of September 30, 2023, the weighted average remaining lease term for our operating lease was 2.0 years, and the weighted average discount rate for our operating lease was 9.625%. As of December 31, 2022, the weighted average remaining lease term for our operating leases was 1.5 years, and the weighted average discount rate for our operating leases was 9.625%.
Future minimum lease payments under the lease agreement as of September 30, 2023 were as follows (in thousands):
Years endedOperating Leases
202348 
2024190 
2025143 
Total lease payments381 
Less: Amounts representing interest(36)
Present value of lease liabilities$345 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
Reverse Stock Split
On September 14, 2022, in connection with the Merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.
Equity Issuances
At The Market Offering Agreement
On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the nine months ended September 30, 2023, the Company issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.
Common Stock
In connection with the Merger closing on September 15, 2022, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.
Stock Options and Warrants
In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2023:
Stock OptionsWarrants
SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 20221,391,352 $10.83 7.03$187.6 1,423,774 $42.57 3.37$— 
Changes during the period:
Granted180,896 3.46 — — 
Exercised(82,500)1.88 — — 
Forfeited(144,594)3.63 — — 
Expired(24,603)29.60 (2,000)88.35 
Outstanding at September 30, 20231,320,551 $10.82 6.30$78.7 1,421,744 $42.51 2.67$— 
Vested at September 30, 2023
or expected to vest in the future		1,316,134 $10.84 6.29$78.7 1,421,744 $42.51 2.67$— 
Vested at September 30, 20231,229,103 $11.25 6.09$78.2 1,421,744 $42.51 2.67$— 


Restricted Stock
During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):
Nine Months Ended September 30,
  20232022
Number of restricted stock issued159,950 70,740 
Value of restricted stock issued$480 $973 

The vesting terms of restricted stock issuances are generally between one and four years.
Restricted Stock Units
During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):
Nine Months Ended September 30,
20232022
Number of restricted stock units issued188,850 111,170 
Value of restricted stock units issued $567 $1,386 
The weighted average estimated fair value of restricted stock units issued for services in the nine months ended September 30, 2023 and 2022 was $3.00 and $12.46 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Share-Based Compensation
We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2023 and 2022 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Research and development$103 $271 $517 $631 
General and administrative203 769 1,048 1,537 
Total share-based compensation expense$306 $1,040 $1,565 $2,168 

Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September 30, 2023 were as follows (in thousands):
Stock OptionsRestricted Stock UnitsRestricted Stock
Unrecognized compensation cost$221 $161 $483 
Expected weighted-average period in years of compensation cost to be recognized1.851.101.69

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2023 and 2022 were as follows (in thousands):
Stock Options
Nine Months Ended September 30,
20232022
Total fair value of shares vested$1,001 $853 
Weighted average estimated fair value of shares granted$2.10 $1.23 

Valuation Assumptions
The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.
As of December 31, 2021, the Company had approximately $281.0 million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $168.8 million of the $281.0 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112.3 million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173 thousand under Internal Revenue Code Section 382.
As of December 31, 2022, the Company had approximately $34.0 million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an
ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0 million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations.
As of December 31, 2022, Cend Therapeutics had approximately $10.9 million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $10.7 million of Federal and $15.0 million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years. Using a fair market value of $36.1 million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $106 thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. Cend’s wholly owned Australian subsidiary has $1.8 million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.
As of December 31, 2022 and 2021, the Company had State NOLs available in New Jersey of $35.5 million and $97.0 million, respectively, California of $10.0 million and $69.5 million, respectively, and New York City of $1.9 million and $13.0 million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.
The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.
As of December 31, 2022 and 2021, the Company’s uncertain tax positions were $344 thousand and $0, respectively. Due to the acquisition of Cend, the Company’s uncertain tax positions increased by $344 thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of September 30, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.
For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from the date of filing.
On April 5, 2023, the Company received final approval from the New Jersey Economic Development Authority (“NJEDA”) under the Technology Business Tax Certificate Transfer Program (“Program”) to sell a percentage of its New Jersey net operating losses (“NJ NOLs”), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2 million. The $2.3 million of NJ NOLs related tax benefits has been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).
On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts & Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company’s results of operations for the year ended December 31, 2022. The Company will continue to monitor the future impact of changes in tax legislation.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Australia Research and Development Tax Incentive
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Australia Research and Development Tax Incentive Australia Research and Development Tax IncentiveThe Company’s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the nine months ended September 30, 2023, $0.5 million was recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed. On September 4, 2023 the Company's Australian subsidiary received a $0.6 million tax refund from the Australian Taxation Office related to the 2022 tax year.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
Contingencies
From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.
In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (“Lingmed”) claiming Lingmed was entitled to a success fee based on Cend’s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend’s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend’s response on July 11, 2022. At a Case Management Conference held on August 4, 2023, the Court set a trial date in the matter for August 2, 2024. The Company denies these allegations made by Lingmed and intends to vigorously defend itself.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Technology Transfer Agreement
 9 Months Ended
Sep. 30, 2023
Technology Transfer Agreement [Abstract]  
Technology Transfer Agreement Technology Transfer Agreement
Impilo Therapeutics
In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (“Impilo”) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 in connection with the Sanford Burnham Prebys license agreement (Note 16) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
License Agreements
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License Agreements License Agreements
Sanford Burnham Prebys
In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (“SBP”) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend’s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6 million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company’s pre-seed preferred stock in Impilo on October 3, 2023.
The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days’ prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.
In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2 million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. On September 14, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.
SBP owned 382,030 shares of the Company’s common stock as of September 30, 2023 and is a related party.
University of California at San Diego
In March 2021, Cend entered into a license agreement with the University of California at San Diego (“UCSD”) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2 million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached.
The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days’ prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.
On August 2, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.
Massachusetts Institute of Technology
In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0 million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3 million.
The agreement expires upon the expiration or abandonment of all valid claims. The agreement may be earlier terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may also be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.
On June 30, 2023, in accordance with the provisions of the license agreement, the Company provided notice to MIT that the license agreement would terminate effective December 30, 2023. Until such date, the license remains in full force and effect.
MIT owned 43,236 shares of the Company’s common stock as of September 30, 2023.
Research Collaboration and License Agreement
Exclusive License and Collaboration Agreement
In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the “Qilu Agreement”) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10 million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5 million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95 million and $125 million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.
Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Research Collaboration and License Agreement
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Research Collaboration and License Agreement License Agreements
Sanford Burnham Prebys
In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (“SBP”) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend’s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6 million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company’s pre-seed preferred stock in Impilo on October 3, 2023.
The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days’ prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.
In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2 million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. On September 14, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.
SBP owned 382,030 shares of the Company’s common stock as of September 30, 2023 and is a related party.
University of California at San Diego
In March 2021, Cend entered into a license agreement with the University of California at San Diego (“UCSD”) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2 million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached.
The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days’ prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.
On August 2, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.
Massachusetts Institute of Technology
In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0 million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3 million.
The agreement expires upon the expiration or abandonment of all valid claims. The agreement may be earlier terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may also be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.
On June 30, 2023, in accordance with the provisions of the license agreement, the Company provided notice to MIT that the license agreement would terminate effective December 30, 2023. Until such date, the license remains in full force and effect.
MIT owned 43,236 shares of the Company’s common stock as of September 30, 2023.
Research Collaboration and License Agreement
Exclusive License and Collaboration Agreement
In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the “Qilu Agreement”) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10 million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5 million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95 million and $125 million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.
Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). Accordingly, actual results could differ from those estimates and assumptions.
Principles of Consolidation Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation
Foreign Currency Remeasurement
Foreign Currency Remeasurement
The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.
Concentration of Risks
Concentration of Risks
The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Marketable Securities
Marketable Securities
The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.
Property and Equipment Property and EquipmentThe cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.
Long-lived Assets
Long-lived Assets
Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Share-Based Compensation Share-Based Compensation  The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.
Loss Per Share Loss Per ShareBasic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.
Treasury Stock
Treasury Stock
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.
Research and Development Costs
Research and Development Costs 
Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.
To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.
In-process Research and Development Expense
In-process Research and Development Expense
Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.
Intangible Assets The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.
Revenue Recognition
Revenue Recognition
The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.
Milestones, Royalties
Milestones
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September 30, 2023 and September 30, 2022, the Company has not recognized revenue related to milestones.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.
Leases The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Property, Plant and Equipment The estimated useful lives of property and equipment are as follows:
Furniture and fixtures10 years
Computer equipment3 years
Software3 years
Leasehold improvementsLife of lease
Property and equipment consisted of the following (in thousands):
September 30, 2023December 31, 2022
Furniture and fixtures$— $25 
Computer equipment589 589 
Leasehold improvements72 99 
Property and equipment, gross661 713 
Accumulated depreciation(457)(417)
Property and equipment, net$204 $296 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Merger (Tables)
 9 Months Ended
Sep. 30, 2023
Asset Acquisition [Abstract]  
Asset Acquisition The following table is a summary of the purchase price calculation (in thousands except per share data).
Number of common shares of the combined company owned by Cend stockholders3,772,768 
Multiplied by the fair value per share of Lisata common stock on September 15, 2022$6.25
Total$23,580
Carrying value of Lisata's cost method investment in Cend10,000 
Incremental fair value of Cend's fully vested stock options2,136 
Lisata transaction costs382 
Total purchase price$36,098
The allocation of the purchase price was as follows (amounts in thousands):

Cash and cash equivalents$7,062
Net working capital (excluding cash)(1,690)
Other liabilities(22)
Acquired in-process research and development 30,393 
License355 
Net assets acquired$36,098
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Available-for-Sale-Securities (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Securities, Available-for-Sale [Abstract]  
Schedule of Available-for-sale Securities Reconciliation
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):
September 30, 2023December 31, 2022
CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueCostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate debt securities$28,828 $— $(16)$28,812 $44,308 $— $(17)$44,291 
Commercial paper1,978 — — 1,978 7,953 — — 7,953 
Money market funds13,572 — — 13,572 4,871 — — 4,871 
Agency bonds1,987 — (1)1,986 — — — — 
Treasury bills3,996 — — 3,996 — — — — 
Municipal debt securities725 — — 725 7,626 — (1)7,625 
Total$51,086 $— $(17)$51,069 $64,758 $— $(18)$64,740 
Schedule of Marketable Securities
Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):
September 30, 2023December 31, 2022
Cash equivalents$29,103 $27,668 
Marketable securities21,966 37,072 
Total$51,069 $64,740 
Investments Classified by Contractual Maturity Date
The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):
September 30, 2023
Amortized CostEstimated Fair Value
Less than one year$51,086 $51,069 
Greater than one year— — 
Total$51,086 $51,069 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment The estimated useful lives of property and equipment are as follows:
Furniture and fixtures10 years
Computer equipment3 years
Software3 years
Leasehold improvementsLife of lease
Property and equipment consisted of the following (in thousands):
September 30, 2023December 31, 2022
Furniture and fixtures$— $25 
Computer equipment589 589 
Leasehold improvements72 99 
Property and equipment, gross661 713 
Accumulated depreciation(457)(417)
Property and equipment, net$204 $296 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Income (Loss) Per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share At September 30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):
 September 30
 20232022
Stock options1,321 1,399 
Warrants1,422 1,424 
Restricted stock units202 48 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Assets Measured at Fair Value on Recurring Basis
The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands):
September 30, 2023December 31, 2022
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$29,103 $— $— $29,103 $27,668 $— $— $27,668 
Marketable securities - available for sale— 21,966 — 21,966 — 37,072 — 37,072 
$29,103 $21,966 $— $51,069 $27,668 $37,072 $— $64,740 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Liabilities (Tables)
 9 Months Ended
Sep. 30, 2023
Accrued Liabilities [Abstract]  
Schedule of Accrued Liabilities
Accrued liabilities as of September 30, 2023 and December 31, 2022 were as follows (in thousands):
September 30, 2023December 31, 2022
Salaries, employee benefits and related taxes$2,366 $2,586 
Clinical and R&D related liabilities915 785 
Accounting & tax consulting liabilities230 — 
Operating lease liabilities — current164 180 
Other145 177 
Total$3,820 $3,728 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Leases (Tables)
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet
Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):
September 30, 2023December 31, 2022
Right-of-Use Assets:
Other assets$348 $487 
Total Right-of-Use Asset$348 $487 
Operating Lease Liabilities:
Accrued liabilities$164 $180 
Other long-term liabilities181 305 
Total Operating Lease Liabilities$345 $485 
Schedule of Future Minimum Lease Payments Under Lease Agreements
Future minimum lease payments under the lease agreement as of September 30, 2023 were as follows (in thousands):
Years endedOperating Leases
202348 
2024190 
2025143 
Total lease payments381 
Less: Amounts representing interest(36)
Present value of lease liabilities$345 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Stock Option and Warrants Activity The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2023:
Stock OptionsWarrants
SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 20221,391,352 $10.83 7.03$187.6 1,423,774 $42.57 3.37$— 
Changes during the period:
Granted180,896 3.46 — — 
Exercised(82,500)1.88 — — 
Forfeited(144,594)3.63 — — 
Expired(24,603)29.60 (2,000)88.35 
Outstanding at September 30, 20231,320,551 $10.82 6.30$78.7 1,421,744 $42.51 2.67$— 
Vested at September 30, 2023
or expected to vest in the future		1,316,134 $10.84 6.29$78.7 1,421,744 $42.51 2.67$— 
Vested at September 30, 20231,229,103 $11.25 6.09$78.2 1,421,744 $42.51 2.67$— 
Schedule of Restricted Stock Activity
During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):
Nine Months Ended September 30,
  20232022
Number of restricted stock issued159,950 70,740 
Value of restricted stock issued$480 $973 
Schedule of Restricted Stock Units Activity
During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):
Nine Months Ended September 30,
20232022
Number of restricted stock units issued188,850 111,170 
Value of restricted stock units issued $567 $1,386 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule Share-based Compensation Expense The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2023 and 2022 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Research and development$103 $271 $517 $631 
General and administrative203 769 1,048 1,537 
Total share-based compensation expense$306 $1,040 $1,565 $2,168 
Schedule of Total Compensation Cost Related to Nonvested Awards
Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September 30, 2023 were as follows (in thousands):
Stock OptionsRestricted Stock UnitsRestricted Stock
Unrecognized compensation cost$221 $161 $483 
Expected weighted-average period in years of compensation cost to be recognized1.851.101.69
Schedule of Fair Value of Share-based Compensation Awards
Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2023 and 2022 were as follows (in thousands):
Stock Options
Nine Months Ended September 30,
20232022
Total fair value of shares vested$1,001 $853 
Weighted average estimated fair value of shares granted$2.10 $1.23 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
The Business (Details)
Jul. 01, 2023
Sep. 15, 2022
shares
Asset Acquisition [Line Items]    
Number of shares authorized to be repurchased (in shares)   1,227,776
Percentage of ownership after transaction   52.00%
Caladrius    
Asset Acquisition [Line Items]    
Conversion ratio 0.067  
CEND    
Asset Acquisition [Line Items]    
Conversion ratio   0.5338
Shares issued (in shares)   3,772,768
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Property and Equipment (Details)
Sep. 30, 2023
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Useful life 10 years
Computer equipment  
Property, Plant and Equipment [Line Items]  
Useful life 3 years
Software  
Property, Plant and Equipment [Line Items]  
Useful life 3 years
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Accounting Policies [Abstract]        
Intangible assets, net $ 400,000   $ 400,000  
Intangible asset, useful life 5 years   5 years  
Amortization of intangible assets $ 18,000   $ 53,000  
Expected amortization, remainder of fiscal year 71,000   71,000  
Expected amortization, year one 71,000   71,000  
Expected amortization, year two 71,000   71,000  
Expected amortization, year three 71,000   71,000  
Expected amortization, year four 71,000   71,000  
Revenue excluding taxes 0 $ 0 0 $ 0
Revenue from collaborative arrangement 0 0 0 0
Disaggregation of Revenue [Line Items]        
Revenue excluding taxes $ 0 $ 0 0 $ 0
Royalty        
Accounting Policies [Abstract]        
Revenue excluding taxes     0  
Disaggregation of Revenue [Line Items]        
Revenue excluding taxes     $ 0  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Merger - Narrative (Details)
$ in Thousands
Sep. 15, 2022
USD ($)
CEND  
Asset Acquisition [Line Items]  
Total purchase price $ 36,098
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Merger (Details) - USD ($)
$ / shares in Units, $ in Thousands
Sep. 15, 2022
Sep. 30, 2023
Dec. 31, 2022
Asset Acquisition [Line Items]      
Number of common shares of the combined company owned by Cend stockholders (in shares)   8,139,449 7,866,061
CEND      
Asset Acquisition [Line Items]      
Number of common shares of the combined company owned by Cend stockholders (in shares) 3,772,768    
Multiplied by the fair value per share of Lisata common stock on September 15, 2022 $ 6.25    
Total $ 23,580    
Carrying value of Lisata's cost method investment in Cend 10,000    
Incremental fair value of Cend's fully vested stock options 2,136    
Lisata transaction costs 382    
Total purchase price 36,098    
Cash and cash equivalents 7,062    
Net working capital (excluding cash) (1,690)    
Other liabilities (22)    
Acquired in-process research and development 30,393    
License $ 355    
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Cost $ 51,086 $ 64,758
Gross Unrealized Gains 0 0
Gross Unrealized Losses (17) (18)
Estimated Fair Value 51,069 64,740
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Cost 28,828 44,308
Gross Unrealized Gains 0 0
Gross Unrealized Losses (16) (17)
Estimated Fair Value 28,812 44,291
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Cost 1,978 7,953
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 1,978 7,953
Money market funds    
Debt Securities, Available-for-sale [Line Items]    
Cost 13,572 4,871
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 13,572 4,871
Agency bonds    
Debt Securities, Available-for-sale [Line Items]    
Cost 1,987 0
Gross Unrealized Gains 0 0
Gross Unrealized Losses (1) 0
Estimated Fair Value 1,986 0
Treasury bills    
Debt Securities, Available-for-sale [Line Items]    
Cost 3,996 0
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 3,996 0
Municipal debt securities    
Debt Securities, Available-for-sale [Line Items]    
Cost 725 7,626
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 (1)
Estimated Fair Value $ 725 $ 7,625
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-Sale [Abstract]    
Cash equivalents $ 29,103 $ 27,668
Marketable securities 21,966 37,072
Total $ 51,069 $ 64,740
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Amortized Cost    
Less than one year $ 51,086  
Greater than one year 0  
Cost 51,086 $ 64,758
Estimated Fair Value    
Less than one year 51,069  
Greater than one year 0  
Total estimated fair value $ 51,069 $ 64,740
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 661   $ 713
Accumulated depreciation (457)   (417)
Property and equipment, net 204   296
Depreciation 89 $ 22  
Furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 0   25
Computer equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 589   589
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 72   $ 99
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Income (Loss) Per Share (Details) - shares
shares in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,321 1,399
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,422 1,424
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 202 48
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details) - Recurring - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 29,103 $ 27,668
Marketable securities - available for sale 21,966 37,072
Assets, fair value disclosure 51,069 64,740
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 29,103 27,668
Marketable securities - available for sale 0 0
Assets, fair value disclosure 29,103 27,668
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Marketable securities - available for sale 21,966 37,072
Assets, fair value disclosure 21,966 37,072
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Marketable securities - available for sale 0 0
Assets, fair value disclosure $ 0 $ 0
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Accrued Liabilities [Abstract]    
Salaries, employee benefits and related taxes $ 2,366 $ 2,586
Clinical and R&D related liabilities 915 785
Accounting & tax consulting liabilities 230 0
Operating lease liabilities — current 164 180
Other 145 177
Total accrued liabilities $ 3,820 $ 3,728
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Leases - Narrative (Details)
Sep. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Weighted average remaining lease term for operating leases (in years) 2 years 1 year 6 months
Weighted average discount rate for operating leases (percent) 9.625% 9.625%
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Leases - Balance Sheet Presentation (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Right-of-Use Assets:    
Right-of-use assets $ 348 $ 487
Operating Lease Liabilities:    
Operating lease liabilities, current 164 180
Operating lease liabilities, noncurrent 181 305
Operating lease liabilities $ 345 $ 485
Right-of-use assets, balance sheet line item Other assets Other assets
Operating lease liabilities, current, balance sheet line item Accrued liabilities  
Operating lease liabilities, noncurrent, balance sheet line item Other long-term liabilities  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Leases - Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Finance Minimum Lease Payments    
2023 $ 48  
2024 190  
2025 143  
Total lease payments 381  
Less: Amounts representing interest (36)  
Present value of lease liabilities $ 345 $ 485
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Equity Issuances (Details) - USD ($)
 9 Months Ended 28 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Dec. 31, 2022
Sep. 15, 2022
Mar. 22, 2022
Jun. 04, 2021
Class of Stock [Line Items]              
Outstanding stock threshold           $ 75,000,000  
Net proceeds from issuance of common stock $ 297,000 $ 29,000          
Number of common shares of the combined company owned by Cend stockholders (in shares) 8,139,449   8,139,449 7,866,061      
CEND              
Class of Stock [Line Items]              
Number of common shares of the combined company owned by Cend stockholders (in shares)         3,772,768    
ATM Agreement              
Class of Stock [Line Items]              
Aggregate offering amount authorized per agreement             $ 50,000,000
Common stock, value, outstanding             43,600,000
Sale of stock available for sale             $ 17,698,943
Percentage held by non-affiliates             33.00%
Stock issued (in shares) 64,394   64,394        
Net proceeds from issuance of common stock $ 270,774   $ 270,774        
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Stock Options and Warrants Narrative (Details) - Stock options
 9 Months Ended
Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting term 4 years
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting term 10 years
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)
 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Stock Options, Shares      
Options, Outstanding, Beginning of Period (in shares) 1,391,352 1,391,352  
Options, Granted (in shares)   180,896  
Options, Exercised (in shares) (1,227,776) (82,500)  
Options, Forfeited (in shares)   (144,594)  
Options, Expired (in shares)   (24,603)  
Options, Outstanding, End of Period (in shares)   1,320,551 1,391,352
Options, Vested and expected to vest (in shares)   1,316,134  
Options, Vested (in shares)   1,229,103  
Stock Options, Weighted Average Exercise Price      
Options, Outstanding. Beginning of Period (in dollars per share) $ 10.83 $ 10.83  
Options, Granted (in dollars per share)   3.46  
Options, Exercised (in dollars per share)   1.88  
Options, Forfeited (in dollars per share)   3.63  
Options, Expired (in dollars per share)   29.60  
Options, Outstanding, End of Period (in dollars per share)   10.82 $ 10.83
Options, Vested and expected to vest (in dollars per share)   10.84  
Options, Vested (in dollars per share)   $ 11.25  
Stock Options, Weighted Average Contractual Term and Intrinsic Value      
Options, Outstanding, Weighted Average Remaining Contractual Term   6 years 3 months 18 days 7 years 10 days
Options, Vested and expected to vest, Weighted Average Remaining Contractual Term   6 years 3 months 14 days  
Options, Vested, Weighted Average Remaining Contractual Term   6 years 1 month 2 days  
Options, Outstanding, Aggregate Intrinsic Value   $ 78,700 $ 187,600
Options, Vested and expected to vest, Aggregate Intrinsic Value   78,700  
Options, Vested, Aggregate Intrinsic Value   $ 78,200  
Warrants, Shares      
Warrants, Outstanding, Beginning of Period (in shares) 1,423,774 1,423,774  
Warrants, Granted (in shares)   0  
Warrants, Exercised (in shares)   0  
Warrants, Forfeited (in shares)   0  
Warrants, Expired (in shares)   (2,000)  
Warrants, Outstanding, End of Period (in shares)   1,421,744 1,423,774
Warrants, Vested and expected to vest (in shares)   1,421,744  
Warrants, Vested (in shares)   1,421,744  
Warrants, Weighted Average Exercise Price      
Warrants Outstanding, Beginning of Period (in dollars per share) $ 42.57 $ 42.57  
Warrants, Granted (in dollars per share)   0  
Warrants, Exercised (in dollars per share)   0  
Warrants, Forfeited (in dollars per share)   0  
Warrants, Expired (in dollars per share)   88.35  
Warrants Outstanding, End of Period (in dollars per share)   42.51 $ 42.57
Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)   42.51  
Warrants, Vested, Weighted Average Exercise Price (in dollars per share)   $ 42.51  
Warrants, Weighted Average Contractual Term and Intrinsic Value      
Warrants, Outstanding, Weighted Average Remaining Contractual Term   2 years 8 months 1 day 3 years 4 months 13 days
Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term   2 years 8 months 1 day  
Warrants, Vested, Weighted Average Remaining Contractual Term   2 years 8 months 1 day  
Warrants Outstanding, Aggregate Intrinsic Value   $ 0 $ 0
Warrants, Vested and expected to vest, Aggregate Intrinsic Value   0  
Warrants, Vested, Aggregate Intrinsic Value   $ 0  
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares issued (in shares) 159,950 70,740
Value of shares issued $ 480 $ 973
Weighted average estimated fair value (usd per share) $ 3.00 $ 12.46
Restricted Stock | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting term 1 year  
Restricted Stock | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting term 4 years  
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares issued (in shares) 188,850 111,170
Value of shares issued $ 567 $ 1,386
Vesting term 1 year  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 306 $ 1,040 $ 1,565 $ 2,168
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense 103 271 517 631
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 203 $ 769 $ 1,048 $ 1,537
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
USD ($)
Stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation cost $ 221
Expected weighted-average period in years of compensation cost to be recognized 1 year 10 months 6 days
Restricted stock units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation cost $ 161
Expected weighted-average period in years of compensation cost to be recognized 1 year 1 month 6 days
Restricted Stock  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation cost $ 483
Expected weighted-average period in years of compensation cost to be recognized 1 year 8 months 8 days
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock options - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total fair value of shares vested $ 1,001 $ 853
Weighted average estimated fair value of shares granted $ 2.10 $ 1.23
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 05, 2023
Sep. 15, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Jan. 01, 2022
Dec. 31, 2021
Operating Loss Carryforwards [Line Items]                  
Operating loss carryforwards subject to expiration             $ 88,200    
Unrecognized tax benefits             344   $ 0
Unrecognized tax benefits, increase resulting from acquisition   $ 344              
Proceeds from sale of NOLs $ 2,200                
Benefit from income taxes 2,300   $ 0 $ 0 $ (2,330) $ (2,479)      
Loss on sale of NOL $ 100                
CEND                  
Operating Loss Carryforwards [Line Items]                  
Fair value market of tax NOLs             $ 36,100    
Effective income tax rate reconciliation             2.54%    
NOL annual limitation             $ 917    
Federal                  
Operating Loss Carryforwards [Line Items]                  
Net operating loss carryforwards               $ 112,300 281,000
Operating loss carryforwards subject to expiration                 168,800
Net operating loss carryforwards, prior to write down             34,000    
Federal | CEND                  
Operating Loss Carryforwards [Line Items]                  
Net operating loss carryforwards   10,700         10,900    
Operating loss carryforwards, post acquisition             106    
Foreign Tax Authority | CEND                  
Operating Loss Carryforwards [Line Items]                  
Net operating loss carryforwards             1,800    
State | CEND                  
Operating Loss Carryforwards [Line Items]                  
Net operating loss carryforwards   $ 15,000              
State | New Jersey                  
Operating Loss Carryforwards [Line Items]                  
Net operating loss carryforwards             35,500   97,000
State | California                  
Operating Loss Carryforwards [Line Items]                  
Net operating loss carryforwards             10,000   69,500
State | New York                  
Operating Loss Carryforwards [Line Items]                  
Net operating loss carryforwards             $ 1,900   $ 13,000
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Australia Research and Development Tax Incentive (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 04, 2023
Sep. 30, 2023
Income Tax Holiday [Line Items]    
Income tax incentive receivable   $ 0.5
Australian Taxation Office    
Income Tax Holiday [Line Items]    
Income tax refunds $ 0.6  
Minimum    
Income Tax Holiday [Line Items]    
Research tax credit rate   43.50%
Maximum    
Income Tax Holiday [Line Items]    
Research tax credit rate   48.50%
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Technology Transfer Agreement (Details) - Impilo - shares
Oct. 03, 2023
Jul. 31, 2023
Investments in and Advances to Affiliates [Line Items]    
Investment owned (in shares)   766,000
Subsequent event    
Investments in and Advances to Affiliates [Line Items]    
Shares canceled (in shares) 766,000  
Preferred stock, shares issued (in shares) 574,500  
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.3
License Agreements (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jul. 31, 2023
Mar. 31, 2022
Oct. 31, 2021
Dec. 31, 2016
Impilo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Investment owned (in shares)   766,000      
Sanford Burnham Prebys | Impilo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Investment owned (in shares)   191,500      
Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued under license agreement (in shares)         382,030
Annual license maintenance fee       $ 20,000 $ 10,000
Annual license maintenance fee, year seven         20,000
Potential milestone payments       $ 23,200 $ 10,600
Royalties, net of sales       4.00% 4.00%
Sublicensing fee         25.00%
Annual license maintenance fee, year four       $ 30,000  
Shares held by third party (in shares) 382,030        
Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sublicensing fee       10.00%  
Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sublicensing fee       25.00%  
University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential milestone payments     $ 1,200    
Royalties, net of sales     1.50%    
University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sublicensing fee     10.00%    
University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sublicensing fee     20.00%    
Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Annual license maintenance fee       $ 20,000  
Potential milestone payments       $ 5,000  
Royalties, net of sales       2.00%  
Annual license maintenance fee, year four       $ 50,000  
Shares held by third party (in shares) 43,236        
Annual license maintenance fee, years two and three       25,000  
Annual license maintenance fee, after first sale       150,000  
Change of control fee       $ 300  
Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | CEND          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued (in shares) 43,236        
Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sublicensing fee       3.00%  
Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sublicensing fee       20.00%  
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Research Collaboration and License Agreement (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 14, 2022
Feb. 28, 2021
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue from contract     $ 0 $ 0 $ 0 $ 0
Exclusive License and Collaboration Agreement | Qilu | License            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contract with customer, liability   $ 10,000,000        
Revenue from contract $ 5,000,000          
Option to terminate   60 days        
Exclusive License and Collaboration Agreement | Qilu | License | Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Variable consideration amounts, milestones   $ 95,000,000        
Percentage of net sale   10.00%        
Percentage of sublicensing revenues   12.00%        
Exclusive License and Collaboration Agreement | Qilu | License | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Variable consideration amounts, milestones   $ 125,000,000        
Percentage of net sale   15.00%        
Percentage of sublicensing revenues   35.00%        
XML 73 lsta-20230930_htm.xml IDEA: XBRL DOCUMENT 0000320017 2023-01-01 2023-09-30 0000320017 2023-11-02 0000320017 2023-09-30 0000320017 2022-12-31 0000320017 2023-07-01 2023-09-30 0000320017 2022-07-01 2022-09-30 0000320017 2022-01-01 2022-09-30 0000320017 us-gaap:CommonStockMember 2022-06-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000320017 us-gaap:RetainedEarningsMember 2022-06-30 0000320017 us-gaap:TreasuryStockCommonMember 2022-06-30 0000320017 us-gaap:ParentMember 2022-06-30 0000320017 us-gaap:NoncontrollingInterestMember 2022-06-30 0000320017 2022-06-30 0000320017 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000320017 us-gaap:ParentMember 2022-07-01 2022-09-30 0000320017 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000320017 us-gaap:CommonStockMember 2022-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000320017 us-gaap:RetainedEarningsMember 2022-09-30 0000320017 us-gaap:TreasuryStockCommonMember 2022-09-30 0000320017 us-gaap:ParentMember 2022-09-30 0000320017 us-gaap:NoncontrollingInterestMember 2022-09-30 0000320017 2022-09-30 0000320017 us-gaap:CommonStockMember 2021-12-31 0000320017 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000320017 us-gaap:RetainedEarningsMember 2021-12-31 0000320017 us-gaap:TreasuryStockCommonMember 2021-12-31 0000320017 us-gaap:ParentMember 2021-12-31 0000320017 us-gaap:NoncontrollingInterestMember 2021-12-31 0000320017 2021-12-31 0000320017 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000320017 us-gaap:ParentMember 2022-01-01 2022-09-30 0000320017 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000320017 us-gaap:CommonStockMember 2023-06-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000320017 us-gaap:RetainedEarningsMember 2023-06-30 0000320017 us-gaap:TreasuryStockCommonMember 2023-06-30 0000320017 us-gaap:ParentMember 2023-06-30 0000320017 us-gaap:NoncontrollingInterestMember 2023-06-30 0000320017 2023-06-30 0000320017 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000320017 us-gaap:ParentMember 2023-07-01 2023-09-30 0000320017 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000320017 us-gaap:CommonStockMember 2023-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000320017 us-gaap:RetainedEarningsMember 2023-09-30 0000320017 us-gaap:TreasuryStockCommonMember 2023-09-30 0000320017 us-gaap:ParentMember 2023-09-30 0000320017 us-gaap:NoncontrollingInterestMember 2023-09-30 0000320017 us-gaap:CommonStockMember 2022-12-31 0000320017 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000320017 us-gaap:RetainedEarningsMember 2022-12-31 0000320017 us-gaap:TreasuryStockCommonMember 2022-12-31 0000320017 us-gaap:ParentMember 2022-12-31 0000320017 us-gaap:NoncontrollingInterestMember 2022-12-31 0000320017 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000320017 us-gaap:ParentMember 2023-01-01 2023-09-30 0000320017 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000320017 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000320017 lsta:CENDMember 2022-09-15 2022-09-15 0000320017 lsta:CENDMember 2022-09-15 0000320017 2022-09-15 0000320017 2022-09-15 2022-09-15 0000320017 lsta:CaladriusMember 2023-07-01 2023-07-01 0000320017 us-gaap:FurnitureAndFixturesMember 2023-09-30 0000320017 us-gaap:ComputerEquipmentMember 2023-09-30 0000320017 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-09-30 0000320017 us-gaap:RoyaltyMember 2023-01-01 2023-09-30 0000320017 us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000320017 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000320017 us-gaap:CommercialPaperMember 2023-09-30 0000320017 us-gaap:CommercialPaperMember 2022-12-31 0000320017 us-gaap:MoneyMarketFundsMember 2023-09-30 0000320017 us-gaap:MoneyMarketFundsMember 2022-12-31 0000320017 us-gaap:BondsMember 2023-09-30 0000320017 us-gaap:BondsMember 2022-12-31 0000320017 us-gaap:USTreasuryBillSecuritiesMember 2023-09-30 0000320017 us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0000320017 us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-09-30 0000320017 us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-12-31 0000320017 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000320017 us-gaap:ComputerEquipmentMember 2022-12-31 0000320017 us-gaap:LeaseholdImprovementsMember 2023-09-30 0000320017 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000320017 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000320017 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000320017 us-gaap:WarrantMember 2022-01-01 2022-09-30 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000320017 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000320017 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000320017 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000320017 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000320017 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000320017 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000320017 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000320017 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000320017 lsta:AtTheMarketOfferingAgreementMember 2021-06-04 0000320017 2022-03-22 0000320017 lsta:AtTheMarketOfferingAgreementMember 2023-01-01 2023-09-30 0000320017 lsta:AtTheMarketOfferingAgreementMember 2021-06-04 2023-09-30 0000320017 2023-01-01 2023-06-30 0000320017 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000320017 2022-01-01 2022-12-31 0000320017 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0000320017 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0000320017 srt:MinimumMember us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0000320017 srt:MaximumMember us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000320017 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0000320017 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0000320017 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0000320017 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2023-09-30 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0000320017 us-gaap:RestrictedStockMember 2023-09-30 0000320017 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000320017 us-gaap:DomesticCountryMember 2021-12-31 0000320017 us-gaap:DomesticCountryMember 2022-01-01 0000320017 us-gaap:DomesticCountryMember 2022-12-31 0000320017 us-gaap:DomesticCountryMember lsta:CENDMember 2022-12-31 0000320017 us-gaap:DomesticCountryMember lsta:CENDMember 2022-09-15 0000320017 us-gaap:StateAndLocalJurisdictionMember lsta:CENDMember 2022-09-15 0000320017 lsta:CENDMember 2022-01-01 2022-12-31 0000320017 lsta:CENDMember 2022-12-31 0000320017 us-gaap:ForeignCountryMember lsta:CENDMember 2022-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewJerseyDivisionOfTaxationMember 2022-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewJerseyDivisionOfTaxationMember 2021-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember 2022-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember 2021-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember 2022-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember 2021-12-31 0000320017 2023-04-05 2023-04-05 0000320017 srt:MinimumMember 2023-01-01 2023-09-30 0000320017 srt:MaximumMember 2023-01-01 2023-09-30 0000320017 us-gaap:AustralianTaxationOfficeMember 2023-09-04 2023-09-04 0000320017 lsta:ImpiloMember 2023-07-31 0000320017 lsta:ImpiloMember us-gaap:SubsequentEventMember 2023-10-03 0000320017 lsta:SanfordBurnhamPrebysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2016-12-31 0000320017 lsta:SanfordBurnhamPrebysMember lsta:ImpiloMember 2023-07-31 0000320017 lsta:SanfordBurnhamPrebysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-10-31 0000320017 lsta:SanfordBurnhamPrebysMember srt:MinimumMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-10-31 0000320017 lsta:SanfordBurnhamPrebysMember srt:MaximumMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-10-31 0000320017 lsta:SanfordBurnhamPrebysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-09-30 0000320017 lsta:UniversityOfCaliforniaAtSanDiegoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-03-31 0000320017 lsta:UniversityOfCaliforniaAtSanDiegoMember srt:MinimumMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-03-31 0000320017 lsta:UniversityOfCaliforniaAtSanDiegoMember srt:MaximumMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-03-31 0000320017 lsta:MassachusettsInstituteOfTechnologyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember lsta:CENDMember 2023-09-30 0000320017 lsta:MassachusettsInstituteOfTechnologyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-10-31 0000320017 lsta:MassachusettsInstituteOfTechnologyMember srt:MinimumMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-10-31 0000320017 lsta:MassachusettsInstituteOfTechnologyMember srt:MaximumMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-10-31 0000320017 lsta:MassachusettsInstituteOfTechnologyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-09-30 0000320017 lsta:QiluMember us-gaap:LicenseMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-28 0000320017 lsta:QiluMember us-gaap:LicenseMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2022-09-14 2022-09-14 0000320017 lsta:QiluMember us-gaap:LicenseMember srt:MinimumMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-28 0000320017 lsta:QiluMember us-gaap:LicenseMember srt:MaximumMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-28 0000320017 lsta:QiluMember us-gaap:LicenseMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-01 2021-02-28 shares iso4217:USD iso4217:USD shares pure 0000320017 --12-31 2023 Q3 false 0.067 http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent P1Y 0.33 10-Q true 2023-09-30 false 001-33650 LISATA THERAPEUTICS, INC. DE 22-2343568 110 Allen Road, 2nd Floor Basking Ridge NJ 07920 908 842-0100 Common Stock, par value $0.001 per share LSTA NASDAQ Yes Yes Non-accelerated Filer true false false 8139449 32428000 32154000 21966000 37072000 2839000 2650000 57233000 71876000 204000 296000 281000 334000 371000 528000 58089000 73034000 1312000 2655000 3820000 3728000 5132000 6383000 253000 327000 5385000 6710000 0.001 0.001 33333333 33333333 8140187 7866799 8139449 7866061 8000 8000 576474000 574548000 738 738 708000 708000 -522716000 -507241000 -100000 -29000 52958000 66578000 -254000 -254000 52704000 66324000 58089000 73034000 3380000 3335000 9721000 9853000 0 30393000 0 30393000 2584000 3992000 9962000 10815000 5964000 37720000 19683000 51061000 -5964000 -37720000 -19683000 -51061000 714000 337000 2053000 496000 -11000 0 -175000 -149000 703000 337000 1878000 347000 -5261000 -37383000 -17805000 -50714000 0 0 -2330000 -2479000 -5261000 -37383000 -15475000 -48235000 0 0 0 0 -5261000 -37383000 -15475000 -48235000 -0.65 -0.65 -7.88 -7.88 -1.92 -1.92 -11.28 -11.28 8141000 8141000 4747000 4747000 8050000 8050000 4276000 4276000 -5261000 -37383000 -15475000 -48235000 0 5000 1000 5000 -50000 -25000 -72000 -25000 -50000 -20000 -71000 -20000 -5311000 -37403000 -15546000 -48255000 4038000 4000 547032000 -70000 -463868000 -708000 82391000 -254000 82137000 -37383000 -37383000 -37383000 52000 940000 939000 939000 3773000 4000 26094000 26098000 26098000 5000 5000 5000 -25000 -25000 -25000 7863000 8000 574066000 -90000 -501251000 -708000 72025000 -254000 71771000 3986000 4000 546044000 -70000 -453016000 -708000 92254000 -254000 92000000 -48235000 -48235000 -48235000 100000 1899000 1899000 1899000 4000 29000 29000 29000 3773000 4000 26094000 26098000 26098000 5000 5000 5000 -25000 -25000 -25000 7863000 8000 574066000 -90000 -501251000 -708000 72025000 -254000 71771000 8133000 8000 576173000 -50000 -517455000 -708000 57968000 -254000 57714000 -5261000 -5261000 -5261000 7000 301000 301000 301000 -50000 -50000 -50000 8140000 8000 576474000 -100000 -522716000 -708000 52958000 -254000 52704000 7867000 8000 574548000 -29000 -507241000 -708000 66578000 -254000 66324000 -15475000 -15475000 -15475000 114000 1474000 1474000 1474000 76000 297000 297000 297000 83000 155000 155000 155000 1000 1000 1000 -72000 -72000 -72000 8140000 8000 576474000 -100000 -522716000 -708000 52958000 -254000 52704000 -15475000 -48235000 1565000 2168000 142000 22000 -3000 0 0 -30393000 709000 -893000 314000 -29000 -130000 -178000 -1305000 -150000 -15963000 -14702000 77355000 68481000 93171000 93865000 0 3320000 0 259000 15816000 21805000 155000 0 91000 267000 297000 29000 361000 -238000 60000 -34000 274000 6831000 32154000 24647000 32428000 31478000 0 23580000 0 2136000 The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment (“TME”), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it is seeking to partner while incurring no additional capital outlay.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company’s current development pipeline includes: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including, metastatic pancreatic ductal adenocarcinoma (mPDAC) and other forms of pancreatic cancer, cholangiocarcinoma, esophageal cancer, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (“Caladrius”), completed its acquisition of Cend Therapeutics, Inc. (“Cend”), a Delaware corporation (the “Merger”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (“Merger Sub”).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the “Effective Time”): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (“Reverse Stock Split”) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata’s common stock based on an exchange ratio of 0.5338, after taking into account the Reverse Stock Split (the “Exchange Ratio”). In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the “Cend Plan”), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata’s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team provided a vast majority of the individuals on the management team and holds the chief executive officer (“CEO”), chief medical officer (“CMO”) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend’s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&amp;D”). Cend’s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company’s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company’s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&amp;D”). Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div> 0.5338 3772768 1227776 0.52 <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&amp;D”). Accordingly, actual results could differ from those estimates and assumptions.</span></div> Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div> Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (“R&amp;D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s intangible asset consists of a single asset, Cend’s license agreement with Qilu Pharmaceutical, Co., Ltd. (“Qilu”) acquired in the Merger, with a value of $0.4 million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18 thousand for the three months ended September 30, 2023 and $53 thousand for the nine months ended September 30, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable. The projected amortization expense is $71 thousand per year for the next five years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September 30, 2023 and 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September 30, 2023 and September 30, 2022, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div> Property and EquipmentThe cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P10Y P3Y P3Y <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span>The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant. Loss Per ShareBasic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. <div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (“R&amp;D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div> 400000 P5Y 18000 53000 The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable. 71000 71000 71000 71000 71000 <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div>If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. 0 0 0 0 <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September 30, 2023 and September 30, 2022, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div> 0 0 0 0 0 Merger<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;D. Cend’s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D being expensed. The fair value of total consideration was $36.1 million. The following table is a summary of the purchase price calculation (in thousands except per share data).</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772,768 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,580</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,062</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div> 36100000 The following table is a summary of the purchase price calculation (in thousands except per share data).<div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772,768 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,580</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,062</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div> 3772768 6.25 23580000 10000000 2136000 382000 36098000 7062000 1690000 22000 30393000 355000 36098000 Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,086 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,072 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,086 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,086 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28828000 0 16000 28812000 44308000 0 17000 44291000 1978000 0 0 1978000 7953000 0 0 7953000 13572000 0 0 13572000 4871000 0 0 4871000 1987000 0 1000 1986000 0 0 0 0 3996000 0 0 3996000 0 0 0 0 725000 0 0 725000 7626000 0 1000 7625000 51086000 0 17000 51069000 64758000 0 18000 64740000 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,072 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29103000 27668000 21966000 37072000 51069000 64740000 <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,086 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 51086000 51069000 0 0 51086000 51069000 Property and Equipment<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s results included depreciation expense of approximately $89 thousand and $22 thousand for the nine months ended September 30, 2023 and 2022, respectively.</span></div> 0 25000 589000 589000 72000 99000 661000 713000 457000 417000 204000 296000 89000 22000 Income (Loss) Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September 30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> At September 30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1321000 1399000 1422000 1424000 202000 48000 Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts payable and accrued expenses approximate fair value as of September 30, 2023 and December 31, 2022, due to the short maturity nature of these items.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,069 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29103000 0 0 29103000 27668000 0 0 27668000 0 21966000 0 21966000 0 37072000 0 37072000 29103000 21966000 0 51069000 27668000 37072000 0 64740000 Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September 30, 2023 and December 31, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities — current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,820 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September 30, 2023 and December 31, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities — current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,820 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2366000 2586000 915000 785000 230000 0 164000 180000 145000 177000 3820000 3728000 Operating LeasesThe Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-566"><span style="-sec-ix-hidden:f-567">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-572"><span style="-sec-ix-hidden:f-573">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-576"><span style="-sec-ix-hidden:f-577">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the weighted average remaining lease term for our operating lease was 2.0 years, and the weighted average discount rate for our operating lease was 9.625%. As of December 31, 2022, the weighted average remaining lease term for our operating leases was 1.5 years, and the weighted average discount rate for our operating leases was 9.625%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of September 30, 2023 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part. <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-566"><span style="-sec-ix-hidden:f-567">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-572"><span style="-sec-ix-hidden:f-573">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-576"><span style="-sec-ix-hidden:f-577">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 348000 487000 348000 487000 164000 180000 181000 305000 345000 485000 P2Y 0.09625 P1Y6M 0.09625 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of September 30, 2023 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 48000 190000 143000 381000 36000 345000 Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the nine months ended September 30, 2023, the Company issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger closing on September 15, 2022, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391,352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.03</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,316,134 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.84 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,229,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.25 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:f-660">one</span> and four years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The weighted average estimated fair value of restricted stock units issued for services in the nine months ended September 30, 2023 and 2022 was $3.00 and $12.46 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones. 50000000 43600000 75000000 17698943 64394 270774 64394 270774 3772768 1227776 P10Y P4Y The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391,352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.03</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,316,134 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.84 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,229,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.25 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1391352 10.83 P7Y10D 187600 1423774 42.57 P3Y4M13D 0 180896 3.46 0 0 82500 1.88 0 0 144594 3.63 0 0 24603 29.60 2000 88.35 1320551 10.82 P6Y3M18D 78700 1421744 42.51 P2Y8M1D 0 1316134 10.84 P6Y3M14D 78700 1421744 42.51 P2Y8M1D 0 1229103 11.25 P6Y1M2D 78200 1421744 42.51 P2Y8M1D 0 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 159950 70740 480000 973000 P4Y <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 188850 111170 567000 1386000 3.00 12.46 P1Y Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2023 and 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September 30, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2023 and 2022 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div> The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2023 and 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table> 103000 271000 517000 631000 203000 769000 1048000 1537000 306000 1040000 1565000 2168000 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September 30, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr></table></div> 221000 161000 483000 P1Y10M6D P1Y1M6D P1Y8M8D <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2023 and 2022 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1001000 853000 2.10 1.23 Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had approximately $281.0 million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $168.8 million of the $281.0 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112.3 million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173 thousand under Internal Revenue Code Section 382. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had approximately $34.0 million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0 million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Cend Therapeutics had approximately $10.9 million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $10.7 million of Federal and $15.0 million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years. Using a fair market value of $36.1 million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $106 thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. Cend’s wholly owned Australian subsidiary has $1.8 million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had State NOLs available in New Jersey of $35.5 million and $97.0 million, respectively, California of $10.0 million and $69.5 million, respectively, and New York City of $1.9 million and $13.0 million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company’s uncertain tax positions were $344 thousand and $0, respectively. Due to the acquisition of Cend, the Company’s uncertain tax positions increased by $344 thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of September 30, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from the date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, the Company received final approval from the New Jersey Economic Development Authority (“NJEDA”) under the Technology Business Tax Certificate Transfer Program (“Program”) to sell a percentage of its New Jersey net operating losses (“NJ NOLs”), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2 million. The $2.3 million of NJ NOLs related tax benefits has been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div>On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company’s results of operations for the year ended December 31, 2022. The Company will continue to monitor the future impact of changes in tax legislation. 281000000 168800000 281000000 112300000 34000000 88200000 34000000 10900000 10700000 15000000 36100000 0.0254 917000 106000 1800000 35500000 97000000 10000000 69500000 1900000 13000000 344000 0 344000 2200000 2300000 100000 Australia Research and Development Tax IncentiveThe Company’s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the nine months ended September 30, 2023, $0.5 million was recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed. On September 4, 2023 the Company's Australian subsidiary received a $0.6 million tax refund from the Australian Taxation Office related to the 2022 tax year. 0.435 0.485 500000 600000 Contingencies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. </span></div>In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (“Lingmed”) claiming Lingmed was entitled to a success fee based on Cend’s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend’s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend’s response on July 11, 2022. At a Case Management Conference held on August 4, 2023, the Court set a trial date in the matter for August 2, 2024. The Company denies these allegations made by Lingmed and intends to vigorously defend itself. Technology Transfer Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impilo Therapeutics </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (“Impilo”) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 in connection with the Sanford Burnham Prebys license agreement (Note 16) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company.</span></div> 766000 766000 574500 License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (“SBP”) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend’s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6 million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company’s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days’ prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2 million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. On September 14, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned 382,030 shares of the Company’s common stock as of September 30, 2023 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (“UCSD”) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2 million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days’ prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0 million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement expires upon the expiration or abandonment of all valid claims. The agreement may be earlier terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may also be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, in accordance with the provisions of the license agreement, the Company provided notice to MIT that the license agreement would terminate effective December 30, 2023. Until such date, the license remains in full force and effect.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIT owned 43,236 shares of the Company’s common stock as of September 30, 2023.</span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the “Qilu Agreement”) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10 million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5 million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95 million and $125 million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</span></div> 382030 10000000 20000000 10600000 0.04 0.25 191500 20000000 30000000 23200000 0.04 0.10 0.25 382030 1200000 0.015 0.10 0.20 43236 20000000 25000000 50000000 150000000 5000000 0.02 0.03 0.20 300000 43236 10000000 5000000 95000000 125000000 0.10 0.15 0.12 0.35 P60D EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

X+2M9[ 0 .TH / M " 9UB 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !P M@6)7=TMQA08" #Q) &@ @ &V9P$ >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !P@6)7_R>G=>,! !L) $P M @ 'T:0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1@!& + "$3 (; $ ! end XML 75 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 178 306 1 false 52 0 false 4 false false R1.htm 0000001 - Document - Cover Sheet http://www.caladrius.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY Sheet http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY CONSOLIDATED STATEMENTS OF EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - The Business Sheet http://www.caladrius.com/role/TheBusiness The Business Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Merger Sheet http://www.caladrius.com/role/Merger Merger Notes 10 false false R11.htm 0000011 - Disclosure - Available-for-Sale-Securities Sheet http://www.caladrius.com/role/AvailableforSaleSecurities Available-for-Sale-Securities Notes 11 false false R12.htm 0000012 - Disclosure - Property and Equipment Sheet http://www.caladrius.com/role/PropertyandEquipment Property and Equipment Notes 12 false false R13.htm 0000013 - Disclosure - Income (Loss) Per Share Sheet http://www.caladrius.com/role/IncomeLossPerShare Income (Loss) Per Share Notes 13 false false R14.htm 0000014 - Disclosure - Fair Value Measurements Sheet http://www.caladrius.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 0000015 - Disclosure - Accrued Liabilities Sheet http://www.caladrius.com/role/AccruedLiabilities Accrued Liabilities Notes 15 false false R16.htm 0000016 - Disclosure - Operating Leases Sheet http://www.caladrius.com/role/OperatingLeases Operating Leases Notes 16 false false R17.htm 0000017 - Disclosure - Stockholders' Equity Sheet http://www.caladrius.com/role/StockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 0000018 - Disclosure - Share-Based Compensation Sheet http://www.caladrius.com/role/ShareBasedCompensation Share-Based Compensation Notes 18 false false R19.htm 0000019 - Disclosure - Income Taxes Sheet http://www.caladrius.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 0000020 - Disclosure - Australia Research and Development Tax Incentive Sheet http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive Australia Research and Development Tax Incentive Notes 20 false false R21.htm 0000021 - Disclosure - Contingencies Sheet http://www.caladrius.com/role/Contingencies Contingencies Notes 21 false false R22.htm 0000022 - Disclosure - Technology Transfer Agreement Sheet http://www.caladrius.com/role/TechnologyTransferAgreement Technology Transfer Agreement Notes 22 false false R23.htm 0000023 - Disclosure - License Agreements Sheet http://www.caladrius.com/role/LicenseAgreements License Agreements Notes 23 false false R24.htm 0000024 - Disclosure - Research Collaboration and License Agreement Sheet http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement Research Collaboration and License Agreement Notes 24 false false R25.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 9954473 - Disclosure - Merger (Tables) Sheet http://www.caladrius.com/role/MergerTables Merger (Tables) Tables http://www.caladrius.com/role/Merger 27 false false R28.htm 9954474 - Disclosure - Available-for-Sale-Securities (Tables) Sheet http://www.caladrius.com/role/AvailableforSaleSecuritiesTables Available-for-Sale-Securities (Tables) Tables http://www.caladrius.com/role/AvailableforSaleSecurities 28 false false R29.htm 9954475 - Disclosure - Property and Equipment (Tables) Sheet http://www.caladrius.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.caladrius.com/role/PropertyandEquipment 29 false false R30.htm 9954476 - Disclosure - Income (Loss) Per Share (Tables) Sheet http://www.caladrius.com/role/IncomeLossPerShareTables Income (Loss) Per Share (Tables) Tables http://www.caladrius.com/role/IncomeLossPerShare 30 false false R31.htm 9954477 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.caladrius.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.caladrius.com/role/FairValueMeasurements 31 false false R32.htm 9954478 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.caladrius.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.caladrius.com/role/AccruedLiabilities 32 false false R33.htm 9954479 - Disclosure - Operating Leases (Tables) Sheet http://www.caladrius.com/role/OperatingLeasesTables Operating Leases (Tables) Tables http://www.caladrius.com/role/OperatingLeases 33 false false R34.htm 9954480 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.caladrius.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.caladrius.com/role/StockholdersEquity 34 false false R35.htm 9954481 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.caladrius.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.caladrius.com/role/ShareBasedCompensation 35 false false R36.htm 9954482 - Disclosure - The Business (Details) Sheet http://www.caladrius.com/role/TheBusinessDetails The Business (Details) Details http://www.caladrius.com/role/TheBusiness 36 false false R37.htm 9954483 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 37 false false R38.htm 9954484 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 38 false false R39.htm 9954485 - Disclosure - Merger - Narrative (Details) Sheet http://www.caladrius.com/role/MergerNarrativeDetails Merger - Narrative (Details) Details 39 false false R40.htm 9954486 - Disclosure - Merger (Details) Sheet http://www.caladrius.com/role/MergerDetails Merger (Details) Details http://www.caladrius.com/role/MergerTables 40 false false R41.htm 9954487 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) Sheet http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) Details 41 false false R42.htm 9954488 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) Sheet http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) Details 42 false false R43.htm 9954489 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) Sheet http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) Details 43 false false R44.htm 9954490 - Disclosure - Property and Equipment (Details) Sheet http://www.caladrius.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://www.caladrius.com/role/PropertyandEquipmentTables 44 false false R45.htm 9954491 - Disclosure - Income (Loss) Per Share (Details) Sheet http://www.caladrius.com/role/IncomeLossPerShareDetails Income (Loss) Per Share (Details) Details http://www.caladrius.com/role/IncomeLossPerShareTables 45 false false R46.htm 9954492 - Disclosure - Fair Value Measurements (Details) Sheet http://www.caladrius.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.caladrius.com/role/FairValueMeasurementsTables 46 false false R47.htm 9954493 - Disclosure - Accrued Liabilities (Details) Sheet http://www.caladrius.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.caladrius.com/role/AccruedLiabilitiesTables 47 false false R48.htm 9954494 - Disclosure - Operating Leases - Narrative (Details) Sheet http://www.caladrius.com/role/OperatingLeasesNarrativeDetails Operating Leases - Narrative (Details) Details 48 false false R49.htm 9954495 - Disclosure - Operating Leases - Balance Sheet Presentation (Details) Sheet http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails Operating Leases - Balance Sheet Presentation (Details) Details 49 false false R50.htm 9954496 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details) Sheet http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails Operating Leases - Future Minimum Lease Payments (Details) Details 50 false false R51.htm 9954497 - Disclosure - Stockholders' Equity - Equity Issuances (Details) Sheet http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails Stockholders' Equity - Equity Issuances (Details) Details 51 false false R52.htm 9954498 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details) Sheet http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails Stockholders' Equity - Stock Options and Warrants Narrative (Details) Details 52 false false R53.htm 9954499 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details) Sheet http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails Stockholders' Equity - Stock Options and Warrants (Details) Details 53 false false R54.htm 9954500 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) Sheet http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) Details 54 false false R55.htm 9954501 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details) Sheet http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails Share-Based Compensation - Share-Based Compensation Expense (Details) Details 55 false false R56.htm 9954502 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details) Sheet http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails Share-Based Compensation - Compensation Cost Not Yet Recognized (Details) Details 56 false false R57.htm 9954503 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) Sheet http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) Details 57 false false R58.htm 9954504 - Disclosure - Income Taxes (Details) Sheet http://www.caladrius.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.caladrius.com/role/IncomeTaxes 58 false false R59.htm 9954505 - Disclosure - Australia Research and Development Tax Incentive (Details) Sheet http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails Australia Research and Development Tax Incentive (Details) Details http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive 59 false false R60.htm 9954506 - Disclosure - Technology Transfer Agreement (Details) Sheet http://www.caladrius.com/role/TechnologyTransferAgreementDetails Technology Transfer Agreement (Details) Details http://www.caladrius.com/role/TechnologyTransferAgreement 60 false false R61.htm 9954507 - Disclosure - License Agreements (Details) Sheet http://www.caladrius.com/role/LicenseAgreementsDetails License Agreements (Details) Details http://www.caladrius.com/role/LicenseAgreements 61 false false R62.htm 9954508 - Disclosure - Research Collaboration and License Agreement (Details) Sheet http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails Research Collaboration and License Agreement (Details) Details http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement 62 false false All Reports Book All Reports lsta-20230930.htm lsta-20230930.xsd lsta-20230930_cal.xml lsta-20230930_def.xml lsta-20230930_lab.xml lsta-20230930_pre.xml lsta-20230930_g1.jpg lsta-20230930_g2.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lsta-20230930.htm": { "nsprefix": "lsta", "nsuri": "http://www.caladrius.com/20230930", "dts": { "inline": { "local": [ "lsta-20230930.htm" ] }, "schema": { "local": [ "lsta-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "lsta-20230930_cal.xml" ] }, "definitionLink": { "local": [ "lsta-20230930_def.xml" ] }, "labelLink": { "local": [ "lsta-20230930_lab.xml" ] }, "presentationLink": { "local": [ "lsta-20230930_pre.xml" ] } }, "keyStandard": 240, "keyCustom": 66, "axisStandard": 19, "axisCustom": 0, "memberStandard": 40, "memberCustom": 9, "hidden": { "total": 14, "http://fasb.org/us-gaap/2023": 8, "http://xbrl.sec.gov/dei/2023": 5, "http://www.caladrius.com/20230930": 1 }, "contextCount": 178, "entityCount": 1, "segmentCount": 52, "elementCount": 467, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 639, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.caladrius.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } }, "R6": { "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-29", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-29", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } }, "R8": { "role": "http://www.caladrius.com/role/TheBusiness", "longName": "0000008 - Disclosure - The Business", "shortName": "The Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "lsta:BusinessTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lsta:BusinessTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.caladrius.com/role/Merger", "longName": "0000010 - Disclosure - Merger", "shortName": "Merger", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.caladrius.com/role/AvailableforSaleSecurities", "longName": "0000011 - Disclosure - Available-for-Sale-Securities", "shortName": "Available-for-Sale-Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.caladrius.com/role/PropertyandEquipment", "longName": "0000012 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.caladrius.com/role/IncomeLossPerShare", "longName": "0000013 - Disclosure - Income (Loss) Per Share", "shortName": "Income (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.caladrius.com/role/FairValueMeasurements", "longName": "0000014 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.caladrius.com/role/AccruedLiabilities", "longName": "0000015 - Disclosure - Accrued Liabilities", "shortName": "Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.caladrius.com/role/OperatingLeases", "longName": "0000016 - Disclosure - Operating Leases", "shortName": "Operating Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.caladrius.com/role/StockholdersEquity", "longName": "0000017 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.caladrius.com/role/ShareBasedCompensation", "longName": "0000018 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.caladrius.com/role/IncomeTaxes", "longName": "0000019 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive", "longName": "0000020 - Disclosure - Australia Research and Development Tax Incentive", "shortName": "Australia Research and Development Tax Incentive", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.caladrius.com/role/Contingencies", "longName": "0000021 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.caladrius.com/role/TechnologyTransferAgreement", "longName": "0000022 - Disclosure - Technology Transfer Agreement", "shortName": "Technology Transfer Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "lsta:TechnologyTransferAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lsta:TechnologyTransferAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.caladrius.com/role/LicenseAgreements", "longName": "0000023 - Disclosure - License Agreements", "shortName": "License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement", "longName": "0000024 - Disclosure - Research Collaboration and License Agreement", "shortName": "Research Collaboration and License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://www.caladrius.com/role/MergerTables", "longName": "9954473 - Disclosure - Merger (Tables)", "shortName": "Merger (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables", "longName": "9954474 - Disclosure - Available-for-Sale-Securities (Tables)", "shortName": "Available-for-Sale-Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.caladrius.com/role/PropertyandEquipmentTables", "longName": "9954475 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.caladrius.com/role/IncomeLossPerShareTables", "longName": "9954476 - Disclosure - Income (Loss) Per Share (Tables)", "shortName": "Income (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.caladrius.com/role/FairValueMeasurementsTables", "longName": "9954477 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables", "longName": "9954478 - Disclosure - Accrued Liabilities (Tables)", "shortName": "Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.caladrius.com/role/OperatingLeasesTables", "longName": "9954479 - Disclosure - Operating Leases (Tables)", "shortName": "Operating Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.caladrius.com/role/StockholdersEquityTables", "longName": "9954480 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.caladrius.com/role/ShareBasedCompensationTables", "longName": "9954481 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.caladrius.com/role/TheBusinessDetails", "longName": "9954482 - Disclosure - The Business (Details)", "shortName": "The Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-76", "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-79", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-79", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } }, "R39": { "role": "http://www.caladrius.com/role/MergerNarrativeDetails", "longName": "9954485 - Disclosure - Merger - Narrative (Details)", "shortName": "Merger - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-74", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.caladrius.com/role/MergerDetails", "longName": "9954486 - Disclosure - Merger (Details)", "shortName": "Merger (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-75", "name": "lsta:AssetAcquisitionSharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } }, "R41": { "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails", "longName": "9954487 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)", "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } }, "R42": { "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails", "longName": "9954488 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)", "shortName": "Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails", "longName": "9954489 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)", "shortName": "Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.caladrius.com/role/PropertyandEquipmentDetails", "longName": "9954490 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails", "longName": "9954491 - Disclosure - Income (Loss) Per Share (Details)", "shortName": "Income (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails", "longName": "9954492 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-108", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails", "longName": "9954493 - Disclosure - Accrued Liabilities (Details)", "shortName": "Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails", "longName": "9954494 - Disclosure - Operating Leases - Narrative (Details)", "shortName": "Operating Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails", "longName": "9954495 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)", "shortName": "Operating Leases - Balance Sheet Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails", "longName": "9954496 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)", "shortName": "Operating Leases - Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails", "longName": "9954497 - Disclosure - Stockholders' Equity - Equity Issuances (Details)", "shortName": "Stockholders' Equity - Equity Issuances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-114", "name": "lsta:OutstandingStockThreshold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-114", "name": "lsta:OutstandingStockThreshold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails", "longName": "9954498 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details)", "shortName": "Stockholders' Equity - Stock Options and Warrants Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-119", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-119", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails", "longName": "9954499 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)", "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } }, "R54": { "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "longName": "9954500 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)", "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-121", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-121", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails", "longName": "9954501 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)", "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "longName": "9954502 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)", "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-135", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-135", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "longName": "9954503 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)", "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-119", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-119", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.caladrius.com/role/IncomeTaxesDetails", "longName": "9954504 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "longName": "9954505 - Disclosure - Australia Research and Development Tax Incentive (Details)", "shortName": "Australia Research and Development Tax Incentive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "lsta:IncomeTaxIncentiveReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "lsta:IncomeTaxIncentiveReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.caladrius.com/role/TechnologyTransferAgreementDetails", "longName": "9954506 - Disclosure - Technology Transfer Agreement (Details)", "shortName": "Technology Transfer Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-158", "name": "us-gaap:InvestmentOwnedBalanceShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "lsta:InvestmentOwnedCanceledShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } }, "R61": { "role": "http://www.caladrius.com/role/LicenseAgreementsDetails", "longName": "9954507 - Disclosure - License Agreements (Details)", "shortName": "License Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-158", "name": "us-gaap:InvestmentOwnedBalanceShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "us-gaap:InvestmentOwnedBalanceShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } }, "R62": { "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "longName": "9954508 - Disclosure - Research Collaboration and License Agreement (Details)", "shortName": "Research Collaboration and License Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "span", "div", "us-gaap:CollaborativeArrangementAccountingPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-174", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20230930.htm", "unique": true } } }, "tag": { "us-gaap_PropertyPlantAndEquipmentImpairment": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentImpairment", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived Assets", "label": "Property, Plant and Equipment, Impairment [Policy Text Block]", "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment." } } }, "auth_ref": [ "r52" ] }, "us-gaap_BondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BondsMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agency bonds", "label": "Bonds [Member]", "documentation": "Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon)." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTextBlock", "presentation": [ "http://www.caladrius.com/role/Merger" ], "lang": { "en-us": { "role": { "terseLabel": "Merger", "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r747" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.caladrius.com/role/PropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r476", "r487", "r681" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r252", "r253", "r254" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r696" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": { "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r710", "r766" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r35", "r145", "r651" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r132", "r135", "r485" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r696" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r712" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r696" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of fixed assets", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r14" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r696" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term for operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r429", "r680" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r698" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r317", "r324", "r355", "r356", "r357", "r441", "r465", "r502", "r522", "r523", "r580", "r599", "r603", "r604", "r632", "r646", "r647", "r660", "r664", "r675", "r683", "r686", "r733", "r739", "r760", "r761", "r762", "r763", "r764" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r699" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r324", "r465", "r502", "r522", "r523", "r580", "r599", "r603", "r604", "r632", "r646", "r647", "r660", "r664", "r675", "r683", "r739", "r759", "r760", "r761", "r762", "r763", "r764" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r317", "r324", "r355", "r356", "r357", "r441", "r465", "r502", "r522", "r523", "r580", "r599", "r603", "r604", "r632", "r646", "r647", "r660", "r664", "r675", "r683", "r686", "r733", "r739", "r760", "r761", "r762", "r763", "r764" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r324", "r465", "r502", "r522", "r523", "r580", "r599", "r603", "r604", "r632", "r646", "r647", "r660", "r664", "r675", "r683", "r739", "r759", "r760", "r761", "r762", "r763", "r764" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r177", "r178", "r284", "r290", "r433", "r652", "r654" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r34", "r160", "r162", "r167", "r473", "r493" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term", "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest", "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r114" ] }, "lsta_WeightedAverageExercisePriceWarrantsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageExercisePriceWarrantsExercised", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Exercised (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Exercised", "documentation": "Weighted Average Exercise Price, Warrants Exercised" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r155", "r156", "r157" ] }, "lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "RevenuePerformanceObligationPercentageOfSublicensingRevenues", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of sublicensing revenues", "label": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues", "documentation": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r97" ] }, "lsta_WeightedAverageRemainingContractualTermwarrantoutstanding": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term", "label": "Weighted Average Remaining Contractual Term warrant outstanding", "documentation": "Weighted Average Remaining Contractual Term warrant outstanding" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "lsta_SharesIssuedUnderLicenseAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "SharesIssuedUnderLicenseAgreement", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under license agreement (in shares)", "label": "Shares Issued Under License Agreement", "documentation": "Shares Issued Under License Agreement" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less than one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Lisata Therapeutics, Inc. stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r82", "r85", "r86", "r102", "r534", "r550", "r572", "r573", "r681", "r694", "r717", "r730", "r753", "r772" ] }, "lsta_InvestmentOwnedCanceledShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "InvestmentOwnedCanceledShares", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares canceled (in shares)", "label": "Investment Owned, Canceled, Shares", "documentation": "Investment Owned, Canceled, Shares" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option and Warrants Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r16", "r17", "r63" ] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-Sale-Securities", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r721" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from option exercises", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r18" ] }, "lsta_CommonStockWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CommonStockWarrantsShares", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)", "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)", "label": "Common Stock Warrants, Shares", "documentation": "Common Stock Warrants, Shares" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r72", "r655" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r92" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative translation adjustment arising during the period", "verboseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r45", "r47" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r14", "r20", "r159", "r162", "r166", "r416", "r417", "r422", "r472", "r491", "r713", "r714" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit from income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r124", "r137", "r190", "r191", "r209", "r374", "r383", "r495" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "lsta_SharesHeldByThirdParty": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "SharesHeldByThirdParty", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares held by third party (in shares)", "label": "Shares Held by Third Party", "documentation": "Shares Held by Third Party" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r40" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r285", "r318", "r319", "r320", "r321", "r322", "r323", "r408", "r438", "r439", "r440", "r662", "r663", "r672", "r673", "r674" ] }, "lsta_QiluMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "QiluMember", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qilu", "label": "Qilu [Member]", "documentation": "Qilu" } } }, "auth_ref": [] }, "lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest", "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "lsta_AssetAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AssetAcquisitionSharePrice", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Multiplied by the fair value per share of Lisata common stock on September 15, 2022", "label": "Asset Acquisition, Share Price", "documentation": "Asset Acquisition, Share Price" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r21" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r40", "r41" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r143", "r154", "r175", "r255", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r389", "r393", "r413", "r681", "r737", "r738", "r757" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New York", "label": "New York State Division of Taxation and Finance [Member]", "documentation": "Designated tax department of the government of the state of New York." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with customer, liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r304", "r305", "r316" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired license - intangible", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r103", "r470" ] }, "lsta_InProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "InProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "In-Process Research and Development", "documentation": "In-Process Research and Development" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r407", "r408", "r409", "r410", "r412" ] }, "lsta_ResearchAndDevelopmentTaxIncentiveTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "ResearchAndDevelopmentTaxIncentiveTextBlock", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" ], "lang": { "en-us": { "role": { "terseLabel": "Australia Research and Development Tax Incentive", "label": "Research and Development Tax Incentive [Text Block]", "documentation": "Research and Development Tax Incentive" } } }, "auth_ref": [] }, "lsta_WeightedAverageRemainingContractualTermwarrantsvested": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageRemainingContractualTermwarrantsvested", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term", "label": "weighted Average Remaining Contractual Term, warrants vested", "documentation": "weighted Average Remaining Contractual Term, warrants vested" } } }, "auth_ref": [] }, "us-gaap_NewJerseyDivisionOfTaxationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewJerseyDivisionOfTaxationMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Jersey", "label": "New Jersey Division of Taxation [Member]", "documentation": "Designated tax department of the government of the state of New Jersey." } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxHolidayTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxHolidayTable", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Holiday [Table]", "label": "Income Tax Holiday [Table]", "documentation": "Income tax-exemptions and reductions which may be granted by a taxing authority for a specified period. Such \"tax holidays\" are typically granted to induce business investment in the tax jurisdiction." } } }, "auth_ref": [ "r115" ] }, "lsta_EPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "EPSAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted loss per share", "label": "EPS [Abstract]", "documentation": "EPS" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Lisata Therapeutics, Inc. common stockholders", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r90", "r100", "r122", "r142", "r158", "r161", "r165", "r175", "r182", "r184", "r185", "r186", "r187", "r190", "r191", "r196", "r206", "r211", "r215", "r217", "r255", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r405", "r413", "r490", "r553", "r569", "r570", "r659", "r692", "r737" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options, Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r351" ] }, "lsta_OptionsVestedweightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "OptionsVestedweightedAverageRemainingContractualTerm", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term", "label": "Options, Vested, weighted Average Remaining Contractual Term", "documentation": "Options, Vested, weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "lsta_RevenuePerformanceObligationPercentageOfNetSale": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "RevenuePerformanceObligationPercentageOfNetSale", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of net sale", "label": "Revenue, Performance Obligation, Percentage of Net Sale", "documentation": "Revenue, Performance Obligation, Percentage of Net Sale" } } }, "auth_ref": [] }, "lsta_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WarrantsExercised", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Warrants, Exercised (in shares)", "label": "Warrants Exercised", "documentation": "Warrants Exercised" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails", "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r222", "r263", "r477" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r168", "r184", "r185", "r186", "r187", "r188", "r195", "r197", "r198", "r199", "r203", "r404", "r405", "r474", "r494", "r657" ] }, "us-gaap_IncomeTaxHolidayLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxHolidayLineItems", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Holiday [Line Items]", "label": "Income Tax Holiday [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r176", "r372", "r376", "r378", "r379", "r382", "r384", "r385", "r386", "r515" ] }, "lsta_WeightedAverageExercisePriceWarrantsExpired": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageExercisePriceWarrantsExpired", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Expired (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Expired", "documentation": "Weighted Average Exercise Price, Warrants Expired" } } }, "auth_ref": [] }, "lsta_OperatingLossCarryforwardsPostAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "OperatingLossCarryforwardsPostAcquisition", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards, post acquisition", "label": "Operating Loss Carryforwards, Post Acquisition", "documentation": "Operating Loss Carryforwards, Post Acquisition" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r351" ] }, "lsta_AssetAcquisitionCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AssetAcquisitionCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Asset Acquisition, Cash and Cash Equivalents", "documentation": "Asset Acquisition, Cash and Cash Equivalents" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities Reconciliation", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "lsta_AssetAcquisitionOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AssetAcquisitionOtherLiabilities", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other liabilities", "label": "Asset Acquisition, Other Liabilities", "documentation": "Asset Acquisition, Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "In process research and development expenses", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r100", "r552", "r692", "r754", "r755", "r771" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized to be repurchased (in shares)", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan." } } }, "auth_ref": [] }, "lsta_UniversityOfCaliforniaAtSanDiegoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "UniversityOfCaliforniaAtSanDiegoMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "University of California at San Diego", "label": "University of California at San Diego [Member]", "documentation": "University of California at San Diego" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "lsta_TechnologyTransferAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "TechnologyTransferAgreementTextBlock", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Technology Transfer Agreement", "label": "Technology Transfer Agreement [Text Block]", "documentation": "Technology Transfer Agreement" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual license maintenance fee, year four", "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four", "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less than one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "lsta_SaleOfStockAvailableForSalePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "SaleOfStockAvailableForSalePercentage", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage held by non-affiliates", "label": "Sale of Stock Available for Sale, Percentage", "documentation": "Sale of Stock Available for Sale, Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r351" ] }, "lsta_SaleOfStockAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "SaleOfStockAvailableForSale", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock available for sale", "label": "Sale of Stock Available for Sale", "documentation": "Sale of Stock Available for Sale" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Greater than one year", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r725" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r169" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "ResearchCollaborationAndLicenseAgreementOptionToTerminate", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to terminate", "label": "Research Collaboration and License Agreement, Option to Terminate", "documentation": "Research Collaboration and License Agreement, Option to Terminate" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/PropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r106", "r146", "r487" ] }, "lsta_AssetAcquisitionNetWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AssetAcquisitionNetWorkingCapital", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net working capital (excluding cash)", "label": "Asset Acquisition, Net Working Capital", "documentation": "Asset Acquisition, Net Working Capital" } } }, "auth_ref": [] }, "lsta_TechnologyTransferAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "TechnologyTransferAgreementAbstract", "lang": { "en-us": { "role": { "label": "Technology Transfer Agreement [Abstract]", "documentation": "Technology Transfer Agreement" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Greater than one year", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value", "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r725" ] }, "lsta_AssetAcquisitionConsiderationTransferredEquityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AssetAcquisitionConsiderationTransferredEquityValue", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Asset Acquisition, Consideration Transferred, Equity Value", "documentation": "Asset Acquisition, Consideration Transferred, Equity Value" } } }, "auth_ref": [] }, "lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet", "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]", "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]" } } }, "auth_ref": [] }, "lsta_CaladriusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CaladriusMember", "presentation": [ "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Caladrius", "label": "Caladrius [Member]", "documentation": "Caladrius" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/Contingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r107", "r269", "r270", "r645", "r734" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageExercisePriceWarrantsOutstanding", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)", "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Outstanding", "documentation": "Weighted Average Exercise Price, Warrants Outstanding" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r696" ] }, "lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with Merger (in shares)", "label": "Stock Issued During Period, Shares, New Issues Related to Merger", "documentation": "Stock Issued During Period, Shares, New Issues Related to Merger" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r406", "r412" ] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r650", "r731", "r732" ] }, "lsta_OperatingLossCarryforwardsBeforeWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "OperatingLossCarryforwardsBeforeWriteDown", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards, prior to write down", "label": "Operating Loss Carryforwards, Before Write Down", "documentation": "Operating Loss Carryforwards, Before Write Down" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails", "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "lsta_AtTheMarketOfferingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AtTheMarketOfferingAgreementMember", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Agreement", "label": "At The Market Offering Agreement [Member]", "documentation": "At The Market Offering Agreement" } } }, "auth_ref": [] }, "lsta_AggregateIntrinsicValueWarrantsvested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AggregateIntrinsicValueWarrantsvested", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value, Warrants vested", "documentation": "Aggregate Intrinsic Value, Warrants vested" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails", "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "lsta_AggregateIntrinsicValueWarrantsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AggregateIntrinsicValueWarrantsOutstanding", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value, Warrants Outstanding", "documentation": "Aggregate Intrinsic Value, Warrants Outstanding" } } }, "auth_ref": [] }, "lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable consideration amounts, milestones", "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount", "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount" } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest", "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/FairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities - available for sale", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r407" ] }, "lsta_WeightedAverageExercisePriceWarrantsExercisable": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageExercisePriceWarrantsExercisable", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Exercisable", "documentation": "Weighted Average Exercise Price, Warrants Exercisable" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit rate", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r745", "r746" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r46", "r49" ] }, "lsta_OperatingLeaseRightOfUseAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "OperatingLeaseRightOfUseAssetAbstract", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Assets:", "label": "Operating Lease, Right-Of-Use Asset [Abstract]", "documentation": "Operating Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "lsta_WarrantsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WarrantsGranted", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Granted (in shares)", "label": "Warrants Granted", "documentation": "Warrants Granted" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r696" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r84", "r112", "r482", "r506", "r508", "r514", "r533", "r681" ] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Table]", "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Options, Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r341" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options, Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r340" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Amounts representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r431" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r743" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average estimated fair value of shares granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r348" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r373", "r377" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)", "periodEndLabel": "Options, Outstanding, End of Period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r334", "r335" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails", "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating lease liabilities", "verboseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)", "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r334", "r335" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r742" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r226" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Domain]", "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r82" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/LicenseAgreements", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreements", "verboseLabel": "Research Collaboration and License Agreement", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r126", "r128", "r139" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r696" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails", "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities \u2014 current", "verboseLabel": "Operating lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r426" ] }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementAccountingPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Milestones, Royalties", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for collaborative arrangements." } } }, "auth_ref": [ "r130" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r225" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r286", "r300", "r401", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r492", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r726", "r727", "r728", "r729" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Axis]", "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r12" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r108", "r688", "r689", "r690", "r691" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,140,187 and 7,866,799 shares at September 30, 2023 and December 31, 2022, respectively; and outstanding, 8,139,449 and 7,866,061 shares at September 30, 2023 and December 31, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r82", "r480", "r681" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r252", "r253", "r254" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r355", "r356", "r357", "r358" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r359", "r371" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r326", "r328", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r355", "r356", "r357", "r358" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r82", "r532" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.caladrius.com/role/MergerDetails", "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock outstanding (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "periodEndLabel": "Common stock, ending balance (in shares)", "terseLabel": "Number of common shares of the combined company owned by Cend stockholders (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r82", "r532", "r550", "r772", "r773" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r326", "r328", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r355", "r356", "r357", "r358" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r426" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average estimated fair value (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r345" ] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTableTextBlock", "presentation": [ "http://www.caladrius.com/role/MergerTables" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition", "label": "Asset Acquisition [Table Text Block]", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": [ "r747" ] }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CaliforniaFranchiseTaxBoardMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California", "label": "California Franchise Tax Board [Member]", "documentation": "Designated tax department of the government of the state of California." } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r362" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r31", "r119", "r175", "r255", "r275", "r277", "r278", "r279", "r282", "r283", "r413", "r483", "r534" ] }, "us-gaap_AustralianTaxationOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AustralianTaxationOfficeMember", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Australian Taxation Office", "label": "Australian Taxation Office [Member]", "documentation": "Designated tax department of the government of Australia." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r138", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r648" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r268", "r556" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r423", "r434" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, non-controlling interests and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r87", "r120", "r484", "r681", "r717", "r730", "r753" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r40" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r148" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r286", "r300", "r401", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r492", "r661", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r726", "r727", "r728", "r729" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r285", "r318", "r319", "r320", "r321", "r322", "r323", "r438", "r439", "r440", "r662", "r663", "r672", "r673", "r674" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, increase resulting from acquisition", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Minimum Lease Payments", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities [Abstract]", "label": "Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/FairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/AccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22", "r681" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset, useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "lsta_CENDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CENDMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails", "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/MergerDetails", "http://www.caladrius.com/role/MergerNarrativeDetails", "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails", "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEND", "label": "CEND [Member]", "documentation": "CEND" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails", "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering amount authorized per agreement", "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement", "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r179", "r180", "r181", "r204", "r469", "r509", "r519", "r524", "r525", "r526", "r527", "r528", "r529", "r532", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r545", "r546", "r547", "r548", "r549", "r551", "r554", "r555", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r687" ] }, "lsta_ImpiloMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "ImpiloMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impilo", "label": "Impilo [Member]", "documentation": "Impilo" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r315", "r665", "r666", "r667", "r668", "r669", "r670", "r671" ] }, "lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsSublicensingFees", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublicensing fee", "label": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees", "documentation": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees" } } }, "auth_ref": [] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization/accretion on marketable securities", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r100" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "lsta_IncomeTaxIncentiveReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "IncomeTaxIncentiveReceivable", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax incentive receivable", "label": "Income Tax Incentive Receivable", "documentation": "Income Tax Incentive Receivable" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r40" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r315", "r665", "r666", "r667", "r668", "r669", "r670", "r671" ] }, "lsta_WarrantsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WarrantsExpired", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Warrants, Expired (in shares)", "label": "Warrants Expired", "documentation": "Warrants Expired" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Risks", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r79", "r131" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "lsta_WarrantsOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WarrantsOtherDisclosuresAbstract", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value", "label": "Warrants Other Disclosures [Abstract]", "documentation": "Warrants Other Disclosures" } } }, "auth_ref": [] }, "lsta_WarrantsVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WarrantsVested", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested (in shares)", "label": "Warrants, Vested", "documentation": "Warrants, Vested" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r200" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r723" ] }, "lsta_WarrantsCanceled": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WarrantsCanceled", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrants, Forfeited (in shares)", "label": "Warrants Canceled", "documentation": "Warrants Canceled" } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "In-process Research and Development Expense", "label": "In Process Research and Development, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r60" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTable", "presentation": [ "http://www.caladrius.com/role/MergerDetails", "http://www.caladrius.com/role/MergerNarrativeDetails", "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Table]", "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r747" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, employee benefits and related taxes", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r60" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.caladrius.com/role/MergerDetails", "http://www.caladrius.com/role/MergerNarrativeDetails", "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails", "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r747" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of noncash investing activities:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityAbstract", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Liabilities:", "label": "Operating Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.caladrius.com/role/MergerDetails", "http://www.caladrius.com/role/MergerNarrativeDetails", "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails", "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r747" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r142", "r158", "r161", "r170", "r175", "r182", "r190", "r191", "r206", "r211", "r215", "r217", "r255", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r388", "r391", "r392", "r405", "r413", "r475", "r489", "r517", "r553", "r569", "r570", "r659", "r678", "r679", "r693", "r715", "r737" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r425" ] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r8" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r140", "r163", "r164", "r165", "r179", "r180", "r181", "r183", "r189", "r191", "r204", "r256", "r257", "r303", "r364", "r365", "r366", "r380", "r381", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r416", "r418", "r419", "r420", "r421", "r422", "r432", "r503", "r504", "r505", "r518", "r571" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost; 738 shares at September 30, 2023 and December 31, 2022", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r30", "r60", "r61" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r13", "r33", "r396", "r399", "r432", "r503", "r504", "r713", "r714", "r715", "r718", "r719", "r720" ] }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax refunds", "label": "Proceeds from Income Tax Refunds", "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r36", "r99" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r676" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r362" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lisata transaction costs", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r677", "r748", "r749", "r750" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://www.caladrius.com/role/MergerDetails", "http://www.caladrius.com/role/MergerNarrativeDetails", "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Line Items]", "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r747" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental fair value of Cend's fully vested stock options", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r748", "r749", "r750" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r415" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r98" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/MergerDetails", "http://www.caladrius.com/role/MergerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r677", "r748", "r749", "r750" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r35", "r98", "r172" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue excluding taxes", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r207", "r208", "r210", "r213", "r214", "r218", "r219", "r220", "r314", "r315", "r469" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Costs", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination." } } }, "auth_ref": [ "r1", "r2", "r80" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r355", "r356", "r357", "r358" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r325", "r329", "r360", "r361", "r363", "r676" ] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Abstract]", "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails", "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated Fair Value", "totalLabel": "Total estimated fair value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r223", "r263", "r471", "r722" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r32", "r33", "r88", "r153", "r481", "r507", "r508" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r171" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r218", "r469", "r496", "r497", "r498", "r499", "r500", "r501", "r649", "r665", "r682", "r702", "r735", "r736", "r740", "r767" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r171" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r98", "r99", "r100" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/PropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r51", "r147", "r486" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r744" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r218", "r469", "r496", "r497", "r498", "r499", "r500", "r501", "r649", "r665", "r682", "r702", "r735", "r736", "r740", "r767" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInAndAdvancesToAffiliatesLineItems", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in and Advances to Affiliates [Line Items]", "label": "Investments in and Advances to Affiliates [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r387" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r267", "r268", "r556" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current, balance sheet line item", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r427" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r81", "r288" ] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalanceShares", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment owned (in shares)", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r520", "r521", "r584", "r610", "r635", "r686" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets, balance sheet line item", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r427" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r70", "r71", "r73", "r140", "r141", "r164", "r179", "r180", "r181", "r183", "r189", "r256", "r257", "r303", "r364", "r365", "r366", "r380", "r381", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r416", "r418", "r422", "r432", "r504", "r505", "r516", "r534", "r550", "r572", "r573", "r643", "r693", "r717", "r730", "r753", "r772" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, noncurrent, balance sheet line item", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r427" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r423", "r434" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r82" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r42", "r43", "r44", "r127", "r129", "r133", "r134" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r428" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r684", "r685", "r686", "r688", "r689", "r690", "r691", "r718", "r719", "r752", "r769", "r772" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income, net", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r93", "r95" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r695" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r325", "r333", "r352", "r353", "r354", "r355", "r358", "r367", "r368", "r369", "r370" ] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryBillSecuritiesMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury bills", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r765" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r78" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r105", "r132", "r135", "r136" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r697" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Share-based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r65" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r74", "r117" ] }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement." } } }, "auth_ref": [ "r751" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue from collaborative arrangement", "terseLabel": "Revenue from contract", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r125", "r751" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r106" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r672", "r674", "r768" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "lsta_LossOnSaleOfNOL": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "LossOnSaleOfNOL", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on sale of NOL", "label": "Loss On Sale of NOL", "documentation": "Loss On Sale of NOL" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USStatesAndPoliticalSubdivisionsMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Municipal debt securities", "label": "US States and Political Subdivisions Debt Securities [Member]", "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments." } } }, "auth_ref": [ "r672", "r768" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r15", "r75" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r69" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r109", "r174", "r287", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r303", "r402", "r574", "r576", "r644" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r118", "r149", "r175", "r206", "r212", "r216", "r255", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r389", "r393", "r413", "r478", "r544", "r681", "r694", "r737", "r738", "r757" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r50" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r206", "r211", "r215", "r217", "r659" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyMember", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r741" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails", "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value, outstanding", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r82", "r532" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r423", "r434" ] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r11", "r62" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from option exercises (in shares)", "negatedTerseLabel": "Options, Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r81", "r82", "r112", "r339" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Non- Controlling Interest in Subsidiary", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r70", "r303", "r718", "r719", "r720", "r772" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r700" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year one", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r104" ] }, "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental fair value of Cend's fully vested stock options assumed", "label": "Liabilities Assumed", "documentation": "The fair value of liabilities assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r37", "r38", "r39" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r91" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": { "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails", "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r77", "r711" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Total Lisata Therapeutics, Inc. Stockholders' Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r104" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r104" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year four", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r104" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate for operating leases (percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r430", "r680" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards subject to expiration", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r375" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, remainder of fiscal year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r101", "r173" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r194", "r199" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with merger", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r37", "r38", "r39" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r168", "r184", "r185", "r186", "r187", "r188", "r193", "r195", "r197", "r198", "r199", "r203", "r404", "r405", "r474", "r494", "r657" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r193", "r199" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r431" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r50" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r144", "r175", "r255", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r390", "r393", "r394", "r413", "r681", "r737", "r757", "r758" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r684", "r685", "r688", "r689", "r690", "r691" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r53", "r54", "r55", "r56", "r57", "r58", "r59", "r110", "r111", "r112", "r150", "r151", "r152", "r205", "r288", "r289", "r290", "r292", "r295", "r300", "r302", "r510", "r511", "r512", "r513", "r664", "r701", "r716" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r151", "r152", "r205", "r288", "r289", "r290", "r292", "r295", "r300", "r302", "r510", "r511", "r512", "r513", "r664", "r701", "r716" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r48", "r466", "r467", "r468", "r470", "r656" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r177", "r178", "r284", "r290", "r433", "r653", "r654" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r89", "r121", "r206", "r211", "r215", "r217", "r475", "r488", "r659" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r68" ] }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "presentation": [ "http://www.caladrius.com/role/TheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership after transaction", "label": "Sale of Stock, Percentage of Ownership after Transaction", "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r756" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r285", "r318", "r323", "r408", "r439", "r662", "r663", "r672", "r673", "r674" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r387" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r756" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r24", "r175", "r255", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r390", "r393", "r394", "r413", "r530", "r658", "r694", "r737", "r757", "r758" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r285", "r318", "r323", "r408", "r438", "r672", "r673", "r674" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r387" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Investments Classified by Contractual Maturity Date", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r712" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock, Name of Transaction [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r387" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r40" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r285", "r318", "r319", "r320", "r321", "r322", "r323", "r408", "r440", "r662", "r663", "r672", "r673", "r674" ] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r10", "r575" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r192", "r200", "r201", "r202" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r113" ] }, "lsta_MassachusettsInstituteOfTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "MassachusettsInstituteOfTechnologyMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Massachusetts Institute of Technology", "label": "Massachusetts Institute of Technology [Member]", "documentation": "Massachusetts Institute of Technology" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Available for sale securities - net unrealized gain", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r155", "r157", "r251" ] }, "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual license maintenance fee, year seven", "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven", "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r96" ] }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Less - net income attributable to noncontrolling interests", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest." } } }, "auth_ref": [ "r70", "r116" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r364", "r365", "r366", "r518", "r718", "r719", "r720", "r752", "r772" ] }, "lsta_BusinessTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "BusinessTextBlock", "presentation": [ "http://www.caladrius.com/role/TheBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "The Business", "label": "The Business [Text Block]", "documentation": "The Business [Text Block]" } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails", "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "lsta_FairValueMarketOfTaxNOLs": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "FairValueMarketOfTaxNOLs", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value market of tax NOLs", "label": "Fair Value Market of Tax NOLs", "documentation": "Fair Value Market of Tax NOLs" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentTables", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 14)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r28", "r76", "r479", "r531" ] }, "lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued liabilities and other liabilities", "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities", "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "NetCarryforwardOperatingLossCarryforwardAnnualLimitation", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NOL annual limitation", "label": "Net Carryforward Operating Loss Carryforward Annual Limitation", "documentation": "Net Carryforward Operating Loss Carryforward Annual Limitation" } } }, "auth_ref": [] }, "lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AssetAcquisitionAcquiredInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development", "label": "Asset Acquisition, Acquired In-Process Research And Development", "documentation": "Asset Acquisition, Acquired In-Process Research And Development" } } }, "auth_ref": [] }, "lsta_ProceedsFromSaleOfNOLS": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "ProceedsFromSaleOfNOLS", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of NOLs", "label": "Proceeds From Sale of NOLS", "documentation": "Proceeds From Sale of NOLS" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r94" ] }, "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual license maintenance fee", "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee", "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuances of common stock", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r81", "r82", "r112", "r518", "r571", "r642", "r693" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.caladrius.com/role/OperatingLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r424" ] }, "lsta_OutstandingStockThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "OutstandingStockThreshold", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding stock threshold", "label": "Outstanding Stock Threshold", "documentation": "Outstanding Stock Threshold" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r338" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of shares vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r349" ] }, "lsta_WarrantsWeightedAverageExercisePriceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WarrantsWeightedAverageExercisePriceRollForward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Weighted Average Exercise Price", "label": "Warrants Weighted Average Exercise Price [Roll Forward]", "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]" } } }, "auth_ref": [] }, "lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential milestone payments", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product", "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of shares issued", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r14", "r81", "r82", "r112" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r339" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r341" ] }, "lsta_SanfordBurnhamPrebysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "SanfordBurnhamPrebysMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanford Burnham Prebys", "label": "Sanford Burnham Prebys [Member]", "documentation": "Sanford Burnham Prebys" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r340" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/FairValueMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets, fair value disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r74" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r14", "r29", "r112" ] }, "lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsChangeOfControlFee", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change of control fee", "label": "Collaborative Arrangement, Rights and Obligations, Change of Control Fee", "documentation": "Collaborative Arrangement, Rights and Obligations, Change of Control Fee" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r179", "r180", "r181", "r204", "r469", "r509", "r519", "r524", "r525", "r526", "r527", "r528", "r529", "r532", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r545", "r546", "r547", "r548", "r549", "r551", "r554", "r555", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r687" ] }, "lsta_Sharesvestedandexpectedtovest": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "Sharesvestedandexpectedtovest", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested and expected to vest (in shares)", "label": "shares, vested and expected to vest", "documentation": "shares, vested and expected to vest" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r406" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuances of common stock (in shares)", "terseLabel": "Stock issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r81", "r82", "r112", "r510", "r571", "r642" ] }, "lsta_ExclusiveLicenseAndCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "ExclusiveLicenseAndCollaborationAgreementMember", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exclusive License and Collaboration Agreement", "label": "Exclusive License and Collaboration Agreement [Member]", "documentation": "Exclusive License and Collaboration Agreement" } } }, "auth_ref": [] }, "lsta_AccruedGrantFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AccruedGrantFunding", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting & tax consulting liabilities", "label": "Accrued Grant Funding", "documentation": "Accrued Grant Funding" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Remeasurement", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r414" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r14", "r81", "r82", "r112" ] }, "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual license maintenance fee, after first sale", "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale", "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of Lisata's cost method investment in Cend", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r123", "r748", "r749", "r750" ] }, "lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "StockIssuedDuringPeriodValueNewIssuesRelatedToMerger", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with Merger", "label": "Stock Issued During Period, Value, New Issues Related to Merger", "documentation": "Stock Issued During Period, Value, New Issues Related to Merger" } } }, "auth_ref": [] }, "lsta_ClinicalAndRDRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "ClinicalAndRDRelatedLiabilities", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical and R&D related liabilities", "label": "Clinical and R&D Related Liabilities", "documentation": "Clinical and R&D Related Liabilities" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Authority", "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r407", "r408", "r411" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r29", "r140", "r163", "r164", "r165", "r179", "r180", "r181", "r183", "r189", "r191", "r204", "r256", "r257", "r303", "r364", "r365", "r366", "r380", "r381", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r416", "r418", "r419", "r420", "r421", "r422", "r432", "r503", "r504", "r505", "r518", "r571" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r66", "r67", "r327" ] }, "lsta_WeightedAverageExercisePriceWarrantsCanceled": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageExercisePriceWarrantsCanceled", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Forfeited (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Canceled", "documentation": "Weighted Average Exercise Price, Warrants Canceled" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Units Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r64" ] }, "lsta_PaymentsForAssetAcquisitionCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "PaymentsForAssetAcquisitionCostsNet", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Asset acquisition costs, net of cash acquired related to merger with Cend", "label": "Payments for Asset Acquisition Costs, Net", "documentation": "Payments for Asset Acquisition Costs, Net" } } }, "auth_ref": [] }, "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual license maintenance fee, years two and three", "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three", "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r19" ] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseMember", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r741" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r106" ] }, "lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties, net of sales", "label": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales", "documentation": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r14", "r112" ] }, "lsta_WeightedAverageExercisePriceWarrantsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "WeightedAverageExercisePriceWarrantsGranted", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Granted (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Granted", "documentation": "Weighted Average Exercise Price, Warrants Granted" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r140", "r179", "r180", "r181", "r183", "r189", "r191", "r256", "r257", "r364", "r365", "r366", "r380", "r381", "r395", "r397", "r398", "r400", "r403", "r503", "r505", "r518", "r772" ] }, "lsta_AssetAcquisitionIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20230930", "localname": "AssetAcquisitionIntangibles", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/MergerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License", "label": "Asset Acquisition, Intangibles", "documentation": "Asset Acquisition, Intangibles" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r83", "r681", "r770" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "SubTopic": "50", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "SubTopic": "40", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r701": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 81 0000320017-23-000063-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000320017-23-000063-xbrl.zip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�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�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

S%?UP1_ M!7QA*"QC&3(90U !$T13JS:2C467.A_DH6Z0*TQ__;CX\C,]>FL'Z).KY7_/ M"T>^3-]LGSA6EB/#8$OU^1+()=N@?*UTK\T"DR#^!5=0=$0=:8$4?1P&KK]M M'"-PM+H6#60WNG6_""W/S9;('IW) 5*=M*B2MQ =DZ0[E:0M):$,^YGXFP\> M3\6'JV;12$X=NGVOIW-\1<'4:A)25M(;#]K5)GO>(7@4!0PS]4:-48:W[GBX MDYB1^U<,'C <)O4.X'.WQ.^WQ1JW!26?9]/U\WJ0OUS5;&55%Y\$P:S)DH$1 MPM1UEL$G8Z"@I36GC5?-1SL_EL:^/,\#H?'=(34-]=0##C?52Z]6JS/,D\0Q M&D:!F"CD5ZL<"T2K-? HM62Q1.&;=RR[]OZ^O-9&^#E4OCU@HZ+\'7X^6Z9/ M885OEXN/RW#ZVUG=KL\/-E8G9^M/BV4]R?ZP>(97OTS,"H56HP A*.Y3.D@( M4E&0KT(H5DG!4NL);4<1W-=6V=!Z/8D&>X!KV)RW59;?XK*.0 P?Z1MO_IC3 M*SY-/Y\4>M>U.>F3I)D6V2($97.=/6' ^QC .9V1.9)O:CVCX;$TCCRZ?AA0 M#JFG;D\_]^M)?U^'KR,.2X]_Z5,VY-^;^>&[]*=D:WL[!UAJC)(CIV!4>,# MDF4L"-U\N.UP7?JOBA%V]]':1&8Y:PJ[=0&I?*&%5OL[Q^S!VI@LH@K"-M^R M]Z1M],OG+9"RNTJDH6(ZV(EW/%I, M1O*44Q:M;=L>9'7:M/%0*.S=MO$PO70 M9=GR_ET?;9$8N?E]&O]["*![>O\ M,!$CI%0[X@H;(!A$*"HG"OBCXJEU3=9N:CH%UJ&*O]UPJHT6.L#3Q:3A2PF= MLZ$IPC&Z%"@&#;$1#$3/#*"P1I*GP8)K?8BP@Y1QLW)#(ZF%_#N"T<7 ZEO# M7R\J*$16-I4$14L2%"/VG(D."O/9.N>5MJTO5NQ%V+BIMZ>"6#O== "XG4*[ MRA$QYAV3N MN_TM++?3AP=/V-YYTU-F:1]F<_C4;"B9JVP3>/2VGDK5JPK< _>%3"1G%*\V MGP,X6&KVEB^P^@W7V^;?]*Z_+1;YC^EL-HE<"IU-+9FM\U9D[3(>R#5 9XHS M'#5CK5-E^]#5;4KV,0BY.Q.GL4(ZV#Y?3BE8QM>T9/,M]JX9:O(W4!AR/:5F M=8*U51#H:Y"V9%&\LK[YK(!]Z!JY)F08D#572 <@.SE=+-?GM\_>E-O+:**= MV+1_?FP^6FT_)#I?+LZ6$U^T#5E*8LL+4()8]85B/!5) MWIXES3H 9Z5T+VRZ/STV'ZVT#J#Y#K_@_ RWLP2WDYW_/EU_>GZV6B].<7F9 MW:J,T__G#^'KA+N((CH+S,=:1,$9A% T)"Y<#((ARZW;G1Q YEZ@]#\8*(=6 M5V^(G-$O++8'"M=: UZR^1UQ3*Q5RC!M(".KUX\+L9[K8N2>?N Q*3XH4H\C M?[\4.ON1(?R$^CT8VE]P&1?MFJ&&CQ^7^/&RU>N&P>VQOL'B=#W,9Y&15!TY MWH&K!%;622[<\!1:]^Q_B)[]X/>C'>$TT\"(IG*U7-?C]7R6UF^6YVV%M^TT MG$ T0D,0RH/R3($3(M4/OIY&.;-?CWUZP37TT%=7R-GU[M$;/3?2ZJ*AB/N MR.IDGL\Y6)T7K D=!1E* >?*[%MS!;?SLO-BR."R]U $X1"RC:8\$5I$63&2O<2ZY*ZT+0&P2,CHYC M%7K;XSE8NAU 8X=E?7U9(X;1"LQ9@;&T!2M=,X6!.--1)\YBT.5V!Z.AO);7 M?91Q-M^+!E%%!] Z))@5(E(LBQZRUG5VET;P3-:R1,&C\CQ(U_HH8:CFU&,XK66]?V[Z)EH);B+J'7K.;0(JM[N 3G;:W"QQRT3LXW M/WKOL*5X$_WOV27\$0+O8&>[MZ\Q.7E,B>+(ZM:[ASG4:24I@J$P0W@N;<#6 MLU-_F"[ACU'O/EW"'R/K#O%R'G3$)+ECR8/7N@#Q0Z&"3!I*1,L+EY[\QX$1 MT\-%].,UO%^7\,>(>_0^LE>=K[DTN2C,H%.UMCHG\+88L%P*ZRQ769CON20_ M0I?P1ZEG1Y?PQ\BJ0[MPY<*+D-%Q%2&F6%UX'<'S)$ 5J5)!Z:,M YN&3L+M MX7>4PZ3>(7SJW)!.6L4QG2QC/S2D#P2): 6[*KF15>AIZ(U&MT_"CU[A,=/T;6 M'>+E/!ZP6BGI7 %I/&V.$A$<.@0I="HQ2]HXAYZDT&UT_"@-[Q<=/T;<'47' M5D?CI$L04=0#-T\>&\N:ODS,!ZT2$W^*&5J/4L^.Z/@QLNK0+EPYYX6C#2QH M0 R)HC\*\YU7''0AA]JCM"FVKJ3[H:+CECO*85+O #[/%Z>GB_EV6,>FU_V; MLS4MB'D]O9R@E(%+7X [,ILJ!P8^H8$0,W/&.:%U:P0]1$]?)N= E=_M?-9& M_F/O-K?%L^'F[7*:<.)M,E*5 HPI":I.PO+2D'UF+I>86&3\N^'O=][1EWTY M#AHMQ=D;*G8E>;9S@^J8=YQ$[IG7JH"UM),K[FD3YP*AQ&)#"D'?:;&^)USV M>'FO$TZ:X:BU CK8PMZ&;YOYW!\6&S[K,MD4,-;K%-NF'H8K69PMH#7/=2QJ M!E\=1*TS";8X8TKSQM;?(ZK7L27';&9M-=$!M!ZW>E[-ZM(9PM1)%]GP:A: \E#&;KJX4#21VY7,0A,Q]#J#P3F:W.% MGB]6ZXEP:+70-3<;!8G:*'"ACB(W@6)K*1*/0R$%"Z!2(5BHA0D>$[>KXV1(J*".0V>(C_JE':X[A2CPN]1>NDN*@FK3V38 MZS_5YG\)L^K%3$H6]%]M81Y\O3-> M(/8X7LR](>?@\78?91'O4 3F'%!SQ$(2@Z%P%R#:FF!1Z MN6MIB-,9?8VK"1:9 M&&D?M'<.E,H6@B5Q^-W4EA>, <)=M.\7(>2>=7+"K&:(DBFBRN10A1Q6))U M3P+&;I0P/+J&T$1O^]E5DR<2G%$Y$[40 UE<)32'Z#4#C[;4YF*6J7P0HJZ] M9#_4_,B)^T,EVFTEX\F7,)W5_$=9+.N8SI8;2+[ MO"'DB'K((T/#R-@V757I6H44O$OAL63U@BA T9X B**T5 M:2,VOWOS7:J.OLR/<7WMJ;?>=UXY;VU$C1R0Z6.*U=:%XRVI']+Y>?:^1!O6H+S2DPAT9OD:_C$*'JO8R6=C8F82;F@$'5':5Y^]@!! MXV)O/)S<*5EKI;0N$'AZBLLJI+?A,RXO1ML:XWCU7C!)\F-,G30:0@;-23I" M*:%L>^3=0\BX96T=(>Y8)76 M%\7<_SV:UC^ ]E,:ZFQ*#"I2L-9!RX9 M":Y8;H1%%DKK>\W77C]NG5LWL#I4(1U@Z??W'Y885F?+;\^FL]F=#3\6Y-P$ M!2F;.AXW,(B>E@=:9Y(2T6K1&EX/4S1NR5HWB&NHMBY ^)YTB%6JM1/V>IK" M[/U9S-,OTQ5I]H(KS807M1^*##4!)15Q%72!I'DJQGF.IG5F93_*QBU-ZPB4 MS=78 3BO9M;OSI%>'2TE10ZKXY$BI'HHK4L$[Q@#D= )%;*0H;7!?!2!(S>. M'3@G.)RN.@#B;99N"7,[L0=S+1!]%E;3U405R00/%N)FAA0*BMOK5F!U*AB] M]4ZJQEA\+(WC9ET&A,OM2LLA=7$JD%X>,F MCOJ']N%:'K\D\?MG_S>E,+$EA,CJM5%?V4-RVB-+&7+TS"B;E.7-^]'L2=NX MF:CQ<-I$5PT'ASU=0=KS65BMIH6"S/J2AZJN!BE$>_SKARY .U(@3U=XQK1, MRHD,/)L JE@!,2<+G$>+D2X,GM:\,*!1*"^1/)_FB=2'*>J^W.PQ*+ESIMA.&1UXH-L#JRJM:_;= M2.-E]M5WSK*F>!%[,,"Z.C!=\!>.I2N+T%=!+J;U(LCH; M%)?98B%$LA7H?7#24#3(FT\T.(;@[EW$QV#L<8%T2U5VX 3LR^P[K(? I-=Z M1KPBZ_0?&);WG$X4&5#[XD#[6@=J^/=JDN&"$D/&I =U4EQT6&^R2[,LP76X2?I=2Q62XMA'!*95 M!6,D>4/AB35/,I4(<2VZLY?E+O^S@5_NB>]R7W$^LP)X$%7'0(JG8, M]\YJL(&E6%3) ;MRN"\I_S'\["-AUM+'/DSG/Q+2=[E15YQ'9,%'2T%%SJPV MC8O@N%0@++KLD[$E/UUGBL=2WZO=[@+Q;77?/>JO'1M)[V(108&,SM)N2;Y< M%$D#AGKWC+9+IH=W,C*S7A0&.1H!2A5R14P6$'B4+!?+I6U],KPO;>,Z MF&UQL_LZ2T/]=+!I[N3FV;=Z0VW3=86$DR-W"3"J0-ZORA UDQ \0VY,$;KY M[,,]R.KEODI+/-R>\]%8.3WCK3)T?O&1,Y8P<0VL2%J=D6GPNEZ9K9=M,":T MO'7,L0=9G5JW0Z&P+]0.U$L'4'MYMIQ/R65%8N?E]&O][+(S@"I%1%F :U:[ M3)!/&6OY#BW1F&BU9MZ\5<-N:CH%UJ&*O]T;KHT6.L#3\\7IYS-ZW*6$SMF0 MSD=Z'[%!?@6QD6C9V1J;!(GGY>(+;FH)SUGA7*N0?*Y]]^MU%!$A%NEKQP@N6)W0$%EC*#U SKC)B*'A MU$H/'4!JIZA>7UYT$M+:;)*IW; C+1+#P2=5LWH\9H8NJ-CZ/N_WJ>KELNX8 M+OQAJND9;)OKF!-5DHTQ:#"V=BUA2'(*W(")6B6G=(S9/!70-A1UZEX=J/]] MX?5X970 K6MW>W]!(B)=-&?_/,.-PN;YO&1B\_V=S$^"4$(9R\!E5B>K!H3 MN*LE0$D9>C&/S8L+&M'>J0_7!JZC*+B?V]T[^?D-UQ/E4TK%69*FH+5J$_DR MC"MP]$WR.$S)^LFR;$1/I\[?P&;SL8KHH 3K^D*:N"QSL"A!)Y'(V(F5=S^A1KWXRWN-Q,OC_B)'+WP]J< M0^Y);*-3R!=A.9_./UZ^Z_(0J00,(DH.&17!R->^(EH&L-SJR)EEJ?F,\UVT M-&RG-U]/\W1V5B>(7QVXO_B:9FTTK;)EXW>WI3;!&W#)*1P&TM"R*EH M6EO>04A9 D5)RCL7K![P9+(%!^-&"DT0]T 7OJ=6<0_QQ'$\/_MV_P,VARV! M1: M1G!LW4]\0'9Z.4Q]>I3>CE Z@4RWJ^>W<'J1 M?:WY=9F)"\%B!O*<&'B5/$2A=.W#H)EKG:W^'DTCUSCW IZ]0'V@)CM Y@OR M1Q??$-^O%^D?;SY7:9XG[@M1RF,14&<%@$(*VZ*FK9,VS6(%VB1\Z^M_.XGI M$8N'ZGPQA (Z0-+?PW(9+D\2'3,RA6+!2(EU+CIM'$S5_A[&831.9=: M@"0I22PR!J.;EZ,^2-#(->1#HJB=(CI U9'>PE52"R-%AK)>4(UUQ(3C9'VM M%%"[8'F)/DG6VFRUHKV7$^ ?/>XX# P__B(X.5V3HL@[UC$"F13R.J2T MM)\0^YH[+)QT$-J?][4@O$<7<6C,M07^ 0#H-AU_>:WJU\T\H6U%TA$9^0>? MUR8IOS_)C?+RER_\9;I*LT5]Y]4U^)R3*%EQ"));J#87?$ #ADEF!3<:FP\R M?8B>HPN8+Y[]>AKB=+99&.=RSF_F[^IB6=):V#2.^'V^B"M; M\^VW&Y3$*%EB$2+WM$J*#K5?)@.4)"]GHXFL=1%8:QY&GDO<"GUWJJ3'5'4' M;L E_\^^77[Z[U-<$E&?OKW&+SC;),$R.?:8A8!0%,4.GGMP000H20A6A(N% M#;; 'Z2L$UB.@IY=4&ZGRIX >GVCN\O?>8QK=8U$10(9M .E* AP(D3 8(U6 MWO/4O);G401V M>&"-D%PN;JZ@F+F_6[VDB,G^= ?';)1)W >%.; *8(3AD! M,HMHDJ7O-A_,^ YG>"L/0AVP>U(C70*+G'.2@B)DPM?6Y*%FK;5FGP=YD 4 M;[T@II)JW?KH 7+&S1V-"ZY#--(IN.0Y*XI)CV3J@2&KXTZ+KP68Y((@+\K4 M!J;8^AK= ^2,FT0?%UR':*0G<#W[=DUL+Y?XGVI,IIPSX^U@@>UNLCIQWUI!88\8X1B]= JUU>4*OC@FE;:D8A1$4[!6 MOI//4"R'XE) IT32:3 O[@&Z.@%;*S#L$Y >HYF>T':R6N%F3,[#.PC]PF^+ M^?+&AG)UB*0BB\)B@H+6U5FT"#[2!Q=<8"9(&UWK*25-&>C$8^QJ$W]R8'2P M*NKP*&+HU@RI>TX.)FA0!5>'4YFZ>0DO:?/"""J[XH+PVKK6?8[V)JX3:_ST M +IG'%A[;78 TVN#S.[C1CL60]8(@=MZORTD6OY2 &.D#A5ISW,:*,#P:= )7( U(J%I(1!N!2)JN=RTJW/JO>24PG6_OH MV&NCK6Y;\YZDM#S#Z](]9J;ASH>=MS0A=NKED3V-+Y%Q>E M$-KP'%2H+7+JQ'.I/(3@,\CB;$@Q\-S\&L;C*&QU ^4=;II9W'WKQ)C,),\" M)%,D@L 2>$4^ 2V2Y%&8$DSKRU'?)6KDS3.Y Q,2"W.&,1#"!5",2 MYOO\BHEYSV[L2\3$1,BRW>T.V])([S7FAYX,M'+CUY)H2,6QKU?:4=@BB_ !,!"\53(:7-$O(Q.,[&K>QS#/>7 T% MTP/,5I]PL9-[$U3>E^0L:%.=55$\1*QGR$03G=9%FM8I_\=WM!?,]$N 63O! M= "SW83P$KG(1H)&64-Q.H&S)@'*E'/6183 R+P!<;<31;9C@KHI> M_EHKFVOUT@G!@J>^LDW(X*"--PH<;):ZAI7WMF3+)2A7U";Z%(IWP*4*4:20 M;6S]SN'N#MH:3G_#Z<=/Y!^\^D*??L3-%,&K'W[ Q6<^(5!KGZR#8JP!59@% MSW2$8+.+Y'&B,F504^KI/8X;%C@!(8\;3XV%T\$]]RA]-1I;:R'?DI MZEL9@\X%#?@H*T=EJA/32(L;;GF4*?K2^OH[=(_C!A6>"WRG"J?;FM5[=\IW M]!NSA.\_(:[>WEJCW=WXU J#7)4'D37,S:FD=YR9#$$@7DU8)*4E;6$H%(N" MMPZIM[DYUR&3N_Q\5\_&F_+;[N^CN$36)EBDG9(%<"B?O-$N()GD0F87$&.!8WQIR.I">*0.VR%!2 M3+3SUD_XG]S4N'IJ!'P=*8]^5=11L_ ]B6I=X?*F_#B=D><\#1=OY\MIE=\/U3M>3N,% MT;Y<37A@7'D5()M(RADUA\#)/A4<=?8ATX]:=VYKM/5Q(3J87?8\HNQ7"6ZM MA@/HEMP*6SN8:H$&E&&\MGVTP$@DV7H6#&_=(_S*=33]??EY_]#9\/;55YL%K#))F.)"T81(-HC 6)#)PZZX?M4K$U7H. MYD46$HU,O/6CK+8I^LVAP#O'9XK+:U9>WHQ64IE)&;("F2P9W3QJ"+&^W_1, M2Z>9\\V3\_OOKJO\Q"&H^*8<>!B!='#]_HQD(^,.C7U%W^;A 4FKZNLE:8&_ M8UA,1#0ZD!Z2SK4W$8_3L#'+ MW-[!.V*CXT9T>H!F$Q$>CE._P>D,/];:UP^#IQU]MBHYP8&%6E&K,$+PU@-7 MW''ADT4V['NNP]*.@Y7H/!/D6HBAX3N)L<.%DWO5VL,$#"=\I)#A??*N@X;_ M>C2'U[/W/LTOZ#0L:U.LU=?-GS\MEY<5P*<$8O?^[C;6*M495JJFGCR8*#GY8T&6YM-'[^[@5/U^,TYOS=;OOKZ^",OEIIV@ M$J7P)!P(6XBX(&O7A/I0U&O27BG:8EJ'NQ[9SKCQK!/D?E^7MV)Y!][4^\NX MG.9I6'Q]'ZX)6C?Y19:=94F",XP(,5("D1 @\-JQBKN N74W@IV;&1-\#B&ZV7T?.OBD?%F&VI%-6BW4V77QSR4$I$\"P.CX]U\?P01103- _ MBI5!M'YQ]/2N1H95&_'?!U5;68S>2V?UX1/^$A;_P-6;0LO73GL?%[C.Q&_[ M-TME;)8B "]UU$N)!9QC#%)MW!R322ZHIPR@/=<:&3"-13L?CL\=**5-,4ZB M6W_S2&-]LDQQOCKQX"/I;"4"0A!20_)<.60^L=Q\9.T#^^AE '/;^^QDCG>( MFNVYBIA#2;1W[NO3(IL$1"\R\,A2*J8Z_\U;*SZXDY&;"9XLX2<@1\CGOGIO.I M+ZQ5Y%9A_GS=UI>ADK%$!4EJNF1C9N"T\. RLJ"BHBNS]77RX$;&S6L.=9^< MSO.Q=<-MP_XCF5,UM']M7JV3"J\N5Y_FB^E_8WZ+BVN+:U*T($.?.RBVM@++ MT8$O=,(*4:>C)(/K?H'&#DUR[ [&U3L-)#]_;C'TH*3FGS_/9VLZUZW"WURN MB/Q-JTS'(K*:M@A!IEHG(LB[K/G^%(4N*J(NK;/ACVQG7 .X';Q:K2\BN)<:]Q!JK MG#:,'!L.MQ7GES"]J%?ZC_-%_7A29+9&D$8D>!,=@1MP##E([Z(C-PL-^ZKE><#RI$,[L V69-3$[R8O[^LAA>1,IWG]Y^(P\M?\8_UCY:3$C1Y M"\*"KW$$Q1F#0. ')5+Q@GNKL?4 FOUV-NXCE?86RP#RZ !E;Q?SA)B7/Q(' MKUX3O"FWK+.)=Q:#C0PTUGII81 \1@Z.%)S>U%[;L^6"KK10Z M@-6MK6\.R&W['HUBZ+,&8:,GJUYKNKN=!1NM1!0ZZ=+Z!,$Z6B5HV;J8I]GFNWIH=@BF M'GEH]HSB[.#"W>R5>ZMS[!*S!>I M%41C%:AB% 3'?>U/IWAB9/J$O9!&WWH+9?2O&X3=6;";MW0C7,['<[X'N&Q1 M[D32V0L&AG$B7#*$H&H%G+%2UM+*5/:JC-T',&,JH!.$=5_<1W!N9('_$OZL MM7+;C7/M?;0J W+O06FAP&53( 5+[E+T+(N]HOQ/B/S.HB,+_1B1S5OPKP.S MY$G5N$LSWD00B36(C!O(K$[&*TC')1 ;LPF!<6TQN-:]MT_?=3?/\D;T&Y]9 M]N>,]O4?_XG+U74VCD]*X;DD8X!++T%E7R"4:(!L2IN*9EJ5YG53#???N:G? M&'NMH'\J$,X_T_$<"8Z1\AK/F,X(/DA!GB((7\T$CQS(;D P&&64+*&(K2-4 MC=,9QYZ@+=OK&<),[OH/?_Z.J;95F=>/KAEDE7+.V@#2,W+;=2(&"<4!?7$B M\*RS;3UW:&"2NDI]'(*_9LIS -&?LU&Q9<>MI/F[^<7%C_-%_>$DEE)2R0ZL MBAP42^2/1G),&)=2T/U6F])T=@ >IN1,#8TAP-KX(#5 SLLZ/[]>;@K8;$2' M2D(N(FR<(E=EPK136AM4-G?CD>XBXKQ/30MD#G=8CH#)T>?D]\W;S558K+HX M+?^VMG1_FFVWCDY M 2 ]7":/O9V^[?;]\">V),U+2$:V/@(' M[W+D>&6',!]6T/TT"3V5]\3L@M/:%/'F4"LTD7,FR%2U]>8+M3V_8""1:V]E M'5;<3>AR-QGCEJ#U>"9&ALJIAZ:+\T)^WG2Q_F]NF. TMR(8"UYRTAPQ&7#& M,1#.,,=TUC*TKB,8@(QQ*_%>X'DY%2HOYY+YUKFJ_6=*L!*XTA:4L"27.G/: MJBP#0VY]:3T991P??+#"PA=X8$Z#R8D^^ ^S/BZ8'1'%;WF3A-&ZIO5%K$.T ML5APE4$N&S36J9QT;T=H7]K.VVOO.28\"+IZ<.R'XAZP68B6#<\) L%IQEA@RU9NO=3B5YQVZ MZ/DD#HRX?YXS.9&2Z6B# !*= F6Y!*>D N9"]LX*%5C'#Q >(^W%Y%8'0?@X M!_(@N)U/-G;G\^T'LVV/,BB7L'[M# M"L_;9SRW C!CZC2MX"#&A. +BI1E0O_\+F9C M&E],TOTL#NB0 #R' ]K(%\_9>9'0@LV>V!(%@ZC((8\J:^-+"EF_Y-#/.:3T MNSB.(\#MG^81P*,<8SXRY;6!Y)FI4@VDMV(!'VT663ARVL^D.K+EN>WV&NTY M8?*,2'P!-^C3B=Y'N95\60^*!99)O*J0T>$Q>@A,:F3H8R[-)S>/2O%YW[=G M>&Z'0.+1YY86CO-.3NZKG->#$L/%]]-ENI@OJQ=_,W/>U?'-P8.4GM=Q8A9\ M8F2"Y%(S3QC)$^CL8#Y*T+AS"U[RN6N'HUZNP_@T,^+!%OX[K-TWZ?/7\]F: M-9?AX@,N/HL)5UDH089^J)-I%0L"HJ9_9F8Q9BV%MH-49S\OF>?]QJ AR!\Z M?ATC[@4$<3>]ZI@7Z/X?.@[^4>TUN1V%V,*LC0RA" *B+$H7;EJ/?AF-V//.!)S=,6V,OG,^IIO6MS_-2%B7ZT=$;U:?6N=1,2812IPHESXO)W93AGT;JN &/'CH4/R-47O2)^G4^ M^[+62[<[CVB1ZM,C 5K6E"/3 ;PI H0U3%D7B7O=5/8>1>&9QOR?$_3/=E!/ M1N#8X<);P[6OYA.L6;&<>"8$B\P!2[9V[H@< H\,2D*MN4&,Z5[WOATQP9U+ MO%0@GPZ*>7,)C5[+NJ;EBH!U82#F26))%HS$E-J<27'Z&]F$'+*32I*]Z(R/ M>V'LWA>?:4[EF9%UBC3&UEM7>[_INQJ\XL:1.Q2\)$M.R$ NAJ7#P;CPQF5E M#\32N7?%'0E-QTED_":%=XAX'68)+X@&ZVTR,ED(3D50*F>(Q1J(,1COE8B^ MY(-0=?7-9QK6'PE41\ECU$:Q]\[$[U-:?"*YUQ@9!^3UB8@HM1!(:3 IE:"S MLX6Q W74^HO/-#@]FH8Z7!J=Z*='C$$=(QE\&62J#3<#*G!)%V Y^5,M^('B=()1>\/140>N5_C>6TQ7 "Y3J!JOB' 3N M&: I14E2XU(=9JGMN?!+=0L&1N008AT=LH_0=$7WK6<2$^-2"-DC1%X'C3'2 M[(%H@J"%#AE]P/NS3'=!]K"%QPGC#B_^^3/)HI/0[!X47@4*C=58 F*)>](I6PAJD3D M:6V81"65\'U!RP'9YT'8Z,U.3%" MTI-#Y@]>=1S#KC]\'26%:80W8*G CD._F:/P[&@2]&BI2DT*Y=I.36PB\U M@S8B?(\5Z^B0O;I-*BL?XII7Q3M-YP]E?=S'A()0D]-!*Q:MB#K:/6,L3ZQT MICU\QHXX-Q'<[I!#L; MA$Q)X5'VZ%&[Z2 Z/1H8VXGI3'"Y/7W;=Q83$9@5S%DHNK:(\9R\S<@UH/8^ M.>=,YD=9D_LMWT'<>FPU>(P@QH;:CFK9AX(,@2N3LLS@= V49L7R7]+\\^;[UX^E/\TO2$[+C5O_CJA;3.L16?^,CLR]3WZ;35?+[W$5IA?+ MN_0MIY]_OW@RP7;JDO]Z0^Q]-FQ7_@9C0Q..?ZZ05$O^7Z=5Z]_KC^!TTM+S M !EEK#42"LC-)+PYN@:3-,6;UB,@[N[@Y.X#Z1/FRPM\4XX?^_-A'5XT(I:$ MSH.M72*4+05\LF1>1L$C,\X7UKRQ0*O-CUMJ?0*FOBGE'T6<'731V.RRENH&\JJS!2?I;M%<6.$UEIQ;=UZ[LX&12_?' <&\E40Z@-/Q MC+LA>Y;?7H39K^$S?C^O#OI$FY"S2 PL3X9,$A$@%BX@QX(Q2/2I\-8:<@ Z MQ@7W";!J-N>ND8P[P/D]\^D7_!QQ,W5#G!98C(_ $X8V(Q.5B-7E7.;B^00KW/B>FP3JZ/!36MY#.*^"! MN8Q!:!'W3R#@$ MA9I0'DHJJ0:98BO C'D-GB"L^^(^@G,C"_R7Z6SZ^?+S=N,^ER(PU2%7N0X. MB 8\3PB(1K.D@TFYA8ZXL^C(0C]&9/,6_!M;\.'/6QO76J1@+8,D:J*+1;*M MG"C 6!&>? NN]FN6^93@;R\ZS@713/!'\Z\#V_3HUW8_3V?XTPH_+RABW#5,\N^![17$_ZGY?(2 M\_>7B^GLX]M-P?2Z2^:;1[&.VFGGT8/&>+H/Y^&%VR^$UZG@W42JQ"71$L"I8&O+?>*K#H%N)71& M*ND2-M?1QVRT\^##* !N*-H>\#O8\_YU'X3E3[,-U^X]&%S_\/NPPA_#=+$9 M0Y$"U%C@4R"\HS$QTKJQ6YI3?R9MKEJ=,YZD<)!$#SGL[O^ MHS[^OE9J?.*4U1XQ@Q'D+9&;3!K,T^6+0IKDG"I%=S.#Z(']GVE;KI%/T*E MZ/?%VH,<>?C36@TQ6^(IC]6.7ZW1.[5&Y#9ZHG;SSO)-N;WT.[RHK79?SY?; MGJNW1P/?/,F,0882O :C7 )59()8WWHGQ07YUM)B;IW\/6W'_3R!0YDEJ0T. MC+L,*GM&K#,<:HE/%-9)<;^WR5]/X)X=L\,]F3M$_!T8,#_-2(/A>Q+RFKB? MZW]0Z5V_J\GU<3V98<94/\HPNH:LM,!M"L(I7G)HG8=_9#LOY3G=00"9#R.M M?H&W?9^ 6<5H"X(008/BTD/D@8%'$8OAB@=LK40?W="XX&LF]OW@=(0,.@#4 M.Y();>#3JUG^'K_@Q?SW2M/6U-JFHD1V/B:;P)=*TJ9ZC9B5-5T1C'LR\UO# M:H]M=0FN8T#P[4.AIA+I &3_AC-6/!S0VDNE ZBU"&C0V2I**F H"JB0 M94WI)$@:96#)@DH'9:'/H.W<:?8><\L^P[0_NIB_3N8'XV83"3JG+U% M2(4'4'1%@.-<0 D%'9&_^?;GZ=;[Z M.Z[>89I_G$W_&W/SR.:^"PX9W#R*Z#[BFP%#,0Y%!2 G6T!G\-%57>TE^LQ$ MWN_][C]A?-,S)D@GD(?)I EC0$7L@ RT1PO6%3D?Y7X#A'?/ 2SP\4W#Q%_ M#W;%G4I!E4HL2#<0DF=)FR\<@B<70"K&A>$Y$E)A.C!>.)!F7(8PB9G(4B@I*R9*-#:Q6Z[_VSEP:>@ ML)WP^D/BEHB"4FIG/'@3)"C+),0ZWE,'9G7 G)D>N$#] .2-]V9U9.0=(:P. M$-<@E%>"3M*H",Z96!O>J3I8,4*)(BKGE OQK[!_CZ[1,\N^ [1?FRRX^#)- M^# #KH?/KVE=?IBOPL53L<=)D2P$J04XK169/(K^IH2"J$NV*OC@LQO*3FU- M3.=V;F-4[K)J1X7(2SXKFV?G/\X7VX_J[_&)0AX#KPG+4!!4S 6B8.LAEQB* MY[;(<"X'Z$$*.[?;S_14G0ZF,TO]7=VP\V,A_NSF9:KZ><:Z/_FO]C. M*VZ>)&R_M2'3B0,SLH_$(P9KHHD<>"*O5Y%OLW9]Z0JR7B/C)L?6)98O)?%H MG(O$/@>R!@Q4CG1=HQ#D&B+]PPB65.LVRW\E'@_%[("]B \0?P?6VMU\A)32 MYQ(+>",9*$XL] (+&,>3".A*R:VQ^R(3CP>!X-'$XR$2Z0!.@P3;./.1UQY< MQDE/#E"R$,AF!.E5L,(YJVWK..9+3SP>!*OG2#P>(N,.<+X[AX5>6(&!?!S+ M,G%6(7@;:K-;9I3F)OG[(Y[^2CP.A9.]$X^'"*T#]#5PRJ,/)05/KJW0'%2Q M 6(4&EB0#E/0'OV9]GX[@^#[*>;!,\N^%[3'IRF.]RG>]G;9^.=7O5VNG7$^ M43YK1T<;(J]](Z5.]3HT8+)7UA;F1!ZDC] M'2NZ1MC\J$C,39 >CDHQXCA MR"9(T=&EBUS175GHUHS,@/^)8V(>VGMMNP6'PM\\4F#;4V]9)S6A1I(;)" MIEX*9.H56R!B$5$[B1> M#=L(H87GZ^E1NO8.0@;!^0#%*!%\U#Z$UO'9AWQ+%K+YTHHA/D_"1TCF!Z!^"A7==& MC^GU_'*V6GR]ZDL1DU>\%.!*>5":.S+/,@.-6H0B8TRF]4.;!S?2&VR.D?&\ M-<,[0,V/\P69^+.[-%B4)GAR/7+6IH[B0>)*YJ2)3<$HO/7-VY<_M(\>.LHT MQLS)[.X ,NLF.Z]F^6?ZS8O_N%Q,EWF:;H7E Y?YZ=,[)YC\K'MS1N*<,@0&HIA XP]2V/:O9H?;=SQ;@KW$/FSH$2KC;V*#7L MKB-'AT9AZVD@NW4CA! !V#Z%?_XC_IE7[^??IDN22YO"A$6;FE:P[-V MQ@6P19)^%98(4I8!PV(32JZ]::V?GMQ4C[ Z1O[S(871 ;I>AXLIJ?#9-/RX M"#-BZ[*R[;LYJ?2KP8:FN"AR@5(8V89&*/!)<2B.-#IGP9;F^NK)3?5FES=" M5UMA=( N.BY_GR_^L385OSTQ9#S^.)T1H5\<3[#' M"V1^.G?KU^R!%8L#XQ#UO7-9.!ZT[# !1>98HC:M4X_[+&M<8>) M#1G%:2V3KF$VT9JL;S*]('M;AW^K #[4H3Q6<W\9_Q^FU8?Y#W_^/EVL93D)$GG$^LJ-F[ I M97"VMK+.+.3D?.*E]1S%TW;<:\BZ#2Z?49ICVU&[*?L.Z6_X-_))R1_]8S;A M&**1T@'#VKO!K&=-)EE3B_2)L$([M9>9M?>2O7I:IX%L0+:/#:;K![R_A,4_ M<+6.-_SZYN?EA*=$AB>O#V@<&:%.$(ML+[X6=72OT:GPU@$H3 MIG9P1?Y0"BG*Z1>\CGF]"RM\/2>'9W9)O-LR<3Y;3H@6YP0Y.NAPR7/P\_3S=B'0B MO?:8BH=2&]>K&J(GQYD3S2CI]$DEQ7ZWWK$[V MNYMS@]GQ"&1MYNSGX=KY< MO4K_=3E=KEM.39Q2VDC2Y[5'26WNQB :ZR Q783S3'L>3S2P[BVY%[;L66)K M&+9W<(W^-EM<=RZKF42<89FNEA.? H84&6#Q1$;0#%S)Y#K7:8516VMBZSE3 M.[:R%ZK#5'_$0 M0U&@?"XJ(PMH6U<-'+O7O8#H7Q@0VTIP[-OS[6*>$/.RTO ^U(8+Y/J\)YWM M5.8Y >=V71Z6(.CH04LC/1;.=&1[794/?_]^45=V;LAIQ=$.U->U=[*=U+=% M_R1&I9+2 I";^E0KD3ML@P9,+"9;Z)IO/NIKQU;VP]#9ANY;"&!LY5)9\V9V M?0@F16I60D+(D5V= 6$5Z4F#042!(=J]M,J]+]X/"F<7+3^9A]U6[K^ZK&7( M%]-P-0\\W)D'3J@G^--?IE_PA,K^(U9I4_E_*GG/T!E THT3R0Z!6$N8E(CD MX=L:ZC2(*%!)R0:K;F[?&>#ZJ_]]?C'-X>MVW#)CB1E4@(+5B5^)SIS-$H2W M.@J>F;2#50W[U(H&^]!1+ZUPU [BS8"2".%]S\5"[V(/KM^RTGO;8J M)=#&F5HS0Q>J4P),TEY*SUU(>^5"]A'^F(_?3A#6?7$?P;F1!?[+=#;]?/EY MN_'HF2N:1TA2D=JSG%QUG3S([)(,(LB4]KH8GA#YG45'%OHQ(INWX-_8@@]_ MWMJXUB(9)2T@J_.297'@DW= KE/RBCRJPO;J0OB4X&\O.LY+GF:"/YI_/04Q MOJV4=#I)'SAMW55*@M40E9>060R\:&-"_&>I3VYG#S3F>[<(VKX>5]X7ST4& M1"] 83+@LLH@N6667/P83>NYMV=9E7R0S ^I2CY$ !V Z3HL,+LJ$WM3RO2Z M1$Q+2[1X \E7:KA*M46VK\6*(207I$^M7]T_OJ,> 76,Y.\/?6@GA@Y =5][ MWX0#21JQWSNNQU;IRR8_#3AM6=J!UKJ=8[\Y!%@N9WDYL2Y+)&\7$MNTMN7@ MT'@P1@=E#!;A;&/=]-A^^KKZVFB@9OSO-D/Y =.GV?QB_O'KAT68+6EGKSXN M<-V*_82,Y![?VB8#>>CV3\PXKA7,(VM>)YPBX\;Y0BA+W- =%#+XG!A$$9GS M*+V+>2_5O<=B[<94_K2>>;L>-K,Q'0-F4R+I1]*,]877NIN'9L!H_S*AREZU M+B?C;3Q&O@R?D=2,F;V@]D3(^I0]]C))\C2,S$<0V,C W$7'57<, MX5S0*4$6N3XU\PH\.@TF^IB"S1GY7F]$GH#>X[L8+V_V?"B8#R*2T7VXS[]/ M+^8WF2.>F"@@BJ[69J&CJ,G+$,A#MMQ&[OE>%__M;QT/&RW%-&_!LPZ7 M<8G_=5E/QI?ZRNUJ_JD)SJ8B#(3:XE&E.G6(*PFE.".E<+25YJ.K'MY*+S,- MFUQ4+=G>)WJVAREJR85&#M)H47OS"W""7-:"3@2GF"%'=GC\])!C:R+JI^%S M!-_[ ]!6AR8NBB.5"T$:.EF1%W Q.HA&6LYJ@Z_4^IWK@QOI#CC'"/EQZ!S! M\0Y@,# :W;_8)U(91,\EQ M)XF5QD*I,[.9*4J(UN98>RI&[GC[[)C>G5,)VD;S3^$SW1#QZW(;:$3A5<@R HO(0(7@P0GD]?UVD871 M!R(]92X^L<:(19O#2'/>GK5C(^2W&:GDQ7*Z^DI:_'H8V*L5D??]%#]>)5.Y M\B74I(BMA*B %J)0BCPEXA9+3#NW7X?D_=8;L>IS>.0,P/*Q4?1+6-(]_NER MB:OJSR]7T]7EBNR"FQ=N6Z**DGK=%-I$;D%E;<%GU&"*K"F4;./]VO$=.-IW MQ7&B',^$I$'8WD$(K6;8WI1;AN(F3^NLSI9. %-UYI V=*NC%,!SBHY5RU"U M;KO]X$9Z>0?WM:+X\-\UV]?-:M(&K/D M'D2H^1)+9'OF#,24G>"*"V2MT=ER_^-"=U"@W1^^.Y;4QPYV7/=1BB5Y:P*K MTR")>YGXZ(I*9/*R)+.U' O;!ZI-6X<]PP./T>-EQXF@!]QLXX=]QPX2VA_ MU2N7J>"=H?^)_;JMGE_?L:,%?S3_.IN>'HC0@-5=2,S3UITEJR;XJO]$Y&1H MH7YLG,,PT],'&]36B8%PJB!Z&KB>R>QE7!#!/BH@:FO;#C*03RVSRX\% MC.' MB&3L*_!.]3/=$,8INANT21%43 E"UAY2B3(ZZY54^UV"9U$Q?I"8=E:,'\*S MCI,&!ZCMGZ]?V(OD?,FQNH>Z&HS$A:A9J>^FO/5!I6!;OW-NN?]QQ]!V#MXH[?9B3S^P4'D\A*M)8["#X16[&.;*F)2.;116%=3/>[NNYZ]?;4 M4N.FL<:#P'PP>8R-KET\?3?]^&G-V#?Q8OIQ,WW\:B;TFMQ?Z(I:87V/CS\B M3A0WF9.] L[6L4&1CG:0VD%!R;TFARSR_:9#-MK0N.]9^D#J&+)](7A^OPJ+ M.K[OU>KO&!;O\0O.)CY'+3-GM7D/V6."!8C"<] Z"V$4<>/^M.=A(?[ 'L=- M!;\HU)^*@',Z"-O,RJN/=(711_C+](*D1$[^!*MM\*738!-G5D@96)+-3\$!&QPWV7%^1V HV9\3_M_-OX:+U127 MO^+J3:F#59>3&&Q(6M?WRZ*&I1WQW=>^Q3994XR45IGF.']@(^/&4\\/SZ?* M\IQP^_Z2_E[OKCIQ'HE09UU.N6@0/ 103D1PW"=RL&/V26"2]Y^>-0#M_5V, M&[8X/\2>),4.0G:/ML916OB4&3D+KC832XR!1\N!Q<*5T=%DW.LQY'.V*[(O M%IO-179.VO(18[^:^#_.+Q<3)5%I;VVU\$V-N4N(.0@0D4Q_4;0P9;^2P,8; MVPNW[L7B=G19CXWSS='\=[S(WWW]\&FZR.OW\Q,?A53H%3 =B*'9&/#.1L@Z M!#JN6JH<]H+KP]^_%^K\RT9= \YW<$??Z1!E%$\JR]K1LZ:5LX^UO -K):ZW M6C/,NGGWY4-[=-U$%%\V]L/^W^ETP86_#E!__6G^M/Z>&2VHCVL M\XB^,).* :Y"Y;PH=,#ICO-D:^=HH](#8/S;?>P'YK^R9*U$V6V3T:LQJ+=X M,:=3FN\_Z#BA]^BA2[1I27H285UU*I66V\ M Z.B ,+:6D]&2)8L9(XJN;)7 M8[B_.I5.!(I0F.-@A2-]X6O_N" %",YJK1SCP;>>)?]7I])3,?T,G4H/P44' MD8R'V[#$I&Q"VKK@M>FU=QIBX37#5Z(-27&=]BJC?I8V2N?4N_0@=.S51ND0 M476 MT-[I^B(Q@0BS_I2'\O% $'2'YQYM*Y8'.&9 '2RH.KS=>2[ ZX*Q"*\E[E5 ,U07 M\'-J2'C,3=I$,&,W.-J[9:AQ"IDI$721 6JG,?!.>G"&^*2E-PQ;E(J>:Q?P M@V1^5!?P0P0P]LWX?Z<7EULMJSC340=2YSKP.K!00M!H0,X^$+7[^9,V!P='0 0N=[DT@F(HK;'YX6H MES*Q_=KG/J$R'EK[Q;7=._:".EDP?0"K\FM+P?)J$FJ2:(IU8*2+]9&'@Q@% M QZ-Y"[F[%B+YFP[-S">%CI=IM\"Y$0&=Q +N,KG;72GD)R53!@C_QA;\G=:E!'-I11UW3N22TU7'12='?GV,CC'E MZONW%H+OK_7KT8(_FG\=6(U-'_Q$;LD*5P%2"+$.4#(0G)*@0PZ.R22)J8V- MSF=O:71.W0%/R8^.!HPN#L5L_1JBSH)X?;EH-TUNF?Q$Q7<@Y%E;V:8Q^$\D]9+3!'IZY,$2<@"T\^KU?1Q];/U!IN_P7U M2CH%W6,!8NQ,RI:6=U@C.$3;6UR4^>)S?:Y^\PCX/\-B6B^\^NQM2H#8P.-S MS4S0'9BBUBB!,4M,+_2W8(H&IB*Q.TF1Y'[YEU-W\H+:'QT#Y.>79B?0?9!& M^C!5\=>7Z[_BIMBB,(699P=%RGHL:P,GSAFY(\ZR((I/_""D[KOP"VI*="HP M!Y'5N>#P=JN/[7^SG"#W3**38%/MBEH=VY S<504YU(40>Y9%G/*+EY0FZ'! M$7JR%,>'ZP/U(:^^K0]Y\WO]P8?Y!UQ\GL[""B>,W%KZOPB1+!E0EHP;)XL! MX71 H6.(>XZA.'H++ZB[T E ?0[Y#5^WM?U!_2.&)?Z?__'_ 5!+ P04 M" !P@6)7R4MLLOX& #I) %P &QS=&$M97@S,3%?,C R,S Y,S N:'1M M[5KO4R,W$OU^?X4.*KM0-69M;+.LEU#% 5M%ZHYL"%?YF))G>A@=FI$C:6R\ M?_V]EL8_P-Z*J82$I>"#\8RZI:?II]8X*7^KCHX)D=OR/HW^V6N+,I'5) ME1>I)>DI$[53U8WX)2-W*UJMQNK4C*96W11>[+?WN^(78V_56,9VK[RFXUD_ M1^_B]=&[,,C1T&33XZ-,C87*OM]2,B7*VGF_E]-AKW_0.^Q\Z![T/_2&Z0?9 M[1T>_-K9@BO,HX_S4TW?;Y6J:A7$XP]Z^WOO^R/_<:(R7PPZ[?9W6\'T^"@W ME<=X%O[Q:^QFI3-/=[XEM;JI!F%*6]%UUIP:;>Q@NQW^/G)+*Y>ETM/!VVM5 MDA.7-!%7II35V\3)RK4<695'0Z>^$# !7KB<1,COT8]6%]O,H'_UB$*.25@:*YI G'VA MG/BIEA:K3T_%%8V,]<)4XI.QI>BT6S\)DXM_*R>]%-<%63FBVJO4)>*B2M%U M_\,W\ R^E5CMWXO5OZ1#A!"+I M3X=[&6?BGXNQNQD(2N:H09Z;,(JX) M* AS--NE=E7ET!/I%?I15:KK#'V".TM!3, [Q1HT0NB9MT;!CA'@P- MYF>*.T[8HM8P !<-"!.&2LQD.2;$3=0)DM\GXNP]2%*R#.%&^-10$X=%$#@VU,H5+!$*JY/J\@W[E^P$BW1,-*"L6P\4'YOH!P#\3P?DA,6G+)?1E4TDAE+?$M3 M[@?= W3Y;)#+W64*GI$#)$0PI*W?IU?"&365M=O6,Q6:+VY#&[*;BP(; B9M-*92K+< M2P?"D,5J@D-BJ.%1KQVV 1U=J0QUI@:0=A?B?S$R--=<3Z6 MN@[RQ6&F/$=)J,8(D%M3VKUUF^APO%Q?YS%CX0<-=;&8')K:?WWH31*%G%L3 M5\KY^OU-#-(RDN&L$ \+D>)S *C .A[EE7E/ASR#A,;8KE*$]]Q-C1=:EAGX M9OMPO_/^HWN,<'*>-VE:6V;"4E)=TVMIG,=]/CU%7RY%1[_%PQRQ\Q67W-06 MFO; N@&.?1*%XP(^2:CJ.:[=B*J0;EZ!L!J&)4!9R!+A>302/A5:W9)NS@X> MV"=_^!&]',8_&YS]=:>$V8SQR4)\H(?+I%O($-/F4=7!BE1+U*G>6#=/XN$& M^BI+Y3W16GT?&A0(W)(I0 KN.V C]-2Q7N,_U\FS)42_U0J(PW*IJS0<$.R^ M;JW^TJW5B485!E J5RGO<'FOG"H"0YI7LP.> MQ_$N;D>PZU@O5C*#HZ.Y5JTA:5-_PAA\0YF8Q.3ND-E=79;837VA,(TF.ZP] M!'LY"O:,:8=MSPE2=,TIC%DP$7[R>*XI#'8_>KD'[R7,S(N_+PSB*>< M8UIY4V?F.#3>FW+07KC(H3.Z]JLNO_-R3_,97S5Z%UYQ^C]02P,$% @ M<(%B5^6I_=]9!0 >!H !8 !L4:P@D)9J& MD"O&K^!=2-5[<)QRU%AD2\FN8@T-K]&$=T*^9]>DH&NF$WI4R1D>%,_# SO) M<"'"Y=$P9-? PM]5B]L=MJ]Z) $?_HU9,7A M!8_2RX2^KJ6,.S$U\_=;#?>PG>G!#0MUW/<][Z>:'7HTC 37.)]$_N*V$+,E M3--;[9"$7?&^5:E6L%;D0"1"]E]X]C'9QYL"\B'*21BGE0I^PX">W,9LP30T&YMX5[I\.4"M MG8!>OO [WF +S ZS!;C.5#Z2W<:3B_GIR>EX-#^=GL'YY<7LSR?'S\KF)S#_90*ST<7/ MH[/)S)G^_F;R!XS&-YV##Z>-O\U.O_*E6;1\I%PGG((!.)L3B<9+EG!!,R$U(/%$R!1\SWD+(H(W3!%-8!Y323*::Q:H.ISRP(4] MP__R1;?1\ 9CD6:$+^V3/]B'2$@K_D,A'B@/,87-:*9INJ"R,%K3JQ=I*V() M4E>89C3()=,,E2<\A,EM$!-^13'9I2E3RN#'OQD98F8$1$81Z#J<0I<*#>*M MPS&Y9B'\ZL)OY.Y.U&$<,QJA;)Q+LVL*TRAB 2)%2490J5 =\)U9M3IDN50Y MP873 M9VC-*@=L< @HA#D9ETO3Z\&F0\OI0_(W)!.%7.]#:A2Q@%VE",Q]<- M1[J$]US]KG1L*,^6&/+2!AB\>,D--+]9@>1; LJ7C'T M,Z[[CM_-OGS]L-L$OEOI\?5G'VQ8RO?8*@'Z-R)":]5R$GZ M(6>2FD)1&4>\=^L]L@\8S'Y[+]Q?.>]]@*Z"L_1@O]=LV3!(;)(NP3CNTBFQZXRI01/D#/&M7>+*7P@SN2&35!G7J!LR21) -@1#$G0< ME:&O(,5P18P3'ICW*#!D5O3FAFI\HWQC-F]5B<:9S5Y?^*+*D\(-1899QTA1 M#\54"08',!&NB7&_W4WR:^,\-GVG33P%XN)Z)J[7YW.)XD]L) +V&@8A8'XNM:L/=B2^XWL%OS-#=GL/0]M4YCEZ[NVM\-/2LV? MM5(%M) &HM@R^SDF/FE&&75;AP-EKUN%\'E\#.:W88SO2_VTE=JQB-_7[QDI M=8[E"C-U*7:LS>[@H]WHWKED6%!E6%%M$7'55\235>%5<9IJZIX^"@*1B6,68MS O0O6_0R!0MJ7D>YY$S%6-XJ MD5!32G_NN0#LJ7RA"@X%IBTS2[RWV-_LU\PQQ#@FF3EUZ30-;6[._<'OUN&2 M,U-HS[2MO,&UL4$L! A0#% @ <(%B5ZX:*/G B0$ @T@" !0 M ( !=(D! &QS=&$M,C R,S Y,S!?9S$N:G!G4$L! A0#% @ <(%B5^HM M2-VG_0 69T! !0 ( !9A,# &QS=&$M,C R,S Y,S!?9S(N M:G!G4$L! A0#% @ <(%B5W>Q?A@PV0 430) !4 ( ! M/Q$$ &QS=&$M,C R,S Y,S!?;&%B+GAM;%!+ 0(4 Q0 ( '"!8E#,Q,5\R,#(S,#DS,"YH=&U02P$"% ,4 " !P@6)7Y:G] MWUD% !X&@ %@ @ &+= 4 ;'-T82UE>#,R7S(P,C,P.3,P :+FAT;5!+!08 "@ * )<" 8>@4 ! end

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